data_2mmw_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mmw _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.119 -1.378 . . . . 73.21 112.414 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.84 -142.94 3.99 Favored Glycine 0 C--N 1.354 1.566 0 CA-C-N 119.897 1.848 . . . . 61.52 111.802 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.53 45.75 1.21 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 119.843 1.822 . . . . 70.31 111.171 -179.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.91 -143.57 12.24 Favored Glycine 0 C--N 1.353 1.516 0 CA-C-O 118.049 -1.417 . . . . 63.45 110.641 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -89.34 -41.49 12.11 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-N 118.765 1.283 . . . . 73.54 112.89 -176.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.7 t -98.6 135.29 21.14 Favored Pre-proline 0 C--N 1.353 0.748 0 CA-C-O 115.363 -2.256 . . . . 65.15 109.661 -166.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -66.66 144.7 73.16 Favored 'Trans proline' 0 C--N 1.362 1.254 0 CA-C-N 124.036 2.477 . . . . 73.22 112.43 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.78 -52.11 5.7 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.275 0.943 . . . . 72.1 108.893 178.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -132.18 174.69 9.95 Favored 'General case' 0 C--N 1.354 0.778 0 CA-C-O 118.731 -0.652 . . . . 61.44 109.449 -174.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -134.76 170.56 15.64 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-O 118.742 -0.647 . . . . 73.32 109.305 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -100.91 -170.4 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.12 -1.437 . . . . 72.32 107.12 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 ttp180 -78.68 65.81 4.03 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-N 120.003 1.274 . . . . 75.34 109.177 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 79.73 77.9 0.91 Allowed Glycine 0 C--N 1.356 1.69 0 CA-C-O 117.986 -1.452 . . . . 61.44 113.438 175.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -165.23 -71.96 0.03 OUTLIER 'General case' 0 C--N 1.358 0.952 0 CA-C-N 119.452 1.626 . . . . 72.22 110.8 170.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.98 150.69 6.34 Favored Pre-proline 0 C--N 1.355 0.818 0 CA-C-O 115.777 -2.059 . . . . 64.44 106.996 -179.024 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.67 173.05 15.16 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.733 2.369 . . . . 74.33 111.432 -176.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -134.25 38.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 108.419 -0.956 . . . . 73.52 108.419 178.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.468 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.8 p 175.08 157.36 0.17 Allowed 'General case' 0 C--N 1.354 0.781 0 CA-C-O 117.445 -1.264 . . . . 72.24 110.798 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.468 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -144.54 176.68 9.22 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 118.267 -0.873 . . . . 73.02 110.378 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.421 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.17 174.45 0.39 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-N 119.567 1.076 . . . . 74.23 111.382 -174.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.508 0 CA-C-N 120.143 1.338 . . . . 74.54 111.798 176.85 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.293 -1.282 . . . . 71.52 112.885 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.61 -144.03 4.29 Favored Glycine 0 C--N 1.354 1.543 0 CA-C-O 117.415 -1.769 . . . . 45.55 111.614 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.61 46.16 1.29 Allowed 'General case' 0 C--N 1.356 0.887 0 CA-C-N 119.751 1.776 . . . . 75.25 110.677 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.61 -139.63 9.2 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 118.034 -1.426 . . . . 53.02 110.798 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -95.31 -35.68 11.69 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 117.482 -1.247 . . . . 71.32 113.285 -173.102 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -105.52 136.13 19.28 Favored Pre-proline 0 C--N 1.355 0.824 0 CA-C-O 115.414 -2.231 . . . . 74.42 109.285 -169.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -66.99 143.78 67.36 Favored 'Trans proline' 0 C--N 1.361 1.211 0 CA-C-N 123.894 2.427 . . . . 73.21 112.289 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.3 mt-10 -85.73 -48.73 8.55 Favored 'General case' 0 C--N 1.358 0.954 0 CA-C-N 118.886 0.766 . . . . 75.11 109.413 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -134.71 175.02 9.93 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.84 -0.6 . . . . 70.01 109.548 -173.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -135.44 171.19 14.8 Favored 'General case' 0 C--N 1.353 0.744 0 N-CA-C 109.105 -0.702 . . . . 74.43 109.105 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.5 m -103.31 -170.32 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.746 0 N-CA-C 107.225 -1.398 . . . . 71.33 107.225 -177.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -72.5 71.32 0.94 Allowed 'General case' 0 C--N 1.353 0.735 0 CA-C-N 119.146 0.885 . . . . 73.33 108.885 172.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.24 80.41 0.2 Allowed Glycine 0 C--N 1.355 1.595 0 CA-C-O 118.19 -1.339 . . . . 73.44 113.812 173.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -164.25 -70.9 0.04 OUTLIER 'General case' 0 C--N 1.357 0.895 0 CA-C-N 119.241 1.52 . . . . 73.1 110.37 170.558 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.83 150.27 6.32 Favored Pre-proline 0 C--N 1.355 0.826 0 CA-C-O 115.871 -2.014 . . . . 72.55 106.839 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -75.42 172.77 15.69 Favored 'Trans proline' 0 C--N 1.356 0.93 0 CA-C-N 123.58 2.314 . . . . 74.45 111.319 -176.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.1 mt -135.32 41.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.981 0 N-CA-C 108.321 -0.992 . . . . 74.21 108.321 178.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.449 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 171.99 156.77 0.09 Allowed 'General case' 0 C--N 1.354 0.803 0 CA-C-O 117.889 -1.053 . . . . 75.42 110.676 -179.266 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.9 m-85 -142.96 177.8 8.11 Favored 'General case' 0 C--N 1.358 0.96 0 CA-C-O 118.106 -0.95 . . . . 71.31 110.123 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.1 m-30 -59.43 175.73 0.31 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.713 1.142 . . . . 74.41 111.234 -174.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.611 0 N-CA-C 109.932 -1.267 . . . . 70.23 109.932 176.422 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.66 0 CA-C-O 118.663 -1.076 . . . . 74.31 111.942 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.98 -144.98 5.52 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.497 -1.724 . . . . 71.43 111.852 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.99 45.67 1.17 Allowed 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.633 1.716 . . . . 73.15 111.374 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.25 -142.47 11.79 Favored Glycine 0 C--N 1.354 1.532 0 CA-C-O 118.033 -1.426 . . . . 64.41 110.494 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.3 m170 -88.57 -45.99 9.44 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 118.983 1.391 . . . . 63.21 113.144 -177.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -93.2 134.39 27.13 Favored Pre-proline 0 C--N 1.353 0.732 0 CA-C-O 115.637 -2.125 . . . . 74.04 109.44 -165.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -66.64 143.99 70.47 Favored 'Trans proline' 0 C--N 1.363 1.3 0 CA-C-N 123.822 2.401 . . . . 74.01 112.183 -177.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.4 mt-10 -86.31 -50.82 6.65 Favored 'General case' 0 C--N 1.358 0.935 0 CA-C-N 118.806 0.73 . . . . 63.55 109.211 178.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -133.44 174.0 10.88 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-O 118.853 -0.594 . . . . 71.51 109.939 -174.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -135.07 170.82 15.32 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 118.694 -0.669 . . . . 75.34 109.256 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -102.63 -169.63 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.737 0 N-CA-C 107.031 -1.47 . . . . 64.55 107.031 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -73.45 70.98 1.28 Allowed 'General case' 0 C--N 1.353 0.729 0 CA-C-N 119.643 1.11 . . . . 74.31 108.875 173.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.97 80.33 0.22 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.118 -1.379 . . . . 61.22 113.621 173.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.67 -68.87 0.05 OUTLIER 'General case' 0 C--N 1.356 0.858 0 CA-C-N 119.155 1.477 . . . . 75.02 109.959 170.066 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -168.56 149.44 4.42 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.964 -1.97 . . . . 74.11 106.895 178.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -75.53 173.42 14.53 Favored 'Trans proline' 0 C--N 1.356 0.973 0 CA-C-N 123.529 2.296 . . . . 64.43 111.226 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.5 39.37 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.906 0 N-CA-C 108.479 -0.934 . . . . 74.03 108.479 179.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.462 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.5 p 174.96 157.13 0.16 Allowed 'General case' 0 C--N 1.354 0.766 0 CA-C-O 117.714 -1.136 . . . . 72.13 111.01 -177.043 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.462 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.1 m-85 -144.53 176.7 9.2 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-O 118.248 -0.882 . . . . 73.4 110.285 -179.722 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.414 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.17 169.63 1.08 Allowed 'General case' 0 C--N 1.355 0.812 0 CA-C-N 119.652 1.115 . . . . 75.44 111.534 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.513 0 C-N-CA 119.303 -1.427 . . . . 62.41 111.491 176.457 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.65 0 CA-C-O 117.919 -1.49 . . . . 72.15 113.325 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.76 -141.77 3.23 Favored Glycine 0 C--N 1.354 1.577 0 CA-C-N 120.159 1.98 . . . . 63.31 111.527 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.62 46.01 1.11 Allowed 'General case' 0 C--N 1.358 0.935 0 CA-C-N 119.898 1.849 . . . . 72.43 111.018 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.66 -137.95 7.81 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 117.788 -1.562 . . . . 51.02 110.844 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -100.76 -24.7 14.34 Favored 'General case' 0 C--N 1.359 0.99 0 CA-C-O 116.653 -1.641 . . . . 75.43 114.039 -172.54 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.3 t -114.21 135.25 22.15 Favored Pre-proline 0 C--N 1.356 0.891 0 CA-C-O 115.384 -2.246 . . . . 75.25 108.685 -171.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -65.96 144.27 75.83 Favored 'Trans proline' 0 C--N 1.361 1.21 0 CA-C-N 123.884 2.423 . . . . 75.22 111.788 -176.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -81.37 -50.67 9.2 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.255 -1.017 . . . . 75.33 108.255 178.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -149.22 172.2 15.24 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.472 -0.775 . . . . 62.31 109.863 -177.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -127.13 168.59 14.44 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.466 -0.778 . . . . 72.13 109.506 -177.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.418 ' O ' ' N ' ' A' ' 13' ' ' GLY . 3.1 m -94.65 -176.99 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.805 0 N-CA-C 107.334 -1.358 . . . . 75.31 107.334 176.181 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -55.2 76.47 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 CA-C-N 118.309 0.504 . . . . 74.31 111.895 170.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 11' ' ' VAL . . . 57.49 78.44 0.13 Allowed Glycine 0 C--N 1.354 1.576 0 CA-C-O 118.056 -1.414 . . . . 74.23 114.097 172.521 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -161.26 -61.86 0.05 Allowed 'General case' 0 C--N 1.356 0.88 0 CA-C-N 119.414 1.607 . . . . 52.14 111.805 173.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -174.52 145.51 0.99 Allowed Pre-proline 0 C--N 1.355 0.833 0 CA-C-O 115.777 -2.059 . . . . 75.02 108.448 -178.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.56 168.52 24.26 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.677 2.349 . . . . 74.22 111.205 -178.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.7 mt -137.45 44.3 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 107.751 -1.203 . . . . 64.41 107.751 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.45 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.0 p 170.03 155.6 0.05 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.878 -1.058 . . . . 63.33 110.496 -179.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.45 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.9 m-85 -141.88 175.82 9.42 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.291 -0.862 . . . . 75.25 109.984 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.437 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -57.98 172.13 0.45 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.497 1.044 . . . . 71.4 111.484 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 1.641 0 N-CA-C 108.308 -1.917 . . . . 75.15 108.308 174.304 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 CA-C-O 118.357 -1.246 . . . . 73.51 112.267 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.62 -143.19 3.87 Favored Glycine 0 C--N 1.355 1.592 0 CA-C-O 117.135 -1.925 . . . . 70.11 111.655 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.52 45.79 1.12 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.957 1.878 . . . . 74.2 111.105 -178.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.94 -144.2 14.27 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.169 -1.351 . . . . 52.51 110.707 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.7 m-70 -88.78 -40.81 12.93 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 118.829 1.314 . . . . 74.54 113.026 -176.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -99.26 135.5 20.73 Favored Pre-proline 0 C--N 1.354 0.775 0 CA-C-O 115.233 -2.318 . . . . 72.14 109.389 -166.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -66.8 144.89 73.05 Favored 'Trans proline' 0 C--N 1.364 1.344 0 CA-C-N 124.001 2.464 . . . . 73.41 111.879 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -82.64 -51.28 7.89 Favored 'General case' 0 C--N 1.359 0.989 0 N-CA-C 108.392 -0.966 . . . . 72.41 108.392 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -149.53 172.95 14.16 Favored 'General case' 0 C--N 1.356 0.861 0 CA-C-O 118.155 -0.926 . . . . 74.41 109.747 -177.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -126.36 168.55 14.01 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 118.551 -0.738 . . . . 74.11 109.974 -176.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -90.09 -169.99 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.881 0 N-CA-C 106.645 -1.613 . . . . 71.25 106.645 177.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -70.73 75.12 0.6 Allowed 'General case' 0 C--N 1.353 0.718 0 CA-C-N 119.479 1.036 . . . . 74.23 109.153 176.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.1 77.45 0.35 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 118.107 -1.385 . . . . 64.21 113.058 173.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -160.03 -65.12 0.07 Allowed 'General case' 0 C--N 1.357 0.919 0 CA-C-N 119.188 1.494 . . . . 55.1 111.279 171.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.09 154.56 3.41 Favored Pre-proline 0 C--N 1.355 0.814 0 CA-C-O 116.027 -1.94 . . . . 74.31 107.6 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -80.87 155.99 20.5 Favored 'Trans proline' 0 C--N 1.36 1.174 0 CA-C-N 123.698 2.357 . . . . 75.0 111.257 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.5 mm -118.73 17.75 6.85 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-O 118.284 -0.865 . . . . 73.33 109.23 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 7.1 m -165.9 158.87 15.29 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 121.102 1.774 . . . . 71.32 110.558 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -142.8 174.94 10.21 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 119.789 1.177 . . . . 73.11 110.713 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.432 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.18 174.02 0.43 Allowed 'General case' 0 C--N 1.356 0.855 0 CA-C-N 119.242 0.928 . . . . 73.2 111.266 -174.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.483 0 N-CA-C 109.036 -1.626 . . . . 70.11 109.036 175.558 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.734 0 CA-C-O 118.463 -1.187 . . . . 75.3 112.278 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.77 -147.08 6.17 Favored Glycine 0 C--N 1.355 1.597 0 CA-C-O 117.486 -1.73 . . . . 75.24 111.859 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.2 46.34 1.15 Allowed 'General case' 0 C--N 1.357 0.925 0 CA-C-N 119.78 1.79 . . . . 72.13 111.357 -178.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.18 -144.69 15.42 Favored Glycine 0 C--N 1.354 1.57 0 CA-C-O 117.9 -1.5 . . . . 54.44 110.249 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -87.76 -43.1 12.13 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-N 119.142 1.471 . . . . 73.21 112.926 -177.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -96.4 134.98 22.74 Favored Pre-proline 0 C--N 1.354 0.764 0 CA-C-O 115.199 -2.334 . . . . 72.34 109.814 -165.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.22 145.05 83.19 Favored 'Trans proline' 0 C--N 1.363 1.323 0 CA-C-N 124.146 2.517 . . . . 72.53 112.257 -177.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 75.9 mt-10 -82.45 -52.14 7.16 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 108.177 -1.045 . . . . 54.43 108.177 178.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -149.32 173.0 13.98 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-O 118.414 -0.803 . . . . 75.5 109.685 -177.4 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -126.4 169.55 12.85 Favored 'General case' 0 C--N 1.354 0.804 0 CA-C-O 118.505 -0.759 . . . . 74.02 110.095 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -93.41 -171.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 N-CA-C 106.872 -1.529 . . . . 74.41 106.872 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.3 mtt-85 -70.38 76.1 0.55 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.826 1.194 . . . . 75.34 109.879 173.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.57 76.97 0.4 Allowed Glycine 0 C--N 1.355 1.613 0 CA-C-O 118.048 -1.418 . . . . 62.03 113.267 172.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -160.59 -67.16 0.07 Allowed 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.203 1.502 . . . . 75.44 110.934 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.07 153.06 3.04 Favored Pre-proline 0 C--N 1.353 0.753 0 CA-C-O 115.754 -2.07 . . . . 75.21 107.253 -178.423 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.38 171.51 15.9 Favored 'Trans proline' 0 C--N 1.357 1.022 0 CA-C-N 123.911 2.433 . . . . 70.42 111.661 -177.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.3 mt -135.9 41.37 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.799 -1.186 . . . . 73.24 107.799 177.072 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.434 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 2.7 p 174.5 156.65 0.15 Allowed 'General case' 0 C--N 1.354 0.774 0 CA-C-O 117.809 -1.091 . . . . 73.45 110.731 -178.034 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.434 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.7 m-85 -143.76 175.69 9.8 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.133 -0.937 . . . . 75.4 110.071 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.78 176.15 0.22 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.654 1.115 . . . . 73.24 111.351 -174.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.574 0 CA-C-N 120.227 1.376 . . . . 65.01 110.641 176.51 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.715 0 CA-C-O 118.521 -1.155 . . . . 73.3 111.246 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.3 -146.45 5.82 Favored Glycine 0 C--N 1.354 1.58 0 CA-C-O 117.389 -1.784 . . . . 74.45 111.753 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.96 45.92 1.09 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.718 1.759 . . . . 65.04 111.318 -178.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.7 -139.65 9.72 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.806 -1.552 . . . . 74.52 110.62 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -93.52 -38.81 11.2 Favored 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.045 1.422 . . . . 63.12 113.151 -174.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.4 t -101.67 135.17 19.83 Favored Pre-proline 0 C--N 1.354 0.799 0 CA-C-O 115.149 -2.358 . . . . 73.34 109.495 -167.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.94 144.53 76.89 Favored 'Trans proline' 0 C--N 1.362 1.255 0 CA-C-N 124.165 2.523 . . . . 73.24 112.218 -176.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -81.87 -51.77 7.77 Favored 'General case' 0 C--N 1.358 0.94 0 CA-C-N 119.486 1.039 . . . . 70.31 108.313 178.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -149.19 172.38 14.93 Favored 'General case' 0 C--N 1.353 0.757 0 CA-C-O 118.342 -0.837 . . . . 70.43 110.116 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -124.77 171.34 10.19 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-O 118.665 -0.683 . . . . 74.45 110.016 -176.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 m -94.87 -166.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 107.484 -1.302 . . . . 72.33 107.484 -178.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 tpt180 -71.01 67.22 0.41 Allowed 'General case' 0 C--N 1.355 0.813 0 CA-C-N 119.801 1.182 . . . . 75.32 109.292 173.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.15 79.39 0.29 Allowed Glycine 0 C--N 1.355 1.604 0 CA-C-O 117.844 -1.531 . . . . 74.01 113.546 176.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -161.1 -71.81 0.06 Allowed 'General case' 0 C--N 1.358 0.972 0 CA-C-N 119.579 1.689 . . . . 72.32 110.48 170.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -163.17 154.56 14.73 Favored Pre-proline 0 C--N 1.355 0.828 0 CA-C-O 116.058 -1.925 . . . . 73.11 107.249 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -78.07 169.28 20.65 Favored 'Trans proline' 0 C--N 1.358 1.069 0 CA-C-N 123.577 2.313 . . . . 73.13 111.238 -177.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -133.37 36.38 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.702 -1.221 . . . . 73.34 107.702 175.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -173.86 158.73 3.27 Favored 'General case' 0 C--N 1.353 0.742 0 CA-C-O 116.702 -1.618 . . . . 43.01 110.204 -177.122 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.5 m-85 -145.21 173.64 11.77 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-N 119.538 1.063 . . . . 65.33 110.053 174.382 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.5 171.31 0.85 Allowed 'General case' 0 C--N 1.354 0.793 0 CA-C-N 119.711 1.141 . . . . 74.34 111.049 -174.267 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.496 0 CA-C-N 120.471 1.487 . . . . 70.43 111.472 175.135 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 CA-C-O 118.486 -1.174 . . . . 73.15 112.13 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.15 -144.12 5.18 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.496 -1.724 . . . . 62.35 112.252 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.94 44.78 1.26 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.526 1.663 . . . . 74.15 111.042 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.64 -141.69 9.42 Favored Glycine 0 C--N 1.353 1.521 0 CA-C-O 118.076 -1.402 . . . . 72.11 110.825 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -93.01 -39.24 11.22 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 118.69 1.245 . . . . 71.35 113.177 -175.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.1 t -99.62 135.12 20.67 Favored Pre-proline 0 C--N 1.353 0.743 0 CA-C-O 115.385 -2.245 . . . . 55.4 109.233 -168.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -66.78 144.27 70.7 Favored 'Trans proline' 0 C--N 1.362 1.244 0 CA-C-N 123.907 2.431 . . . . 64.03 112.22 -177.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.9 mt-10 -86.13 -51.53 6.25 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 118.9 0.773 . . . . 72.33 109.167 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -132.18 174.31 10.34 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 118.91 -0.567 . . . . 71.23 109.543 -174.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -134.06 171.8 13.72 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.099 -0.704 . . . . 72.5 109.099 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -104.28 -165.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.775 0 N-CA-C 106.939 -1.504 . . . . 72.15 106.939 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -74.95 67.22 1.66 Allowed 'General case' 0 C--N 1.352 0.705 0 CA-C-N 119.602 1.092 . . . . 74.12 108.93 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 66.75 80.63 0.18 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 117.963 -1.465 . . . . 65.55 113.615 175.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -164.87 -64.03 0.03 OUTLIER 'General case' 0 C--N 1.358 0.941 0 CA-C-N 119.486 1.643 . . . . 70.23 111.028 172.626 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -169.87 143.28 2.09 Favored Pre-proline 0 C--N 1.354 0.773 0 CA-C-O 115.756 -2.069 . . . . 73.01 108.364 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -73.74 173.19 14.37 Favored 'Trans proline' 0 C--N 1.359 1.094 0 CA-C-N 123.956 2.449 . . . . 64.52 111.087 -177.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -135.05 38.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 108.631 -0.877 . . . . 75.51 108.631 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.9 p 175.52 156.88 0.2 Allowed 'General case' 0 C--N 1.355 0.835 0 CA-C-O 117.706 -1.14 . . . . 65.41 110.902 -176.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.6 m-85 -144.81 176.38 9.49 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-O 118.291 -0.861 . . . . 74.44 110.542 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.23 174.4 0.29 Allowed 'General case' 0 C--N 1.355 0.823 0 CA-C-N 119.369 0.986 . . . . 75.43 112.117 -174.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.639 0 N-CA-C 109.34 -1.504 . . . . 72.45 109.34 176.648 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 CA-C-O 118.529 -1.151 . . . . 65.23 112.108 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.29 -144.97 5.58 Favored Glycine 0 C--N 1.355 1.617 0 CA-C-O 117.43 -1.761 . . . . 72.03 111.61 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.34 45.6 1.23 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-N 119.717 1.759 . . . . 70.11 111.099 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.35 -145.79 17.03 Favored Glycine 0 C--N 1.354 1.53 0 CA-C-O 118.256 -1.302 . . . . 70.21 110.529 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -85.89 -45.99 11.02 Favored 'General case' 0 C--N 1.357 0.892 0 CA-C-N 118.928 1.364 . . . . 61.25 112.91 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -92.76 134.74 27.16 Favored Pre-proline 0 C--N 1.354 0.795 0 CA-C-O 115.312 -2.28 . . . . 74.33 109.678 -164.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.45 143.8 64.73 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 123.876 2.42 . . . . 73.4 112.281 -177.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -86.11 -47.44 9.52 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 118.885 0.766 . . . . 75.24 109.364 177.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -135.83 175.76 9.3 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 118.668 -0.682 . . . . 70.24 109.724 -173.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -136.14 170.41 16.06 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 118.771 -0.633 . . . . 74.02 109.301 178.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.66 -167.53 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.787 0 N-CA-C 106.854 -1.536 . . . . 75.21 106.854 -178.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -76.05 65.62 2.11 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-N 120.309 1.413 . . . . 75.24 109.286 175.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 72.85 79.67 0.46 Allowed Glycine 0 C--N 1.356 1.66 0 CA-C-O 117.884 -1.509 . . . . 73.5 113.552 175.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -165.16 -65.81 0.03 OUTLIER 'General case' 0 C--N 1.359 1.019 0 CA-C-N 119.582 1.691 . . . . 75.11 111.376 171.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.4 t -169.49 142.95 2.2 Favored Pre-proline 0 C--N 1.355 0.813 0 CA-C-O 115.644 -2.122 . . . . 74.3 108.437 179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.51 172.77 15.04 Favored 'Trans proline' 0 C--N 1.359 1.098 0 CA-C-N 124.036 2.477 . . . . 71.52 111.542 -176.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -135.46 40.71 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.927 0 N-CA-C 108.629 -0.878 . . . . 75.42 108.629 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.457 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.2 p 173.85 156.75 0.13 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-O 117.713 -1.137 . . . . 73.2 110.617 -178.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.457 ' CD1' ' C ' ' A' ' 18' ' ' SER . 33.1 m-85 -144.18 177.37 8.64 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-O 118.324 -0.846 . . . . 75.32 110.636 -178.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.412 ' O ' ' N ' ' A' ' 4' ' ' GLY . 7.9 m-30 -60.03 173.97 0.56 Allowed 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.547 1.067 . . . . 74.03 111.346 -174.018 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.634 0 N-CA-C 110.375 -1.09 . . . . 75.41 110.375 176.184 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.687 0 CA-C-O 118.063 -1.41 . . . . 73.31 112.331 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.46 -140.75 3.81 Favored Glycine 0 C--N 1.354 1.546 0 CA-C-N 120.011 1.906 . . . . 64.11 112.287 178.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.12 44.95 1.25 Allowed 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.799 1.799 . . . . 72.44 110.947 -178.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.07 -141.44 8.85 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.971 -1.46 . . . . 71.53 110.939 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -94.99 -34.71 12.25 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 117.224 -1.37 . . . . 74.41 112.927 -173.197 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -105.76 136.16 19.31 Favored Pre-proline 0 C--N 1.355 0.817 0 CA-C-O 115.362 -2.256 . . . . 74.11 109.159 -169.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -66.75 144.57 72.07 Favored 'Trans proline' 0 C--N 1.362 1.267 0 CA-C-N 124.097 2.499 . . . . 75.02 112.29 -177.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -86.77 -51.53 6.04 Favored 'General case' 0 C--N 1.358 0.956 0 CA-C-N 119.155 0.889 . . . . 65.44 108.896 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -131.41 174.52 9.99 Favored 'General case' 0 C--N 1.355 0.84 0 CA-C-O 118.738 -0.648 . . . . 74.14 109.314 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -134.35 170.39 15.8 Favored 'General case' 0 C--N 1.354 0.765 0 CA-C-O 118.607 -0.711 . . . . 75.03 109.187 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.21 -169.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.764 0 N-CA-C 106.728 -1.582 . . . . 73.53 106.728 -179.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 86.8 mtm-85 -77.69 68.58 3.8 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-N 120.061 1.3 . . . . 74.23 109.249 174.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 75.03 77.78 0.67 Allowed Glycine 0 C--N 1.358 1.754 0 CA-C-O 117.768 -1.573 . . . . 62.5 113.618 173.056 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -165.63 -65.45 0.03 OUTLIER 'General case' 0 C--N 1.358 0.971 0 CA-C-N 119.517 1.659 . . . . 74.25 111.42 172.225 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -171.0 143.77 1.68 Allowed Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.644 -2.122 . . . . 71.12 108.327 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -73.15 172.43 15.56 Favored 'Trans proline' 0 C--N 1.359 1.079 0 CA-C-N 123.989 2.46 . . . . 74.22 111.517 -176.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -134.14 38.82 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.939 0 N-CA-C 108.506 -0.924 . . . . 74.13 108.506 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.469 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 173.93 156.18 0.13 Allowed 'General case' 0 C--N 1.355 0.826 0 CA-C-N 119.735 1.152 . . . . 62.03 110.79 -176.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.469 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.2 m-85 -144.43 176.74 9.15 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-O 118.288 -0.863 . . . . 72.31 110.556 -178.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.409 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.46 176.39 0.19 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-N 119.2 0.909 . . . . 74.41 112.144 -174.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.632 0 N-CA-C 109.864 -1.295 . . . . 65.44 109.864 176.758 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.118 -1.379 . . . . 63.24 112.618 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.46 -141.94 3.6 Favored Glycine 0 C--N 1.355 1.6 0 CA-C-N 120.001 1.9 . . . . 73.14 111.735 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.93 46.01 1.17 Allowed 'General case' 0 C--N 1.357 0.912 0 CA-C-N 119.965 1.882 . . . . 75.32 111.169 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.01 -145.0 14.56 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.075 -1.403 . . . . 54.23 110.415 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 4.0 m80 -87.85 -42.29 12.64 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-N 118.86 1.33 . . . . 75.05 112.808 -177.103 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.7 t -96.87 134.96 22.37 Favored Pre-proline 0 C--N 1.353 0.734 0 CA-C-O 115.402 -2.237 . . . . 72.0 109.788 -166.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.95 143.77 67.59 Favored 'Trans proline' 0 C--N 1.362 1.253 0 CA-C-N 124.028 2.474 . . . . 74.23 112.158 -177.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 -86.18 -49.5 7.69 Favored 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.238 0.927 . . . . 71.21 109.111 178.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -133.13 175.54 9.29 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.697 -0.668 . . . . 75.25 109.331 -174.093 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -135.87 169.86 16.91 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.15 -0.685 . . . . 73.41 109.15 177.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -101.3 -169.4 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.757 0 N-CA-C 106.502 -1.666 . . . . 74.45 106.502 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.7 mtm180 -74.4 70.64 1.73 Allowed 'General case' 0 C--N 1.354 0.764 0 CA-C-N 120.038 1.29 . . . . 75.12 109.725 173.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.05 79.07 0.29 Allowed Glycine 0 C--N 1.355 1.619 0 CA-C-O 118.087 -1.396 . . . . 45.44 113.373 173.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -164.75 -64.7 0.04 OUTLIER 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.249 1.524 . . . . 73.13 110.903 172.371 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -170.99 143.2 1.6 Allowed Pre-proline 0 C--N 1.355 0.805 0 CA-C-O 115.551 -2.166 . . . . 75.24 108.416 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.16 172.52 15.38 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 124.023 2.472 . . . . 72.13 111.544 -176.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.3 mt -134.92 40.81 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.957 0 N-CA-C 108.587 -0.894 . . . . 74.0 108.587 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.6 p 172.8 156.56 0.1 Allowed 'General case' 0 C--N 1.353 0.754 0 CA-C-O 117.776 -1.107 . . . . 71.43 110.581 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.8 m-85 -142.99 176.7 8.89 Favored 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.169 -0.92 . . . . 72.13 110.238 -178.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.423 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.84 173.07 0.46 Allowed 'General case' 0 C--N 1.355 0.807 0 CA-C-N 119.619 1.099 . . . . 75.3 111.272 -174.031 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.48 0 N-CA-C 108.656 -1.778 . . . . 74.15 108.656 174.73 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 CA-C-O 118.275 -1.292 . . . . 62.21 112.026 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.49 -142.66 4.1 Favored Glycine 0 C--N 1.355 1.588 0 CA-C-O 117.224 -1.875 . . . . 74.03 111.812 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.48 45.71 1.13 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.972 1.886 . . . . 61.15 111.289 -178.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.4 -145.96 17.54 Favored Glycine 0 C--N 1.354 1.549 0 CA-C-O 118.179 -1.345 . . . . 61.15 110.626 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -85.71 -43.8 13.08 Favored 'General case' 0 C--N 1.357 0.894 0 CA-C-N 118.904 1.352 . . . . 74.01 112.884 -177.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.0 t -95.06 134.48 24.65 Favored Pre-proline 0 C--N 1.353 0.726 0 CA-C-O 115.257 -2.306 . . . . 74.4 109.959 -165.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -66.63 144.32 71.78 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 124.024 2.473 . . . . 72.44 112.229 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -86.67 -52.22 5.66 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.322 0.965 . . . . 62.52 108.755 178.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -131.09 174.51 9.95 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 118.713 -0.661 . . . . 73.15 109.392 -174.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -134.42 170.72 15.32 Favored 'General case' 0 C--N 1.353 0.755 0 N-CA-C 109.038 -0.727 . . . . 74.53 109.038 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -102.38 -169.53 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 N-CA-C 106.933 -1.506 . . . . 65.4 106.933 -178.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.2 ttm180 -70.05 70.71 0.37 Allowed 'General case' 0 C--N 1.352 0.688 0 CA-C-N 119.394 0.997 . . . . 74.42 109.312 172.281 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.43 81.63 0.1 OUTLIER Glycine 0 C--N 1.355 1.591 0 CA-C-O 117.956 -1.469 . . . . 63.53 113.918 174.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -164.94 -64.41 0.03 OUTLIER 'General case' 0 C--N 1.357 0.911 0 CA-C-N 119.525 1.662 . . . . 72.52 110.966 171.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -170.37 142.95 1.83 Allowed Pre-proline 0 C--N 1.354 0.783 0 CA-C-O 115.616 -2.135 . . . . 71.13 108.387 178.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.3 172.51 15.46 Favored 'Trans proline' 0 C--N 1.359 1.115 0 CA-C-N 124.016 2.47 . . . . 73.41 111.237 -177.06 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -134.35 38.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 N-CA-C 108.46 -0.941 . . . . 75.14 108.46 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.0 p 175.26 157.01 0.18 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.581 -1.199 . . . . 62.42 110.733 -176.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.1 m-85 -144.89 176.26 9.6 Favored 'General case' 0 C--N 1.358 0.97 0 CA-C-O 118.286 -0.864 . . . . 74.11 110.499 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.425 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.09 171.21 0.56 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-N 119.565 1.075 . . . . 74.51 111.57 -174.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.484 0 C-N-CA 119.503 -1.332 . . . . 74.1 112.417 176.404 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.368 -1.24 . . . . 74.54 112.596 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.34 -143.97 5.16 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 117.271 -1.85 . . . . 70.0 112.876 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.82 44.54 1.09 Allowed 'General case' 0 C--N 1.358 0.961 0 CA-C-N 119.585 1.693 . . . . 63.43 112.072 -177.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.5 -144.74 12.41 Favored Glycine 0 C--N 1.353 1.486 0 CA-C-O 118.144 -1.365 . . . . 63.35 110.533 178.522 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -89.33 -40.79 12.54 Favored 'General case' 0 C--N 1.358 0.959 0 CA-C-N 118.951 1.376 . . . . 70.13 113.46 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.6 t -95.93 133.6 25.1 Favored Pre-proline 0 C--N 1.354 0.761 0 CA-C-O 115.422 -2.228 . . . . 75.25 109.526 -166.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -65.45 145.33 82.51 Favored 'Trans proline' 0 C--N 1.362 1.275 0 CA-C-N 123.891 2.425 . . . . 72.42 112.058 -177.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 78.8 mt-10 -81.99 -51.71 7.78 Favored 'General case' 0 C--N 1.359 0.985 0 N-CA-C 108.352 -0.981 . . . . 72.2 108.352 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.5 p90 -150.04 172.59 15.01 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 118.506 -0.759 . . . . 74.24 110.279 -177.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -125.64 170.95 11.0 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 118.668 -0.682 . . . . 71.41 109.484 -177.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -94.42 -166.9 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.868 0 N-CA-C 107.67 -1.233 . . . . 64.52 107.67 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.4 tpt85 -68.52 67.75 0.13 Allowed 'General case' 0 C--N 1.354 0.779 0 CA-C-N 119.335 0.971 . . . . 73.33 109.544 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.58 80.48 0.2 Allowed Glycine 0 C--N 1.356 1.646 0 CA-C-O 117.882 -1.51 . . . . 64.03 113.591 177.406 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -161.31 -66.19 0.06 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-N 119.495 1.648 . . . . 74.31 111.314 170.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -171.42 153.59 3.61 Favored Pre-proline 0 C--N 1.356 0.85 0 CA-C-O 115.966 -1.969 . . . . 71.12 106.763 -177.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -79.97 169.47 17.81 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.657 2.342 . . . . 70.22 111.644 -177.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.0 mt -135.71 41.89 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.92 0 N-CA-C 107.591 -1.262 . . . . 74.42 107.591 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.446 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.3 OUTLIER 175.65 157.33 0.21 Allowed 'General case' 0 C--N 1.352 0.71 0 CA-C-O 117.809 -1.091 . . . . 74.2 110.753 -178.503 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.446 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.2 m-85 -144.99 174.97 10.57 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-O 118.208 -0.901 . . . . 74.41 110.113 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.67 175.49 0.25 Allowed 'General case' 0 C--N 1.356 0.87 0 CA-C-N 119.143 0.883 . . . . 74.13 112.208 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.582 0 N-CA-C 109.746 -1.342 . . . . 74.42 109.746 176.645 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.635 0 CA-C-O 118.427 -1.207 . . . . 73.21 112.322 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.85 -141.16 3.36 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.217 -1.88 . . . . 52.21 111.493 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.49 45.5 1.21 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 119.881 1.84 . . . . 74.04 111.167 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.15 -145.73 15.36 Favored Glycine 0 C--N 1.353 1.496 0 CA-C-O 118.323 -1.265 . . . . 74.44 110.705 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -88.31 -40.6 13.47 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-N 118.557 1.179 . . . . 70.52 113.115 -176.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.9 t -98.09 134.89 21.66 Favored Pre-proline 0 C--N 1.353 0.758 0 CA-C-O 115.502 -2.189 . . . . 75.13 109.498 -166.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -67.41 144.52 67.88 Favored 'Trans proline' 0 C--N 1.362 1.288 0 CA-C-N 123.763 2.38 . . . . 72.41 112.121 -178.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -87.15 -49.65 7.15 Favored 'General case' 0 C--N 1.358 0.961 0 CA-C-N 118.869 0.759 . . . . 61.41 109.301 178.077 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -133.46 175.71 9.18 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.744 -0.646 . . . . 75.34 109.677 -174.206 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -137.04 166.86 22.69 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.63 -0.7 . . . . 73.4 109.411 177.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -96.03 -168.03 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.841 0 N-CA-C 106.424 -1.695 . . . . 74.32 106.424 178.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.7 mtp180 -74.85 71.23 1.99 Allowed 'General case' 0 C--N 1.354 0.772 0 CA-C-N 120.3 1.409 . . . . 74.24 109.329 176.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.43 78.23 0.37 Allowed Glycine 0 C--N 1.355 1.624 0 CA-C-O 118.093 -1.393 . . . . 74.41 112.978 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -163.01 -63.42 0.04 OUTLIER 'General case' 0 C--N 1.357 0.899 0 CA-C-N 119.26 1.53 . . . . 71.52 111.28 172.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -170.12 144.11 2.12 Favored Pre-proline 0 C--N 1.355 0.821 0 CA-C-O 115.91 -1.995 . . . . 64.3 108.643 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -76.03 158.26 38.19 Favored 'Trans proline' 0 C--N 1.36 1.137 0 CA-C-N 123.585 2.316 . . . . 64.01 110.93 -178.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 15.9 mm -119.99 22.59 5.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.916 0 O-C-N 123.916 0.76 . . . . 74.41 109.764 -176.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.443 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 12.1 p -175.19 157.58 2.27 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-N 120.451 1.478 . . . . 74.33 110.753 -175.672 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.0 m-85 -142.34 177.68 8.1 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.139 -0.934 . . . . 62.52 110.887 -176.442 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -58.3 172.77 0.42 Allowed 'General case' 0 C--N 1.355 0.815 0 CA-C-N 119.538 1.063 . . . . 74.3 111.593 -174.246 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.596 0 N-CA-C 108.817 -1.713 . . . . 73.33 108.817 175.011 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 CA-C-O 118.379 -1.234 . . . . 71.4 112.442 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.3 -141.73 3.25 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.221 -1.877 . . . . 71.12 111.235 179.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.51 45.99 1.04 Allowed 'General case' 0 C--N 1.356 0.886 0 CA-C-N 120.05 1.925 . . . . 75.53 111.52 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.95 -146.53 19.68 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.18 -1.344 . . . . 74.1 110.371 179.35 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -87.11 -41.01 14.13 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-N 118.931 1.366 . . . . 72.52 113.19 -178.209 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.45 133.73 25.41 Favored Pre-proline 0 C--N 1.353 0.744 0 CA-C-O 115.43 -2.224 . . . . 74.22 109.536 -166.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.46 144.27 72.69 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.915 2.434 . . . . 74.05 111.684 -178.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -82.24 -50.75 8.63 Favored 'General case' 0 C--N 1.356 0.876 0 N-CA-C 108.411 -0.959 . . . . 73.34 108.411 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -148.9 172.59 14.44 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 118.368 -0.825 . . . . 74.5 109.729 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -126.08 168.24 14.26 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.513 -0.756 . . . . 73.34 109.808 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -91.95 -171.07 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.835 0 N-CA-C 105.918 -1.882 . . . . 71.03 105.918 175.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.8 mtt-85 -71.2 76.81 0.71 Allowed 'General case' 0 C--N 1.353 0.75 0 CA-C-N 120.366 1.439 . . . . 73.22 110.071 177.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.53 75.93 0.44 Allowed Glycine 0 C--N 1.355 1.631 0 CA-C-O 118.104 -1.387 . . . . 54.54 112.985 172.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -161.9 -61.5 0.05 OUTLIER 'General case' 0 C--N 1.356 0.886 0 CA-C-N 119.212 1.506 . . . . 73.35 111.801 173.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -173.87 144.67 1.05 Allowed Pre-proline 0 C--N 1.355 0.832 0 CA-C-O 115.892 -2.004 . . . . 72.13 109.035 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.6 156.07 31.8 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 123.608 2.324 . . . . 74.34 110.79 -178.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 15.7 mm -118.85 21.42 5.96 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-O 118.625 -0.702 . . . . 73.34 109.427 -176.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.437 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 13.4 p -174.9 158.62 2.59 Favored 'General case' 0 C--N 1.356 0.868 0 CA-C-N 120.435 1.47 . . . . 64.42 110.994 -175.047 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.437 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -142.05 176.6 8.82 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.136 -0.935 . . . . 74.03 111.013 -177.042 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.417 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.2 m-30 -58.72 173.12 0.44 Allowed 'General case' 0 C--N 1.356 0.852 0 CA-C-N 119.609 1.095 . . . . 64.44 111.372 -174.468 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.587 0 C-N-CA 119.614 -1.279 . . . . 75.32 110.956 177.397 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.648 0 CA-C-O 117.923 -1.487 . . . . 64.44 113.841 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -164.96 -142.69 3.48 Favored Glycine 0 C--N 1.353 1.502 0 CA-C-N 120.06 1.93 . . . . 72.41 111.708 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.51 47.66 1.11 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 120.021 1.911 . . . . 75.3 111.209 -178.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.67 -145.71 18.21 Favored Glycine 0 C--N 1.354 1.551 0 CA-C-O 118.007 -1.44 . . . . 73.01 109.813 179.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -88.18 -41.72 12.8 Favored 'General case' 0 C--N 1.356 0.879 0 CA-C-N 119.029 1.415 . . . . 74.13 113.221 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -94.51 133.67 26.59 Favored Pre-proline 0 C--N 1.354 0.771 0 CA-C-O 115.456 -2.211 . . . . 71.21 109.712 -165.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.0 144.25 75.47 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 123.937 2.442 . . . . 75.31 111.634 -177.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -82.12 -50.07 9.47 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.473 -0.936 . . . . 71.4 108.473 178.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -149.92 173.09 14.19 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.398 -0.81 . . . . 75.3 109.732 -177.316 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -127.95 169.2 14.25 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.509 -0.757 . . . . 72.44 109.6 -178.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -92.49 -170.9 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.852 0 N-CA-C 107.109 -1.441 . . . . 75.32 107.109 177.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -69.86 73.8 0.43 Allowed 'General case' 0 C--N 1.352 0.679 0 CA-C-N 119.203 0.91 . . . . 75.4 109.441 174.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.79 76.8 0.43 Allowed Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.034 -1.426 . . . . 72.4 113.563 173.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -160.67 -66.16 0.06 Allowed 'General case' 0 C--N 1.356 0.853 0 CA-C-N 119.244 1.522 . . . . 64.34 111.077 170.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -170.91 152.15 3.52 Favored Pre-proline 0 C--N 1.357 0.913 0 CA-C-O 116.018 -1.944 . . . . 75.51 108.36 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -76.32 165.21 29.75 Favored 'Trans proline' 0 C--N 1.356 0.933 0 CA-C-N 123.474 2.277 . . . . 65.54 111.479 -177.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.9 mt -135.81 47.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.886 0 N-CA-C 107.382 -1.34 . . . . 73.42 107.382 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.435 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.9 p 166.32 156.53 0.03 OUTLIER 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.032 -0.985 . . . . 73.32 110.175 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' A' ' 18' ' ' SER . 34.3 m-85 -141.79 178.1 7.72 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 117.877 -1.059 . . . . 74.21 109.828 179.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.444 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.86 177.6 0.14 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 119.693 1.133 . . . . 73.1 110.751 -175.72 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.57 0 CA-C-N 120.615 1.552 . . . . 65.12 109.915 176.231 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.694 0 CA-C-O 117.858 -1.524 . . . . 74.11 113.611 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.06 -143.02 3.58 Favored Glycine 0 C--N 1.354 1.583 0 CA-C-N 120.216 2.008 . . . . 75.31 111.261 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.17 45.23 1.07 Allowed 'General case' 0 C--N 1.357 0.899 0 CA-C-N 120.067 1.934 . . . . 74.25 111.464 -178.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.74 -145.53 16.85 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.166 -1.352 . . . . 74.51 110.657 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -87.6 -39.99 14.6 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-N 118.778 1.289 . . . . 74.15 112.911 -176.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -98.77 134.54 21.51 Favored Pre-proline 0 C--N 1.354 0.79 0 CA-C-O 115.368 -2.254 . . . . 74.43 109.743 -166.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.99 147.31 84.43 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 124.019 2.471 . . . . 74.54 112.136 -177.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.4 mt-10 -83.93 -50.64 7.85 Favored 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.341 0.973 . . . . 71.14 108.38 178.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -151.5 174.64 13.16 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.417 -0.801 . . . . 74.11 110.412 -176.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -127.94 178.24 6.31 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.88 -1.057 . . . . 73.11 109.484 -176.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.36 -162.23 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.947 0 N-CA-C 105.265 -2.124 . . . . 71.33 105.265 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 70.0 mmt-85 -75.99 73.19 2.88 Favored 'General case' 0 C--N 1.355 0.804 0 CA-C-N 121.32 1.873 . . . . 72.24 108.221 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.05 79.71 0.24 Allowed Glycine 0 C--N 1.354 1.561 0 CA-C-O 118.382 -1.232 . . . . 64.03 110.858 176.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -156.21 -69.53 0.11 Allowed 'General case' 0 C--N 1.356 0.849 0 CA-C-N 118.846 1.323 . . . . 74.5 111.067 176.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 178.53 150.8 0.44 Allowed Pre-proline 0 C--N 1.353 0.759 0 CA-C-O 116.063 -1.922 . . . . 74.31 106.836 -177.389 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -75.58 167.21 26.98 Favored 'Trans proline' 0 C--N 1.356 0.968 0 CA-C-N 124.027 2.474 . . . . 63.41 110.814 -176.14 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mt -134.08 37.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.854 0 N-CA-C 107.908 -1.145 . . . . 72.51 107.908 178.606 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.43 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.3 p 171.75 155.71 0.08 Allowed 'General case' 0 C--N 1.354 0.801 0 CA-C-O 117.546 -1.216 . . . . 74.12 110.205 -175.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.43 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -141.34 175.83 9.35 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-O 118.244 -0.884 . . . . 73.33 110.332 -178.76 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.69 171.89 0.58 Allowed 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.636 1.107 . . . . 74.3 111.377 -174.274 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.538 0 C-N-CA 119.351 -1.404 . . . . 65.2 112.024 176.21 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.733 0 CA-C-O 118.102 -1.388 . . . . 42.11 113.273 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.15 -143.25 3.7 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-O 117.208 -1.885 . . . . 71.43 111.309 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -149.03 44.99 0.99 Allowed 'General case' 0 C--N 1.357 0.923 0 CA-C-N 120.158 1.979 . . . . 64.33 111.711 -179.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.03 -146.48 18.43 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 118.112 -1.382 . . . . 73.54 110.534 179.226 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 m170 -87.97 -38.52 15.47 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-N 119.012 1.406 . . . . 74.55 113.145 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.94 133.2 24.57 Favored Pre-proline 0 C--N 1.353 0.749 0 CA-C-O 115.339 -2.267 . . . . 73.3 109.688 -167.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -66.35 146.45 80.68 Favored 'Trans proline' 0 C--N 1.363 1.321 0 CA-C-N 123.987 2.46 . . . . 73.33 112.003 -177.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 -82.78 -50.58 8.52 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.317 -0.994 . . . . 52.45 108.317 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -150.69 173.57 14.01 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.544 -0.741 . . . . 73.45 110.302 -177.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.7 176.95 6.85 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 118.042 -0.98 . . . . 74.42 109.415 -176.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.0 -167.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.902 0 N-CA-C 105.068 -2.197 . . . . 72.41 105.068 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -74.13 75.78 1.77 Allowed 'General case' 0 C--N 1.354 0.767 0 CA-C-N 120.686 1.584 . . . . 74.23 108.907 178.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.96 76.59 0.33 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.134 -1.37 . . . . 73.33 111.179 175.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -156.83 -69.75 0.1 Allowed 'General case' 0 C--N 1.355 0.838 0 CA-C-N 119.028 1.414 . . . . 71.11 111.389 178.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -178.39 143.68 0.46 Allowed Pre-proline 0 C--N 1.354 0.787 0 CA-C-O 116.011 -1.947 . . . . 75.12 108.465 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -71.75 165.62 31.97 Favored 'Trans proline' 0 C--N 1.358 1.027 0 CA-C-N 123.791 2.39 . . . . 63.34 110.233 -177.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.44 37.72 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.877 0 N-CA-C 107.915 -1.142 . . . . 70.11 107.915 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.5 p 173.46 154.46 0.1 Allowed 'General case' 0 C--N 1.355 0.833 0 CA-C-O 117.494 -1.241 . . . . 74.34 110.185 -176.017 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.7 m-85 -141.57 175.63 9.53 Favored 'General case' 0 C--N 1.357 0.925 0 CA-C-O 118.3 -0.857 . . . . 74.41 110.246 -178.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -59.75 169.39 1.4 Allowed 'General case' 0 C--N 1.355 0.82 0 CA-C-N 119.688 1.131 . . . . 74.41 111.438 -173.201 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.581 0 N-CA-C 109.444 -1.462 . . . . 71.35 109.444 173.683 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.676 0 CA-C-O 118.316 -1.269 . . . . 74.31 112.64 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.05 -144.66 4.39 Favored Glycine 0 C--N 1.354 1.55 0 CA-C-O 117.351 -1.805 . . . . 72.23 111.467 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.01 46.26 1.08 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.782 1.791 . . . . 71.22 111.48 -179.113 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.84 -144.17 14.11 Favored Glycine 0 C--N 1.353 1.508 0 CA-C-O 118.102 -1.388 . . . . 65.23 110.195 179.151 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -88.95 -42.51 11.76 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.019 1.41 . . . . 74.24 113.508 -178.213 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.1 t -93.87 133.41 27.8 Favored Pre-proline 0 C--N 1.353 0.755 0 CA-C-O 115.446 -2.216 . . . . 72.52 109.478 -166.247 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -65.32 144.41 80.35 Favored 'Trans proline' 0 C--N 1.363 1.312 0 CA-C-N 123.943 2.444 . . . . 75.53 111.866 -177.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -81.5 -51.39 8.33 Favored 'General case' 0 C--N 1.358 0.968 0 N-CA-C 108.359 -0.978 . . . . 71.42 108.359 179.001 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.4 p90 -148.87 172.06 15.29 Favored 'General case' 0 C--N 1.354 0.796 0 CA-C-O 118.535 -0.745 . . . . 74.32 109.941 -177.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -125.01 170.27 11.3 Favored 'General case' 0 C--N 1.355 0.845 0 CA-C-O 118.857 -0.592 . . . . 74.21 109.614 -177.16 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -94.67 -170.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.808 0 N-CA-C 106.563 -1.643 . . . . 74.41 106.563 177.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.1 mtt180 -70.08 75.32 0.49 Allowed 'General case' 0 C--N 1.354 0.771 0 CA-C-N 119.876 1.216 . . . . 74.44 109.924 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.72 78.02 0.24 Allowed Glycine 0 C--N 1.355 1.587 0 CA-C-O 118.11 -1.383 . . . . 72.4 113.579 172.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -162.62 -63.31 0.05 OUTLIER 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.204 1.502 . . . . 63.13 111.296 172.101 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -172.92 143.99 1.17 Allowed Pre-proline 0 C--N 1.356 0.855 0 CA-C-O 115.713 -2.089 . . . . 73.41 108.281 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.52 170.74 19.61 Favored 'Trans proline' 0 C--N 1.357 0.984 0 CA-C-N 123.835 2.405 . . . . 75.51 111.17 -177.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -135.77 39.94 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.977 0 N-CA-C 108.488 -0.93 . . . . 74.31 108.488 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.433 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 19.2 p 175.1 155.42 0.15 Allowed 'General case' 0 C--N 1.353 0.747 0 CA-C-O 117.795 -1.097 . . . . 72.03 110.932 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.6 m-85 -142.59 175.19 9.99 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.049 -0.977 . . . . 72.32 110.169 -179.756 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.428 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.8 m-30 -58.46 172.43 0.48 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.509 1.05 . . . . 74.44 111.333 -174.05 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.528 0 N-CA-C 109.18 -1.568 . . . . 74.32 109.18 174.201 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.681 0 CA-C-O 118.145 -1.364 . . . . 63.0 112.89 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.85 -142.12 3.41 Favored Glycine 0 C--N 1.354 1.552 0 CA-C-O 117.177 -1.902 . . . . 75.11 112.144 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.8 46.22 1.02 Allowed 'General case' 0 C--N 1.358 0.945 0 CA-C-N 119.887 1.843 . . . . 71.34 111.697 -178.44 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.62 -144.56 15.59 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.146 -1.363 . . . . 53.01 110.6 179.559 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.2 m80 -87.44 -41.82 13.26 Favored 'General case' 0 C--N 1.356 0.88 0 CA-C-N 118.788 1.294 . . . . 71.43 113.141 -177.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -97.45 134.57 22.43 Favored Pre-proline 0 C--N 1.354 0.785 0 CA-C-O 115.397 -2.239 . . . . 61.44 109.693 -166.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -65.74 144.25 77.15 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 123.909 2.432 . . . . 75.1 111.81 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -81.52 -51.42 8.29 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.48 -0.933 . . . . 71.03 108.48 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -148.37 172.0 15.11 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-O 118.366 -0.826 . . . . 73.33 109.553 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -124.34 170.13 11.12 Favored 'General case' 0 C--N 1.355 0.823 0 O-C-N 123.781 0.675 . . . . 74.24 109.628 -177.084 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 m -92.59 -166.29 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 106.477 -1.675 . . . . 73.41 106.477 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 42.8 mtp180 -75.52 69.08 2.24 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-N 120.005 1.275 . . . . 75.51 109.56 175.425 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.29 78.21 0.46 Allowed Glycine 0 C--N 1.356 1.669 0 CA-C-O 118.01 -1.439 . . . . 74.2 113.208 174.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -164.28 -63.45 0.04 OUTLIER 'General case' 0 C--N 1.357 0.916 0 CA-C-N 119.376 1.588 . . . . 64.44 111.503 172.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -171.5 144.52 1.63 Allowed Pre-proline 0 C--N 1.355 0.809 0 CA-C-O 115.511 -2.185 . . . . 75.31 108.307 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -75.36 171.36 18.41 Favored 'Trans proline' 0 C--N 1.357 1.01 0 CA-C-N 123.95 2.447 . . . . 72.32 111.361 -177.497 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -136.06 40.33 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 108.413 -0.958 . . . . 75.02 108.413 178.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.8 p 174.31 155.93 0.13 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.77 -1.11 . . . . 55.02 111.08 -177.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.6 m-85 -143.25 175.91 9.53 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-O 118.283 -0.865 . . . . 64.41 110.559 -179.489 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.0 m-30 -60.13 176.57 0.31 Allowed 'General case' 0 C--N 1.356 0.866 0 CA-C-N 119.354 0.979 . . . . 75.21 111.775 -174.268 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.594 0 C-N-CA 119.514 -1.327 . . . . 72.42 109.894 173.474 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.119 -1.378 . . . . 73.21 112.414 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.84 -142.94 3.99 Favored Glycine 0 C--N 1.354 1.566 0 CA-C-N 119.897 1.848 . . . . 61.52 111.802 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.53 45.75 1.21 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 119.843 1.822 . . . . 70.31 111.171 -179.013 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.91 -143.57 12.24 Favored Glycine 0 C--N 1.353 1.516 0 CA-C-O 118.049 -1.417 . . . . 63.45 110.641 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -89.34 -41.49 12.11 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-N 118.765 1.283 . . . . 73.54 112.89 -176.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.7 t -98.6 135.29 21.14 Favored Pre-proline 0 C--N 1.353 0.748 0 CA-C-O 115.363 -2.256 . . . . 65.15 109.661 -166.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -66.66 144.7 73.16 Favored 'Trans proline' 0 C--N 1.362 1.254 0 CA-C-N 124.036 2.477 . . . . 73.22 112.43 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.78 -52.11 5.7 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.275 0.943 . . . . 72.1 108.893 178.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -132.18 174.69 9.95 Favored 'General case' 0 C--N 1.354 0.778 0 CA-C-O 118.731 -0.652 . . . . 61.44 109.449 -174.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -134.76 170.56 15.64 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-O 118.742 -0.647 . . . . 73.32 109.305 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -100.91 -170.4 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.12 -1.437 . . . . 72.32 107.12 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 ttp180 -78.68 65.81 4.03 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-N 120.003 1.274 . . . . 75.34 109.177 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 79.73 77.9 0.91 Allowed Glycine 0 C--N 1.356 1.69 0 CA-C-O 117.986 -1.452 . . . . 61.44 113.438 175.436 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -165.23 -71.96 0.03 OUTLIER 'General case' 0 C--N 1.358 0.952 0 CA-C-N 119.452 1.626 . . . . 72.22 110.8 170.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.98 150.69 6.34 Favored Pre-proline 0 C--N 1.355 0.818 0 CA-C-O 115.777 -2.059 . . . . 64.44 106.996 -179.024 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.67 173.05 15.16 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.733 2.369 . . . . 74.33 111.432 -176.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -134.25 38.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 108.419 -0.956 . . . . 73.52 108.419 178.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.468 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.8 p 175.08 157.36 0.17 Allowed 'General case' 0 C--N 1.354 0.781 0 CA-C-O 117.445 -1.264 . . . . 72.24 110.798 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.468 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -144.54 176.68 9.22 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 118.267 -0.873 . . . . 73.02 110.378 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.421 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.17 174.45 0.39 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-N 119.567 1.076 . . . . 74.23 111.382 -174.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.508 0 CA-C-N 120.143 1.338 . . . . 74.54 111.798 176.85 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.293 -1.282 . . . . 71.52 112.885 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.61 -144.03 4.29 Favored Glycine 0 C--N 1.354 1.543 0 CA-C-O 117.415 -1.769 . . . . 45.55 111.614 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.61 46.16 1.29 Allowed 'General case' 0 C--N 1.356 0.887 0 CA-C-N 119.751 1.776 . . . . 75.25 110.677 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.61 -139.63 9.2 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 118.034 -1.426 . . . . 53.02 110.798 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -95.31 -35.68 11.69 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 117.482 -1.247 . . . . 71.32 113.285 -173.102 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -105.52 136.13 19.28 Favored Pre-proline 0 C--N 1.355 0.824 0 CA-C-O 115.414 -2.231 . . . . 74.42 109.285 -169.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -66.99 143.78 67.36 Favored 'Trans proline' 0 C--N 1.361 1.211 0 CA-C-N 123.894 2.427 . . . . 73.21 112.289 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.3 mt-10 -85.73 -48.73 8.55 Favored 'General case' 0 C--N 1.358 0.954 0 CA-C-N 118.886 0.766 . . . . 75.11 109.413 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -134.71 175.02 9.93 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.84 -0.6 . . . . 70.01 109.548 -173.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -135.44 171.19 14.8 Favored 'General case' 0 C--N 1.353 0.744 0 N-CA-C 109.105 -0.702 . . . . 74.43 109.105 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.5 m -103.31 -170.32 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.746 0 N-CA-C 107.225 -1.398 . . . . 71.33 107.225 -177.428 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -72.5 71.32 0.94 Allowed 'General case' 0 C--N 1.353 0.735 0 CA-C-N 119.146 0.885 . . . . 73.33 108.885 172.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.24 80.41 0.2 Allowed Glycine 0 C--N 1.355 1.595 0 CA-C-O 118.19 -1.339 . . . . 73.44 113.812 173.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -164.25 -70.9 0.04 OUTLIER 'General case' 0 C--N 1.357 0.895 0 CA-C-N 119.241 1.52 . . . . 73.1 110.37 170.558 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.83 150.27 6.32 Favored Pre-proline 0 C--N 1.355 0.826 0 CA-C-O 115.871 -2.014 . . . . 72.55 106.839 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -75.42 172.77 15.69 Favored 'Trans proline' 0 C--N 1.356 0.93 0 CA-C-N 123.58 2.314 . . . . 74.45 111.319 -176.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.1 mt -135.32 41.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.981 0 N-CA-C 108.321 -0.992 . . . . 74.21 108.321 178.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.449 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 171.99 156.77 0.09 Allowed 'General case' 0 C--N 1.354 0.803 0 CA-C-O 117.889 -1.053 . . . . 75.42 110.676 -179.266 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.9 m-85 -142.96 177.8 8.11 Favored 'General case' 0 C--N 1.358 0.96 0 CA-C-O 118.106 -0.95 . . . . 71.31 110.123 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.1 m-30 -59.43 175.73 0.31 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.713 1.142 . . . . 74.41 111.234 -174.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.611 0 N-CA-C 109.932 -1.267 . . . . 70.23 109.932 176.422 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.66 0 CA-C-O 118.663 -1.076 . . . . 74.31 111.942 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.98 -144.98 5.52 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.497 -1.724 . . . . 71.43 111.852 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.99 45.67 1.17 Allowed 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.633 1.716 . . . . 73.15 111.374 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.25 -142.47 11.79 Favored Glycine 0 C--N 1.354 1.532 0 CA-C-O 118.033 -1.426 . . . . 64.41 110.494 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.3 m170 -88.57 -45.99 9.44 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 118.983 1.391 . . . . 63.21 113.144 -177.21 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -93.2 134.39 27.13 Favored Pre-proline 0 C--N 1.353 0.732 0 CA-C-O 115.637 -2.125 . . . . 74.04 109.44 -165.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -66.64 143.99 70.47 Favored 'Trans proline' 0 C--N 1.363 1.3 0 CA-C-N 123.822 2.401 . . . . 74.01 112.183 -177.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.4 mt-10 -86.31 -50.82 6.65 Favored 'General case' 0 C--N 1.358 0.935 0 CA-C-N 118.806 0.73 . . . . 63.55 109.211 178.02 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -133.44 174.0 10.88 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-O 118.853 -0.594 . . . . 71.51 109.939 -174.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -135.07 170.82 15.32 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 118.694 -0.669 . . . . 75.34 109.256 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -102.63 -169.63 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.737 0 N-CA-C 107.031 -1.47 . . . . 64.55 107.031 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -73.45 70.98 1.28 Allowed 'General case' 0 C--N 1.353 0.729 0 CA-C-N 119.643 1.11 . . . . 74.31 108.875 173.027 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.97 80.33 0.22 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.118 -1.379 . . . . 61.22 113.621 173.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.67 -68.87 0.05 OUTLIER 'General case' 0 C--N 1.356 0.858 0 CA-C-N 119.155 1.477 . . . . 75.02 109.959 170.066 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -168.56 149.44 4.42 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.964 -1.97 . . . . 74.11 106.895 178.773 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -75.53 173.42 14.53 Favored 'Trans proline' 0 C--N 1.356 0.973 0 CA-C-N 123.529 2.296 . . . . 64.43 111.226 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.5 39.37 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.906 0 N-CA-C 108.479 -0.934 . . . . 74.03 108.479 179.053 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.462 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.5 p 174.96 157.13 0.16 Allowed 'General case' 0 C--N 1.354 0.766 0 CA-C-O 117.714 -1.136 . . . . 72.13 111.01 -177.043 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.462 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.1 m-85 -144.53 176.7 9.2 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-O 118.248 -0.882 . . . . 73.4 110.285 -179.722 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.414 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.17 169.63 1.08 Allowed 'General case' 0 C--N 1.355 0.812 0 CA-C-N 119.652 1.115 . . . . 75.44 111.534 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.513 0 C-N-CA 119.303 -1.427 . . . . 62.41 111.491 176.457 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.65 0 CA-C-O 117.919 -1.49 . . . . 72.15 113.325 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.76 -141.77 3.23 Favored Glycine 0 C--N 1.354 1.577 0 CA-C-N 120.159 1.98 . . . . 63.31 111.527 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.62 46.01 1.11 Allowed 'General case' 0 C--N 1.358 0.935 0 CA-C-N 119.898 1.849 . . . . 72.43 111.018 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.66 -137.95 7.81 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 117.788 -1.562 . . . . 51.02 110.844 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -100.76 -24.7 14.34 Favored 'General case' 0 C--N 1.359 0.99 0 CA-C-O 116.653 -1.641 . . . . 75.43 114.039 -172.54 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.3 t -114.21 135.25 22.15 Favored Pre-proline 0 C--N 1.356 0.891 0 CA-C-O 115.384 -2.246 . . . . 75.25 108.685 -171.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -65.96 144.27 75.83 Favored 'Trans proline' 0 C--N 1.361 1.21 0 CA-C-N 123.884 2.423 . . . . 75.22 111.788 -176.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -81.37 -50.67 9.2 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.255 -1.017 . . . . 75.33 108.255 178.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -149.22 172.2 15.24 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.472 -0.775 . . . . 62.31 109.863 -177.686 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -127.13 168.59 14.44 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.466 -0.778 . . . . 72.13 109.506 -177.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.418 ' O ' ' N ' ' A' ' 13' ' ' GLY . 3.1 m -94.65 -176.99 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.805 0 N-CA-C 107.334 -1.358 . . . . 75.31 107.334 176.181 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -55.2 76.47 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 CA-C-N 118.309 0.504 . . . . 74.31 111.895 170.44 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . 0.418 ' N ' ' O ' ' A' ' 11' ' ' VAL . . . 57.49 78.44 0.13 Allowed Glycine 0 C--N 1.354 1.576 0 CA-C-O 118.056 -1.414 . . . . 74.23 114.097 172.521 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -161.26 -61.86 0.05 Allowed 'General case' 0 C--N 1.356 0.88 0 CA-C-N 119.414 1.607 . . . . 52.14 111.805 173.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -174.52 145.51 0.99 Allowed Pre-proline 0 C--N 1.355 0.833 0 CA-C-O 115.777 -2.059 . . . . 75.02 108.448 -178.605 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.56 168.52 24.26 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.677 2.349 . . . . 74.22 111.205 -178.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.7 mt -137.45 44.3 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 107.751 -1.203 . . . . 64.41 107.751 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.45 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.0 p 170.03 155.6 0.05 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.878 -1.058 . . . . 63.33 110.496 -179.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.45 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.9 m-85 -141.88 175.82 9.42 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.291 -0.862 . . . . 75.25 109.984 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.437 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -57.98 172.13 0.45 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.497 1.044 . . . . 71.4 111.484 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 1.641 0 N-CA-C 108.308 -1.917 . . . . 75.15 108.308 174.304 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 CA-C-O 118.357 -1.246 . . . . 73.51 112.267 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.62 -143.19 3.87 Favored Glycine 0 C--N 1.355 1.592 0 CA-C-O 117.135 -1.925 . . . . 70.11 111.655 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.52 45.79 1.12 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.957 1.878 . . . . 74.2 111.105 -178.489 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.94 -144.2 14.27 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.169 -1.351 . . . . 52.51 110.707 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.7 m-70 -88.78 -40.81 12.93 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 118.829 1.314 . . . . 74.54 113.026 -176.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -99.26 135.5 20.73 Favored Pre-proline 0 C--N 1.354 0.775 0 CA-C-O 115.233 -2.318 . . . . 72.14 109.389 -166.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -66.8 144.89 73.05 Favored 'Trans proline' 0 C--N 1.364 1.344 0 CA-C-N 124.001 2.464 . . . . 73.41 111.879 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -82.64 -51.28 7.89 Favored 'General case' 0 C--N 1.359 0.989 0 N-CA-C 108.392 -0.966 . . . . 72.41 108.392 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -149.53 172.95 14.16 Favored 'General case' 0 C--N 1.356 0.861 0 CA-C-O 118.155 -0.926 . . . . 74.41 109.747 -177.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -126.36 168.55 14.01 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 118.551 -0.738 . . . . 74.11 109.974 -176.916 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -90.09 -169.99 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.881 0 N-CA-C 106.645 -1.613 . . . . 71.25 106.645 177.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -70.73 75.12 0.6 Allowed 'General case' 0 C--N 1.353 0.718 0 CA-C-N 119.479 1.036 . . . . 74.23 109.153 176.198 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.1 77.45 0.35 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 118.107 -1.385 . . . . 64.21 113.058 173.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -160.03 -65.12 0.07 Allowed 'General case' 0 C--N 1.357 0.919 0 CA-C-N 119.188 1.494 . . . . 55.1 111.279 171.45 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.09 154.56 3.41 Favored Pre-proline 0 C--N 1.355 0.814 0 CA-C-O 116.027 -1.94 . . . . 74.31 107.6 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -80.87 155.99 20.5 Favored 'Trans proline' 0 C--N 1.36 1.174 0 CA-C-N 123.698 2.357 . . . . 75.0 111.257 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.5 mm -118.73 17.75 6.85 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-O 118.284 -0.865 . . . . 73.33 109.23 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 7.1 m -165.9 158.87 15.29 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 121.102 1.774 . . . . 71.32 110.558 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -142.8 174.94 10.21 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 119.789 1.177 . . . . 73.11 110.713 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.432 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.18 174.02 0.43 Allowed 'General case' 0 C--N 1.356 0.855 0 CA-C-N 119.242 0.928 . . . . 73.2 111.266 -174.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.483 0 N-CA-C 109.036 -1.626 . . . . 70.11 109.036 175.558 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.734 0 CA-C-O 118.463 -1.187 . . . . 75.3 112.278 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.77 -147.08 6.17 Favored Glycine 0 C--N 1.355 1.597 0 CA-C-O 117.486 -1.73 . . . . 75.24 111.859 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.2 46.34 1.15 Allowed 'General case' 0 C--N 1.357 0.925 0 CA-C-N 119.78 1.79 . . . . 72.13 111.357 -178.508 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.18 -144.69 15.42 Favored Glycine 0 C--N 1.354 1.57 0 CA-C-O 117.9 -1.5 . . . . 54.44 110.249 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -87.76 -43.1 12.13 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-N 119.142 1.471 . . . . 73.21 112.926 -177.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -96.4 134.98 22.74 Favored Pre-proline 0 C--N 1.354 0.764 0 CA-C-O 115.199 -2.334 . . . . 72.34 109.814 -165.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.22 145.05 83.19 Favored 'Trans proline' 0 C--N 1.363 1.323 0 CA-C-N 124.146 2.517 . . . . 72.53 112.257 -177.432 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 75.9 mt-10 -82.45 -52.14 7.16 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 108.177 -1.045 . . . . 54.43 108.177 178.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -149.32 173.0 13.98 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-O 118.414 -0.803 . . . . 75.5 109.685 -177.4 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -126.4 169.55 12.85 Favored 'General case' 0 C--N 1.354 0.804 0 CA-C-O 118.505 -0.759 . . . . 74.02 110.095 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -93.41 -171.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 N-CA-C 106.872 -1.529 . . . . 74.41 106.872 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.3 mtt-85 -70.38 76.1 0.55 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.826 1.194 . . . . 75.34 109.879 173.719 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.57 76.97 0.4 Allowed Glycine 0 C--N 1.355 1.613 0 CA-C-O 118.048 -1.418 . . . . 62.03 113.267 172.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -160.59 -67.16 0.07 Allowed 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.203 1.502 . . . . 75.44 110.934 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.07 153.06 3.04 Favored Pre-proline 0 C--N 1.353 0.753 0 CA-C-O 115.754 -2.07 . . . . 75.21 107.253 -178.423 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.38 171.51 15.9 Favored 'Trans proline' 0 C--N 1.357 1.022 0 CA-C-N 123.911 2.433 . . . . 70.42 111.661 -177.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.3 mt -135.9 41.37 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.799 -1.186 . . . . 73.24 107.799 177.072 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.434 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 2.7 p 174.5 156.65 0.15 Allowed 'General case' 0 C--N 1.354 0.774 0 CA-C-O 117.809 -1.091 . . . . 73.45 110.731 -178.034 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.434 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.7 m-85 -143.76 175.69 9.8 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.133 -0.937 . . . . 75.4 110.071 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.78 176.15 0.22 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.654 1.115 . . . . 73.24 111.351 -174.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.574 0 CA-C-N 120.227 1.376 . . . . 65.01 110.641 176.51 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.715 0 CA-C-O 118.521 -1.155 . . . . 73.3 111.246 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.3 -146.45 5.82 Favored Glycine 0 C--N 1.354 1.58 0 CA-C-O 117.389 -1.784 . . . . 74.45 111.753 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.96 45.92 1.09 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.718 1.759 . . . . 65.04 111.318 -178.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.7 -139.65 9.72 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.806 -1.552 . . . . 74.52 110.62 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -93.52 -38.81 11.2 Favored 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.045 1.422 . . . . 63.12 113.151 -174.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.4 t -101.67 135.17 19.83 Favored Pre-proline 0 C--N 1.354 0.799 0 CA-C-O 115.149 -2.358 . . . . 73.34 109.495 -167.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.94 144.53 76.89 Favored 'Trans proline' 0 C--N 1.362 1.255 0 CA-C-N 124.165 2.523 . . . . 73.24 112.218 -176.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -81.87 -51.77 7.77 Favored 'General case' 0 C--N 1.358 0.94 0 CA-C-N 119.486 1.039 . . . . 70.31 108.313 178.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -149.19 172.38 14.93 Favored 'General case' 0 C--N 1.353 0.757 0 CA-C-O 118.342 -0.837 . . . . 70.43 110.116 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -124.77 171.34 10.19 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-O 118.665 -0.683 . . . . 74.45 110.016 -176.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 m -94.87 -166.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 107.484 -1.302 . . . . 72.33 107.484 -178.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 tpt180 -71.01 67.22 0.41 Allowed 'General case' 0 C--N 1.355 0.813 0 CA-C-N 119.801 1.182 . . . . 75.32 109.292 173.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.15 79.39 0.29 Allowed Glycine 0 C--N 1.355 1.604 0 CA-C-O 117.844 -1.531 . . . . 74.01 113.546 176.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -161.1 -71.81 0.06 Allowed 'General case' 0 C--N 1.358 0.972 0 CA-C-N 119.579 1.689 . . . . 72.32 110.48 170.044 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -163.17 154.56 14.73 Favored Pre-proline 0 C--N 1.355 0.828 0 CA-C-O 116.058 -1.925 . . . . 73.11 107.249 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -78.07 169.28 20.65 Favored 'Trans proline' 0 C--N 1.358 1.069 0 CA-C-N 123.577 2.313 . . . . 73.13 111.238 -177.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -133.37 36.38 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.702 -1.221 . . . . 73.34 107.702 175.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -173.86 158.73 3.27 Favored 'General case' 0 C--N 1.353 0.742 0 CA-C-O 116.702 -1.618 . . . . 43.01 110.204 -177.122 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.5 m-85 -145.21 173.64 11.77 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-N 119.538 1.063 . . . . 65.33 110.053 174.382 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.5 171.31 0.85 Allowed 'General case' 0 C--N 1.354 0.793 0 CA-C-N 119.711 1.141 . . . . 74.34 111.049 -174.267 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.496 0 CA-C-N 120.471 1.487 . . . . 70.43 111.472 175.135 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 CA-C-O 118.486 -1.174 . . . . 73.15 112.13 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.15 -144.12 5.18 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.496 -1.724 . . . . 62.35 112.252 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.94 44.78 1.26 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.526 1.663 . . . . 74.15 111.042 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.64 -141.69 9.42 Favored Glycine 0 C--N 1.353 1.521 0 CA-C-O 118.076 -1.402 . . . . 72.11 110.825 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -93.01 -39.24 11.22 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 118.69 1.245 . . . . 71.35 113.177 -175.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.1 t -99.62 135.12 20.67 Favored Pre-proline 0 C--N 1.353 0.743 0 CA-C-O 115.385 -2.245 . . . . 55.4 109.233 -168.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -66.78 144.27 70.7 Favored 'Trans proline' 0 C--N 1.362 1.244 0 CA-C-N 123.907 2.431 . . . . 64.03 112.22 -177.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.9 mt-10 -86.13 -51.53 6.25 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 118.9 0.773 . . . . 72.33 109.167 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -132.18 174.31 10.34 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 118.91 -0.567 . . . . 71.23 109.543 -174.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -134.06 171.8 13.72 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.099 -0.704 . . . . 72.5 109.099 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -104.28 -165.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.775 0 N-CA-C 106.939 -1.504 . . . . 72.15 106.939 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -74.95 67.22 1.66 Allowed 'General case' 0 C--N 1.352 0.705 0 CA-C-N 119.602 1.092 . . . . 74.12 108.93 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 66.75 80.63 0.18 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 117.963 -1.465 . . . . 65.55 113.615 175.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -164.87 -64.03 0.03 OUTLIER 'General case' 0 C--N 1.358 0.941 0 CA-C-N 119.486 1.643 . . . . 70.23 111.028 172.626 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -169.87 143.28 2.09 Favored Pre-proline 0 C--N 1.354 0.773 0 CA-C-O 115.756 -2.069 . . . . 73.01 108.364 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -73.74 173.19 14.37 Favored 'Trans proline' 0 C--N 1.359 1.094 0 CA-C-N 123.956 2.449 . . . . 64.52 111.087 -177.481 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -135.05 38.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 108.631 -0.877 . . . . 75.51 108.631 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.9 p 175.52 156.88 0.2 Allowed 'General case' 0 C--N 1.355 0.835 0 CA-C-O 117.706 -1.14 . . . . 65.41 110.902 -176.802 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.6 m-85 -144.81 176.38 9.49 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-O 118.291 -0.861 . . . . 74.44 110.542 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.23 174.4 0.29 Allowed 'General case' 0 C--N 1.355 0.823 0 CA-C-N 119.369 0.986 . . . . 75.43 112.117 -174.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.639 0 N-CA-C 109.34 -1.504 . . . . 72.45 109.34 176.648 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 CA-C-O 118.529 -1.151 . . . . 65.23 112.108 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.29 -144.97 5.58 Favored Glycine 0 C--N 1.355 1.617 0 CA-C-O 117.43 -1.761 . . . . 72.03 111.61 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.34 45.6 1.23 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-N 119.717 1.759 . . . . 70.11 111.099 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.35 -145.79 17.03 Favored Glycine 0 C--N 1.354 1.53 0 CA-C-O 118.256 -1.302 . . . . 70.21 110.529 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -85.89 -45.99 11.02 Favored 'General case' 0 C--N 1.357 0.892 0 CA-C-N 118.928 1.364 . . . . 61.25 112.91 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -92.76 134.74 27.16 Favored Pre-proline 0 C--N 1.354 0.795 0 CA-C-O 115.312 -2.28 . . . . 74.33 109.678 -164.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.45 143.8 64.73 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 123.876 2.42 . . . . 73.4 112.281 -177.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -86.11 -47.44 9.52 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 118.885 0.766 . . . . 75.24 109.364 177.924 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -135.83 175.76 9.3 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 118.668 -0.682 . . . . 70.24 109.724 -173.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -136.14 170.41 16.06 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 118.771 -0.633 . . . . 74.02 109.301 178.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.66 -167.53 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.787 0 N-CA-C 106.854 -1.536 . . . . 75.21 106.854 -178.554 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -76.05 65.62 2.11 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-N 120.309 1.413 . . . . 75.24 109.286 175.357 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 72.85 79.67 0.46 Allowed Glycine 0 C--N 1.356 1.66 0 CA-C-O 117.884 -1.509 . . . . 73.5 113.552 175.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -165.16 -65.81 0.03 OUTLIER 'General case' 0 C--N 1.359 1.019 0 CA-C-N 119.582 1.691 . . . . 75.11 111.376 171.616 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.4 t -169.49 142.95 2.2 Favored Pre-proline 0 C--N 1.355 0.813 0 CA-C-O 115.644 -2.122 . . . . 74.3 108.437 179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.51 172.77 15.04 Favored 'Trans proline' 0 C--N 1.359 1.098 0 CA-C-N 124.036 2.477 . . . . 71.52 111.542 -176.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -135.46 40.71 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.927 0 N-CA-C 108.629 -0.878 . . . . 75.42 108.629 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.457 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.2 p 173.85 156.75 0.13 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-O 117.713 -1.137 . . . . 73.2 110.617 -178.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.457 ' CD1' ' C ' ' A' ' 18' ' ' SER . 33.1 m-85 -144.18 177.37 8.64 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-O 118.324 -0.846 . . . . 75.32 110.636 -178.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.412 ' O ' ' N ' ' A' ' 4' ' ' GLY . 7.9 m-30 -60.03 173.97 0.56 Allowed 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.547 1.067 . . . . 74.03 111.346 -174.018 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.634 0 N-CA-C 110.375 -1.09 . . . . 75.41 110.375 176.184 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.687 0 CA-C-O 118.063 -1.41 . . . . 73.31 112.331 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.46 -140.75 3.81 Favored Glycine 0 C--N 1.354 1.546 0 CA-C-N 120.011 1.906 . . . . 64.11 112.287 178.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.12 44.95 1.25 Allowed 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.799 1.799 . . . . 72.44 110.947 -178.491 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.07 -141.44 8.85 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.971 -1.46 . . . . 71.53 110.939 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -94.99 -34.71 12.25 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 117.224 -1.37 . . . . 74.41 112.927 -173.197 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -105.76 136.16 19.31 Favored Pre-proline 0 C--N 1.355 0.817 0 CA-C-O 115.362 -2.256 . . . . 74.11 109.159 -169.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -66.75 144.57 72.07 Favored 'Trans proline' 0 C--N 1.362 1.267 0 CA-C-N 124.097 2.499 . . . . 75.02 112.29 -177.346 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -86.77 -51.53 6.04 Favored 'General case' 0 C--N 1.358 0.956 0 CA-C-N 119.155 0.889 . . . . 65.44 108.896 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -131.41 174.52 9.99 Favored 'General case' 0 C--N 1.355 0.84 0 CA-C-O 118.738 -0.648 . . . . 74.14 109.314 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -134.35 170.39 15.8 Favored 'General case' 0 C--N 1.354 0.765 0 CA-C-O 118.607 -0.711 . . . . 75.03 109.187 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.21 -169.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.764 0 N-CA-C 106.728 -1.582 . . . . 73.53 106.728 -179.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 86.8 mtm-85 -77.69 68.58 3.8 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-N 120.061 1.3 . . . . 74.23 109.249 174.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 75.03 77.78 0.67 Allowed Glycine 0 C--N 1.358 1.754 0 CA-C-O 117.768 -1.573 . . . . 62.5 113.618 173.056 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -165.63 -65.45 0.03 OUTLIER 'General case' 0 C--N 1.358 0.971 0 CA-C-N 119.517 1.659 . . . . 74.25 111.42 172.225 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -171.0 143.77 1.68 Allowed Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.644 -2.122 . . . . 71.12 108.327 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -73.15 172.43 15.56 Favored 'Trans proline' 0 C--N 1.359 1.079 0 CA-C-N 123.989 2.46 . . . . 74.22 111.517 -176.889 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -134.14 38.82 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.939 0 N-CA-C 108.506 -0.924 . . . . 74.13 108.506 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.469 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 173.93 156.18 0.13 Allowed 'General case' 0 C--N 1.355 0.826 0 CA-C-N 119.735 1.152 . . . . 62.03 110.79 -176.877 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.469 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.2 m-85 -144.43 176.74 9.15 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-O 118.288 -0.863 . . . . 72.31 110.556 -178.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.409 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.46 176.39 0.19 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-N 119.2 0.909 . . . . 74.41 112.144 -174.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.632 0 N-CA-C 109.864 -1.295 . . . . 65.44 109.864 176.758 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.118 -1.379 . . . . 63.24 112.618 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.46 -141.94 3.6 Favored Glycine 0 C--N 1.355 1.6 0 CA-C-N 120.001 1.9 . . . . 73.14 111.735 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.93 46.01 1.17 Allowed 'General case' 0 C--N 1.357 0.912 0 CA-C-N 119.965 1.882 . . . . 75.32 111.169 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.01 -145.0 14.56 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.075 -1.403 . . . . 54.23 110.415 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 4.0 m80 -87.85 -42.29 12.64 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-N 118.86 1.33 . . . . 75.05 112.808 -177.103 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.7 t -96.87 134.96 22.37 Favored Pre-proline 0 C--N 1.353 0.734 0 CA-C-O 115.402 -2.237 . . . . 72.0 109.788 -166.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.95 143.77 67.59 Favored 'Trans proline' 0 C--N 1.362 1.253 0 CA-C-N 124.028 2.474 . . . . 74.23 112.158 -177.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 -86.18 -49.5 7.69 Favored 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.238 0.927 . . . . 71.21 109.111 178.266 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -133.13 175.54 9.29 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.697 -0.668 . . . . 75.25 109.331 -174.093 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -135.87 169.86 16.91 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.15 -0.685 . . . . 73.41 109.15 177.505 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -101.3 -169.4 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.757 0 N-CA-C 106.502 -1.666 . . . . 74.45 106.502 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.7 mtm180 -74.4 70.64 1.73 Allowed 'General case' 0 C--N 1.354 0.764 0 CA-C-N 120.038 1.29 . . . . 75.12 109.725 173.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.05 79.07 0.29 Allowed Glycine 0 C--N 1.355 1.619 0 CA-C-O 118.087 -1.396 . . . . 45.44 113.373 173.322 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -164.75 -64.7 0.04 OUTLIER 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.249 1.524 . . . . 73.13 110.903 172.371 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -170.99 143.2 1.6 Allowed Pre-proline 0 C--N 1.355 0.805 0 CA-C-O 115.551 -2.166 . . . . 75.24 108.416 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.16 172.52 15.38 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 124.023 2.472 . . . . 72.13 111.544 -176.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.3 mt -134.92 40.81 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.957 0 N-CA-C 108.587 -0.894 . . . . 74.0 108.587 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.6 p 172.8 156.56 0.1 Allowed 'General case' 0 C--N 1.353 0.754 0 CA-C-O 117.776 -1.107 . . . . 71.43 110.581 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.8 m-85 -142.99 176.7 8.89 Favored 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.169 -0.92 . . . . 72.13 110.238 -178.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.423 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.84 173.07 0.46 Allowed 'General case' 0 C--N 1.355 0.807 0 CA-C-N 119.619 1.099 . . . . 75.3 111.272 -174.031 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.48 0 N-CA-C 108.656 -1.778 . . . . 74.15 108.656 174.73 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 CA-C-O 118.275 -1.292 . . . . 62.21 112.026 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.49 -142.66 4.1 Favored Glycine 0 C--N 1.355 1.588 0 CA-C-O 117.224 -1.875 . . . . 74.03 111.812 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.48 45.71 1.13 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.972 1.886 . . . . 61.15 111.289 -178.877 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.425 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.4 -145.96 17.54 Favored Glycine 0 C--N 1.354 1.549 0 CA-C-O 118.179 -1.345 . . . . 61.15 110.626 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -85.71 -43.8 13.08 Favored 'General case' 0 C--N 1.357 0.894 0 CA-C-N 118.904 1.352 . . . . 74.01 112.884 -177.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.0 t -95.06 134.48 24.65 Favored Pre-proline 0 C--N 1.353 0.726 0 CA-C-O 115.257 -2.306 . . . . 74.4 109.959 -165.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -66.63 144.32 71.78 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 124.024 2.473 . . . . 72.44 112.229 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -86.67 -52.22 5.66 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.322 0.965 . . . . 62.52 108.755 178.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -131.09 174.51 9.95 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 118.713 -0.661 . . . . 73.15 109.392 -174.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -134.42 170.72 15.32 Favored 'General case' 0 C--N 1.353 0.755 0 N-CA-C 109.038 -0.727 . . . . 74.53 109.038 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -102.38 -169.53 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 N-CA-C 106.933 -1.506 . . . . 65.4 106.933 -178.863 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.2 ttm180 -70.05 70.71 0.37 Allowed 'General case' 0 C--N 1.352 0.688 0 CA-C-N 119.394 0.997 . . . . 74.42 109.312 172.281 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.43 81.63 0.1 OUTLIER Glycine 0 C--N 1.355 1.591 0 CA-C-O 117.956 -1.469 . . . . 63.53 113.918 174.621 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -164.94 -64.41 0.03 OUTLIER 'General case' 0 C--N 1.357 0.911 0 CA-C-N 119.525 1.662 . . . . 72.52 110.966 171.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -170.37 142.95 1.83 Allowed Pre-proline 0 C--N 1.354 0.783 0 CA-C-O 115.616 -2.135 . . . . 71.13 108.387 178.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.3 172.51 15.46 Favored 'Trans proline' 0 C--N 1.359 1.115 0 CA-C-N 124.016 2.47 . . . . 73.41 111.237 -177.06 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -134.35 38.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 N-CA-C 108.46 -0.941 . . . . 75.14 108.46 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.0 p 175.26 157.01 0.18 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.581 -1.199 . . . . 62.42 110.733 -176.707 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.1 m-85 -144.89 176.26 9.6 Favored 'General case' 0 C--N 1.358 0.97 0 CA-C-O 118.286 -0.864 . . . . 74.11 110.499 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.425 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.09 171.21 0.56 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-N 119.565 1.075 . . . . 74.51 111.57 -174.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.484 0 C-N-CA 119.503 -1.332 . . . . 74.1 112.417 176.404 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.368 -1.24 . . . . 74.54 112.596 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.34 -143.97 5.16 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 117.271 -1.85 . . . . 70.0 112.876 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.82 44.54 1.09 Allowed 'General case' 0 C--N 1.358 0.961 0 CA-C-N 119.585 1.693 . . . . 63.43 112.072 -177.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.5 -144.74 12.41 Favored Glycine 0 C--N 1.353 1.486 0 CA-C-O 118.144 -1.365 . . . . 63.35 110.533 178.522 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -89.33 -40.79 12.54 Favored 'General case' 0 C--N 1.358 0.959 0 CA-C-N 118.951 1.376 . . . . 70.13 113.46 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.6 t -95.93 133.6 25.1 Favored Pre-proline 0 C--N 1.354 0.761 0 CA-C-O 115.422 -2.228 . . . . 75.25 109.526 -166.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -65.45 145.33 82.51 Favored 'Trans proline' 0 C--N 1.362 1.275 0 CA-C-N 123.891 2.425 . . . . 72.42 112.058 -177.319 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 78.8 mt-10 -81.99 -51.71 7.78 Favored 'General case' 0 C--N 1.359 0.985 0 N-CA-C 108.352 -0.981 . . . . 72.2 108.352 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.5 p90 -150.04 172.59 15.01 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 118.506 -0.759 . . . . 74.24 110.279 -177.948 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -125.64 170.95 11.0 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 118.668 -0.682 . . . . 71.41 109.484 -177.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -94.42 -166.9 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.868 0 N-CA-C 107.67 -1.233 . . . . 64.52 107.67 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.4 tpt85 -68.52 67.75 0.13 Allowed 'General case' 0 C--N 1.354 0.779 0 CA-C-N 119.335 0.971 . . . . 73.33 109.544 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.58 80.48 0.2 Allowed Glycine 0 C--N 1.356 1.646 0 CA-C-O 117.882 -1.51 . . . . 64.03 113.591 177.406 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -161.31 -66.19 0.06 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-N 119.495 1.648 . . . . 74.31 111.314 170.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -171.42 153.59 3.61 Favored Pre-proline 0 C--N 1.356 0.85 0 CA-C-O 115.966 -1.969 . . . . 71.12 106.763 -177.857 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -79.97 169.47 17.81 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.657 2.342 . . . . 70.22 111.644 -177.462 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.0 mt -135.71 41.89 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.92 0 N-CA-C 107.591 -1.262 . . . . 74.42 107.591 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.446 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.3 OUTLIER 175.65 157.33 0.21 Allowed 'General case' 0 C--N 1.352 0.71 0 CA-C-O 117.809 -1.091 . . . . 74.2 110.753 -178.503 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.446 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.2 m-85 -144.99 174.97 10.57 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-O 118.208 -0.901 . . . . 74.41 110.113 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.67 175.49 0.25 Allowed 'General case' 0 C--N 1.356 0.87 0 CA-C-N 119.143 0.883 . . . . 74.13 112.208 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.582 0 N-CA-C 109.746 -1.342 . . . . 74.42 109.746 176.645 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.635 0 CA-C-O 118.427 -1.207 . . . . 73.21 112.322 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.85 -141.16 3.36 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.217 -1.88 . . . . 52.21 111.493 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.49 45.5 1.21 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 119.881 1.84 . . . . 74.04 111.167 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.15 -145.73 15.36 Favored Glycine 0 C--N 1.353 1.496 0 CA-C-O 118.323 -1.265 . . . . 74.44 110.705 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -88.31 -40.6 13.47 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-N 118.557 1.179 . . . . 70.52 113.115 -176.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.9 t -98.09 134.89 21.66 Favored Pre-proline 0 C--N 1.353 0.758 0 CA-C-O 115.502 -2.189 . . . . 75.13 109.498 -166.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -67.41 144.52 67.88 Favored 'Trans proline' 0 C--N 1.362 1.288 0 CA-C-N 123.763 2.38 . . . . 72.41 112.121 -178.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -87.15 -49.65 7.15 Favored 'General case' 0 C--N 1.358 0.961 0 CA-C-N 118.869 0.759 . . . . 61.41 109.301 178.077 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -133.46 175.71 9.18 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.744 -0.646 . . . . 75.34 109.677 -174.206 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -137.04 166.86 22.69 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.63 -0.7 . . . . 73.4 109.411 177.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -96.03 -168.03 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.841 0 N-CA-C 106.424 -1.695 . . . . 74.32 106.424 178.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.7 mtp180 -74.85 71.23 1.99 Allowed 'General case' 0 C--N 1.354 0.772 0 CA-C-N 120.3 1.409 . . . . 74.24 109.329 176.735 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.43 78.23 0.37 Allowed Glycine 0 C--N 1.355 1.624 0 CA-C-O 118.093 -1.393 . . . . 74.41 112.978 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -163.01 -63.42 0.04 OUTLIER 'General case' 0 C--N 1.357 0.899 0 CA-C-N 119.26 1.53 . . . . 71.52 111.28 172.819 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -170.12 144.11 2.12 Favored Pre-proline 0 C--N 1.355 0.821 0 CA-C-O 115.91 -1.995 . . . . 64.3 108.643 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -76.03 158.26 38.19 Favored 'Trans proline' 0 C--N 1.36 1.137 0 CA-C-N 123.585 2.316 . . . . 64.01 110.93 -178.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 15.9 mm -119.99 22.59 5.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.916 0 O-C-N 123.916 0.76 . . . . 74.41 109.764 -176.661 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.443 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 12.1 p -175.19 157.58 2.27 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-N 120.451 1.478 . . . . 74.33 110.753 -175.672 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.0 m-85 -142.34 177.68 8.1 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.139 -0.934 . . . . 62.52 110.887 -176.442 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -58.3 172.77 0.42 Allowed 'General case' 0 C--N 1.355 0.815 0 CA-C-N 119.538 1.063 . . . . 74.3 111.593 -174.246 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.596 0 N-CA-C 108.817 -1.713 . . . . 73.33 108.817 175.011 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 CA-C-O 118.379 -1.234 . . . . 71.4 112.442 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.3 -141.73 3.25 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.221 -1.877 . . . . 71.12 111.235 179.697 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.51 45.99 1.04 Allowed 'General case' 0 C--N 1.356 0.886 0 CA-C-N 120.05 1.925 . . . . 75.53 111.52 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.95 -146.53 19.68 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.18 -1.344 . . . . 74.1 110.371 179.35 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -87.11 -41.01 14.13 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-N 118.931 1.366 . . . . 72.52 113.19 -178.209 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.45 133.73 25.41 Favored Pre-proline 0 C--N 1.353 0.744 0 CA-C-O 115.43 -2.224 . . . . 74.22 109.536 -166.2 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.46 144.27 72.69 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.915 2.434 . . . . 74.05 111.684 -178.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -82.24 -50.75 8.63 Favored 'General case' 0 C--N 1.356 0.876 0 N-CA-C 108.411 -0.959 . . . . 73.34 108.411 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -148.9 172.59 14.44 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 118.368 -0.825 . . . . 74.5 109.729 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -126.08 168.24 14.26 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.513 -0.756 . . . . 73.34 109.808 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -91.95 -171.07 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.835 0 N-CA-C 105.918 -1.882 . . . . 71.03 105.918 175.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.8 mtt-85 -71.2 76.81 0.71 Allowed 'General case' 0 C--N 1.353 0.75 0 CA-C-N 120.366 1.439 . . . . 73.22 110.071 177.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.53 75.93 0.44 Allowed Glycine 0 C--N 1.355 1.631 0 CA-C-O 118.104 -1.387 . . . . 54.54 112.985 172.283 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -161.9 -61.5 0.05 OUTLIER 'General case' 0 C--N 1.356 0.886 0 CA-C-N 119.212 1.506 . . . . 73.35 111.801 173.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -173.87 144.67 1.05 Allowed Pre-proline 0 C--N 1.355 0.832 0 CA-C-O 115.892 -2.004 . . . . 72.13 109.035 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.6 156.07 31.8 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 123.608 2.324 . . . . 74.34 110.79 -178.75 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 15.7 mm -118.85 21.42 5.96 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-O 118.625 -0.702 . . . . 73.34 109.427 -176.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.437 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 13.4 p -174.9 158.62 2.59 Favored 'General case' 0 C--N 1.356 0.868 0 CA-C-N 120.435 1.47 . . . . 64.42 110.994 -175.047 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.437 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -142.05 176.6 8.82 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.136 -0.935 . . . . 74.03 111.013 -177.042 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.417 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.2 m-30 -58.72 173.12 0.44 Allowed 'General case' 0 C--N 1.356 0.852 0 CA-C-N 119.609 1.095 . . . . 64.44 111.372 -174.468 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.587 0 C-N-CA 119.614 -1.279 . . . . 75.32 110.956 177.397 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.648 0 CA-C-O 117.923 -1.487 . . . . 64.44 113.841 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -164.96 -142.69 3.48 Favored Glycine 0 C--N 1.353 1.502 0 CA-C-N 120.06 1.93 . . . . 72.41 111.708 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.51 47.66 1.11 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 120.021 1.911 . . . . 75.3 111.209 -178.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.67 -145.71 18.21 Favored Glycine 0 C--N 1.354 1.551 0 CA-C-O 118.007 -1.44 . . . . 73.01 109.813 179.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -88.18 -41.72 12.8 Favored 'General case' 0 C--N 1.356 0.879 0 CA-C-N 119.029 1.415 . . . . 74.13 113.221 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -94.51 133.67 26.59 Favored Pre-proline 0 C--N 1.354 0.771 0 CA-C-O 115.456 -2.211 . . . . 71.21 109.712 -165.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.0 144.25 75.47 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 123.937 2.442 . . . . 75.31 111.634 -177.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -82.12 -50.07 9.47 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.473 -0.936 . . . . 71.4 108.473 178.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -149.92 173.09 14.19 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.398 -0.81 . . . . 75.3 109.732 -177.316 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -127.95 169.2 14.25 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.509 -0.757 . . . . 72.44 109.6 -178.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -92.49 -170.9 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.852 0 N-CA-C 107.109 -1.441 . . . . 75.32 107.109 177.345 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -69.86 73.8 0.43 Allowed 'General case' 0 C--N 1.352 0.679 0 CA-C-N 119.203 0.91 . . . . 75.4 109.441 174.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.79 76.8 0.43 Allowed Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.034 -1.426 . . . . 72.4 113.563 173.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -160.67 -66.16 0.06 Allowed 'General case' 0 C--N 1.356 0.853 0 CA-C-N 119.244 1.522 . . . . 64.34 111.077 170.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -170.91 152.15 3.52 Favored Pre-proline 0 C--N 1.357 0.913 0 CA-C-O 116.018 -1.944 . . . . 75.51 108.36 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -76.32 165.21 29.75 Favored 'Trans proline' 0 C--N 1.356 0.933 0 CA-C-N 123.474 2.277 . . . . 65.54 111.479 -177.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.9 mt -135.81 47.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.886 0 N-CA-C 107.382 -1.34 . . . . 73.42 107.382 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.435 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.9 p 166.32 156.53 0.03 OUTLIER 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.032 -0.985 . . . . 73.32 110.175 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' A' ' 18' ' ' SER . 34.3 m-85 -141.79 178.1 7.72 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 117.877 -1.059 . . . . 74.21 109.828 179.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.444 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.86 177.6 0.14 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 119.693 1.133 . . . . 73.1 110.751 -175.72 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.57 0 CA-C-N 120.615 1.552 . . . . 65.12 109.915 176.231 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.694 0 CA-C-O 117.858 -1.524 . . . . 74.11 113.611 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.06 -143.02 3.58 Favored Glycine 0 C--N 1.354 1.583 0 CA-C-N 120.216 2.008 . . . . 75.31 111.261 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.17 45.23 1.07 Allowed 'General case' 0 C--N 1.357 0.899 0 CA-C-N 120.067 1.934 . . . . 74.25 111.464 -178.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.74 -145.53 16.85 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.166 -1.352 . . . . 74.51 110.657 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -87.6 -39.99 14.6 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-N 118.778 1.289 . . . . 74.15 112.911 -176.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -98.77 134.54 21.51 Favored Pre-proline 0 C--N 1.354 0.79 0 CA-C-O 115.368 -2.254 . . . . 74.43 109.743 -166.713 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.99 147.31 84.43 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 124.019 2.471 . . . . 74.54 112.136 -177.339 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.4 mt-10 -83.93 -50.64 7.85 Favored 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.341 0.973 . . . . 71.14 108.38 178.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -151.5 174.64 13.16 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.417 -0.801 . . . . 74.11 110.412 -176.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -127.94 178.24 6.31 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.88 -1.057 . . . . 73.11 109.484 -176.571 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.36 -162.23 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.947 0 N-CA-C 105.265 -2.124 . . . . 71.33 105.265 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 70.0 mmt-85 -75.99 73.19 2.88 Favored 'General case' 0 C--N 1.355 0.804 0 CA-C-N 121.32 1.873 . . . . 72.24 108.221 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.05 79.71 0.24 Allowed Glycine 0 C--N 1.354 1.561 0 CA-C-O 118.382 -1.232 . . . . 64.03 110.858 176.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -156.21 -69.53 0.11 Allowed 'General case' 0 C--N 1.356 0.849 0 CA-C-N 118.846 1.323 . . . . 74.5 111.067 176.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 178.53 150.8 0.44 Allowed Pre-proline 0 C--N 1.353 0.759 0 CA-C-O 116.063 -1.922 . . . . 74.31 106.836 -177.389 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -75.58 167.21 26.98 Favored 'Trans proline' 0 C--N 1.356 0.968 0 CA-C-N 124.027 2.474 . . . . 63.41 110.814 -176.14 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mt -134.08 37.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.854 0 N-CA-C 107.908 -1.145 . . . . 72.51 107.908 178.606 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.43 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.3 p 171.75 155.71 0.08 Allowed 'General case' 0 C--N 1.354 0.801 0 CA-C-O 117.546 -1.216 . . . . 74.12 110.205 -175.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.43 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -141.34 175.83 9.35 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-O 118.244 -0.884 . . . . 73.33 110.332 -178.76 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.69 171.89 0.58 Allowed 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.636 1.107 . . . . 74.3 111.377 -174.274 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.538 0 C-N-CA 119.351 -1.404 . . . . 65.2 112.024 176.21 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.733 0 CA-C-O 118.102 -1.388 . . . . 42.11 113.273 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.15 -143.25 3.7 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-O 117.208 -1.885 . . . . 71.43 111.309 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -149.03 44.99 0.99 Allowed 'General case' 0 C--N 1.357 0.923 0 CA-C-N 120.158 1.979 . . . . 64.33 111.711 -179.046 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.03 -146.48 18.43 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 118.112 -1.382 . . . . 73.54 110.534 179.226 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 m170 -87.97 -38.52 15.47 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-N 119.012 1.406 . . . . 74.55 113.145 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.94 133.2 24.57 Favored Pre-proline 0 C--N 1.353 0.749 0 CA-C-O 115.339 -2.267 . . . . 73.3 109.688 -167.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -66.35 146.45 80.68 Favored 'Trans proline' 0 C--N 1.363 1.321 0 CA-C-N 123.987 2.46 . . . . 73.33 112.003 -177.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 -82.78 -50.58 8.52 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.317 -0.994 . . . . 52.45 108.317 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -150.69 173.57 14.01 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.544 -0.741 . . . . 73.45 110.302 -177.37 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.7 176.95 6.85 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 118.042 -0.98 . . . . 74.42 109.415 -176.197 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.0 -167.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.902 0 N-CA-C 105.068 -2.197 . . . . 72.41 105.068 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -74.13 75.78 1.77 Allowed 'General case' 0 C--N 1.354 0.767 0 CA-C-N 120.686 1.584 . . . . 74.23 108.907 178.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.96 76.59 0.33 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.134 -1.37 . . . . 73.33 111.179 175.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -156.83 -69.75 0.1 Allowed 'General case' 0 C--N 1.355 0.838 0 CA-C-N 119.028 1.414 . . . . 71.11 111.389 178.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -178.39 143.68 0.46 Allowed Pre-proline 0 C--N 1.354 0.787 0 CA-C-O 116.011 -1.947 . . . . 75.12 108.465 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -71.75 165.62 31.97 Favored 'Trans proline' 0 C--N 1.358 1.027 0 CA-C-N 123.791 2.39 . . . . 63.34 110.233 -177.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.44 37.72 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.877 0 N-CA-C 107.915 -1.142 . . . . 70.11 107.915 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.5 p 173.46 154.46 0.1 Allowed 'General case' 0 C--N 1.355 0.833 0 CA-C-O 117.494 -1.241 . . . . 74.34 110.185 -176.017 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.7 m-85 -141.57 175.63 9.53 Favored 'General case' 0 C--N 1.357 0.925 0 CA-C-O 118.3 -0.857 . . . . 74.41 110.246 -178.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -59.75 169.39 1.4 Allowed 'General case' 0 C--N 1.355 0.82 0 CA-C-N 119.688 1.131 . . . . 74.41 111.438 -173.201 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.581 0 N-CA-C 109.444 -1.462 . . . . 71.35 109.444 173.683 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.676 0 CA-C-O 118.316 -1.269 . . . . 74.31 112.64 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.05 -144.66 4.39 Favored Glycine 0 C--N 1.354 1.55 0 CA-C-O 117.351 -1.805 . . . . 72.23 111.467 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.01 46.26 1.08 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.782 1.791 . . . . 71.22 111.48 -179.113 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.84 -144.17 14.11 Favored Glycine 0 C--N 1.353 1.508 0 CA-C-O 118.102 -1.388 . . . . 65.23 110.195 179.151 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -88.95 -42.51 11.76 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.019 1.41 . . . . 74.24 113.508 -178.213 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.1 t -93.87 133.41 27.8 Favored Pre-proline 0 C--N 1.353 0.755 0 CA-C-O 115.446 -2.216 . . . . 72.52 109.478 -166.247 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -65.32 144.41 80.35 Favored 'Trans proline' 0 C--N 1.363 1.312 0 CA-C-N 123.943 2.444 . . . . 75.53 111.866 -177.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -81.5 -51.39 8.33 Favored 'General case' 0 C--N 1.358 0.968 0 N-CA-C 108.359 -0.978 . . . . 71.42 108.359 179.001 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.4 p90 -148.87 172.06 15.29 Favored 'General case' 0 C--N 1.354 0.796 0 CA-C-O 118.535 -0.745 . . . . 74.32 109.941 -177.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -125.01 170.27 11.3 Favored 'General case' 0 C--N 1.355 0.845 0 CA-C-O 118.857 -0.592 . . . . 74.21 109.614 -177.16 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -94.67 -170.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.808 0 N-CA-C 106.563 -1.643 . . . . 74.41 106.563 177.409 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.1 mtt180 -70.08 75.32 0.49 Allowed 'General case' 0 C--N 1.354 0.771 0 CA-C-N 119.876 1.216 . . . . 74.44 109.924 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.72 78.02 0.24 Allowed Glycine 0 C--N 1.355 1.587 0 CA-C-O 118.11 -1.383 . . . . 72.4 113.579 172.25 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -162.62 -63.31 0.05 OUTLIER 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.204 1.502 . . . . 63.13 111.296 172.101 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -172.92 143.99 1.17 Allowed Pre-proline 0 C--N 1.356 0.855 0 CA-C-O 115.713 -2.089 . . . . 73.41 108.281 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.52 170.74 19.61 Favored 'Trans proline' 0 C--N 1.357 0.984 0 CA-C-N 123.835 2.405 . . . . 75.51 111.17 -177.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -135.77 39.94 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.977 0 N-CA-C 108.488 -0.93 . . . . 74.31 108.488 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.433 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 19.2 p 175.1 155.42 0.15 Allowed 'General case' 0 C--N 1.353 0.747 0 CA-C-O 117.795 -1.097 . . . . 72.03 110.932 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.6 m-85 -142.59 175.19 9.99 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.049 -0.977 . . . . 72.32 110.169 -179.756 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.428 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.8 m-30 -58.46 172.43 0.48 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.509 1.05 . . . . 74.44 111.333 -174.05 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.528 0 N-CA-C 109.18 -1.568 . . . . 74.32 109.18 174.201 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.681 0 CA-C-O 118.145 -1.364 . . . . 63.0 112.89 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.85 -142.12 3.41 Favored Glycine 0 C--N 1.354 1.552 0 CA-C-O 117.177 -1.902 . . . . 75.11 112.144 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.8 46.22 1.02 Allowed 'General case' 0 C--N 1.358 0.945 0 CA-C-N 119.887 1.843 . . . . 71.34 111.697 -178.44 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.62 -144.56 15.59 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.146 -1.363 . . . . 53.01 110.6 179.559 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.2 m80 -87.44 -41.82 13.26 Favored 'General case' 0 C--N 1.356 0.88 0 CA-C-N 118.788 1.294 . . . . 71.43 113.141 -177.016 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -97.45 134.57 22.43 Favored Pre-proline 0 C--N 1.354 0.785 0 CA-C-O 115.397 -2.239 . . . . 61.44 109.693 -166.186 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -65.74 144.25 77.15 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 123.909 2.432 . . . . 75.1 111.81 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -81.52 -51.42 8.29 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.48 -0.933 . . . . 71.03 108.48 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -148.37 172.0 15.11 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-O 118.366 -0.826 . . . . 73.33 109.553 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -124.34 170.13 11.12 Favored 'General case' 0 C--N 1.355 0.823 0 O-C-N 123.781 0.675 . . . . 74.24 109.628 -177.084 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 m -92.59 -166.29 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 106.477 -1.675 . . . . 73.41 106.477 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 42.8 mtp180 -75.52 69.08 2.24 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-N 120.005 1.275 . . . . 75.51 109.56 175.425 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.29 78.21 0.46 Allowed Glycine 0 C--N 1.356 1.669 0 CA-C-O 118.01 -1.439 . . . . 74.2 113.208 174.378 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -164.28 -63.45 0.04 OUTLIER 'General case' 0 C--N 1.357 0.916 0 CA-C-N 119.376 1.588 . . . . 64.44 111.503 172.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -171.5 144.52 1.63 Allowed Pre-proline 0 C--N 1.355 0.809 0 CA-C-O 115.511 -2.185 . . . . 75.31 108.307 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -75.36 171.36 18.41 Favored 'Trans proline' 0 C--N 1.357 1.01 0 CA-C-N 123.95 2.447 . . . . 72.32 111.361 -177.497 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -136.06 40.33 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 108.413 -0.958 . . . . 75.02 108.413 178.232 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.8 p 174.31 155.93 0.13 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.77 -1.11 . . . . 55.02 111.08 -177.995 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.6 m-85 -143.25 175.91 9.53 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-O 118.283 -0.865 . . . . 64.41 110.559 -179.489 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.0 m-30 -60.13 176.57 0.31 Allowed 'General case' 0 C--N 1.356 0.866 0 CA-C-N 119.354 0.979 . . . . 75.21 111.775 -174.268 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.594 0 C-N-CA 119.514 -1.327 . . . . 72.42 109.894 173.474 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.119 -1.378 . . . . 73.209999999999994 112.414 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.84 -142.94 3.99 Favored Glycine 0 C--N 1.354 1.566 0 CA-C-N 119.897 1.848 . . . . 61.520000000000003 111.802 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.53 45.75 1.21 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 119.843 1.822 . . . . 64.319999999999993 111.171 -179.013 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.91 -143.57 12.24 Favored Glycine 0 C--N 1.353 1.516 0 CA-C-O 118.049 -1.417 . . . . 55.340000000000003 110.641 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -89.34 -41.49 12.11 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-N 118.765 1.283 . . . . 73.540000000000006 112.89 -176.214 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.7 t -98.6 135.29 21.14 Favored Pre-proline 0 C--N 1.353 0.748 0 CA-C-O 115.363 -2.256 . . . . 65.150000000000006 109.661 -166.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -66.66 144.7 73.16 Favored 'Trans proline' 0 C--N 1.362 1.254 0 CA-C-N 124.036 2.477 . . . . 62.109999999999999 112.43 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.78 -52.11 5.7 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.275 0.943 . . . . 72.099999999999994 108.893 178.238 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -132.18 174.69 9.95 Favored 'General case' 0 C--N 1.354 0.778 0 CA-C-O 118.731 -0.652 . . . . 61.439999999999998 109.449 -174.458 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -134.76 170.56 15.64 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-O 118.742 -0.647 . . . . 73.209999999999994 109.305 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -100.91 -170.4 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.12 -1.437 . . . . 71.019999999999996 107.12 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 ttp180 -78.68 65.81 4.03 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-N 120.003 1.274 . . . . 72.140000000000001 109.177 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 79.73 77.9 0.91 Allowed Glycine 0 C--N 1.356 1.69 0 CA-C-O 117.986 -1.452 . . . . 60.32 113.438 175.436 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -165.23 -71.96 0.03 OUTLIER 'General case' 0 C--N 1.358 0.952 0 CA-C-N 119.452 1.626 . . . . 72.219999999999999 110.8 170.411 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.98 150.69 6.34 Favored Pre-proline 0 C--N 1.355 0.818 0 CA-C-O 115.777 -2.059 . . . . 62.340000000000003 106.996 -179.024 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.67 173.05 15.16 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.733 2.369 . . . . 65.120000000000005 111.432 -176.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -134.25 38.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 108.419 -0.956 . . . . 72.239999999999995 108.419 178.592 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.468 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.8 p 175.08 157.36 0.17 Allowed 'General case' 0 C--N 1.354 0.781 0 CA-C-O 117.445 -1.264 . . . . 72.239999999999995 110.798 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.468 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -144.54 176.68 9.22 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 118.267 -0.873 . . . . 65.420000000000002 110.378 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.421 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.17 174.45 0.39 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-N 119.567 1.076 . . . . 74.230000000000004 111.382 -174.378 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.508 0 CA-C-N 120.143 1.338 . . . . 74.540000000000006 111.798 176.85 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.293 -1.282 . . . . 71.519999999999996 112.885 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.61 -144.03 4.29 Favored Glycine 0 C--N 1.354 1.543 0 CA-C-O 117.415 -1.769 . . . . 44.109999999999999 111.614 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.61 46.16 1.29 Allowed 'General case' 0 C--N 1.356 0.887 0 CA-C-N 119.751 1.776 . . . . 54.119999999999997 110.677 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.61 -139.63 9.2 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 118.034 -1.426 . . . . 53.020000000000003 110.798 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -95.31 -35.68 11.69 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 117.482 -1.247 . . . . 52.530000000000001 113.285 -173.102 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -105.52 136.13 19.28 Favored Pre-proline 0 C--N 1.355 0.824 0 CA-C-O 115.414 -2.231 . . . . 65.040000000000006 109.285 -169.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -66.99 143.78 67.36 Favored 'Trans proline' 0 C--N 1.361 1.211 0 CA-C-N 123.894 2.427 . . . . 73.209999999999994 112.289 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.3 mt-10 -85.73 -48.73 8.55 Favored 'General case' 0 C--N 1.358 0.954 0 CA-C-N 118.886 0.766 . . . . 65.200000000000003 109.413 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -134.71 175.02 9.93 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.84 -0.6 . . . . 63.310000000000002 109.548 -173.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -135.44 171.19 14.8 Favored 'General case' 0 C--N 1.353 0.744 0 N-CA-C 109.105 -0.702 . . . . 72.25 109.105 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.5 m -103.31 -170.32 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.746 0 N-CA-C 107.225 -1.398 . . . . 61.420000000000002 107.225 -177.428 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -72.5 71.32 0.94 Allowed 'General case' 0 C--N 1.353 0.735 0 CA-C-N 119.146 0.885 . . . . 71.219999999999999 108.885 172.533 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.24 80.41 0.2 Allowed Glycine 0 C--N 1.355 1.595 0 CA-C-O 118.19 -1.339 . . . . 73.439999999999998 113.812 173.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -164.25 -70.9 0.04 OUTLIER 'General case' 0 C--N 1.357 0.895 0 CA-C-N 119.241 1.52 . . . . 73.099999999999994 110.37 170.558 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.83 150.27 6.32 Favored Pre-proline 0 C--N 1.355 0.826 0 CA-C-O 115.871 -2.014 . . . . 55.030000000000001 106.839 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -75.42 172.77 15.69 Favored 'Trans proline' 0 C--N 1.356 0.93 0 CA-C-N 123.58 2.314 . . . . 74.450000000000003 111.319 -176.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.1 mt -135.32 41.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.981 0 N-CA-C 108.321 -0.992 . . . . 74.209999999999994 108.321 178.508 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.449 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 171.99 156.77 0.09 Allowed 'General case' 0 C--N 1.354 0.803 0 CA-C-O 117.889 -1.053 . . . . 71.209999999999994 110.676 -179.266 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.9 m-85 -142.96 177.8 8.11 Favored 'General case' 0 C--N 1.358 0.96 0 CA-C-O 118.106 -0.95 . . . . 62.130000000000003 110.123 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.1 m-30 -59.43 175.73 0.31 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.713 1.142 . . . . 74.409999999999997 111.234 -174.716 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.611 0 N-CA-C 109.932 -1.267 . . . . 70.230000000000004 109.932 176.422 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.66 0 CA-C-O 118.663 -1.076 . . . . 74.310000000000002 111.942 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.98 -144.98 5.52 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.497 -1.724 . . . . 71.430000000000007 111.852 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.99 45.67 1.17 Allowed 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.633 1.716 . . . . 53.539999999999999 111.374 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.25 -142.47 11.79 Favored Glycine 0 C--N 1.354 1.532 0 CA-C-O 118.033 -1.426 . . . . 60.130000000000003 110.494 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.3 m170 -88.57 -45.99 9.44 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 118.983 1.391 . . . . 63.210000000000001 113.144 -177.21 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -93.2 134.39 27.13 Favored Pre-proline 0 C--N 1.353 0.732 0 CA-C-O 115.637 -2.125 . . . . 71.150000000000006 109.44 -165.381 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -66.64 143.99 70.47 Favored 'Trans proline' 0 C--N 1.363 1.3 0 CA-C-N 123.822 2.401 . . . . 71.140000000000001 112.183 -177.831 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.4 mt-10 -86.31 -50.82 6.65 Favored 'General case' 0 C--N 1.358 0.935 0 CA-C-N 118.806 0.73 . . . . 63.240000000000002 109.211 178.02 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -133.44 174.0 10.88 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-O 118.853 -0.594 . . . . 71.409999999999997 109.939 -174.343 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -135.07 170.82 15.32 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 118.694 -0.669 . . . . 74.310000000000002 109.256 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -102.63 -169.63 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.737 0 N-CA-C 107.031 -1.47 . . . . 64.549999999999997 107.031 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -73.45 70.98 1.28 Allowed 'General case' 0 C--N 1.353 0.729 0 CA-C-N 119.643 1.11 . . . . 74.019999999999996 108.875 173.027 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.97 80.33 0.22 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.118 -1.379 . . . . 61.219999999999999 113.621 173.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.67 -68.87 0.05 OUTLIER 'General case' 0 C--N 1.356 0.858 0 CA-C-N 119.155 1.477 . . . . 75.019999999999996 109.959 170.066 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -168.56 149.44 4.42 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.964 -1.97 . . . . 72.150000000000006 106.895 178.773 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -75.53 173.42 14.53 Favored 'Trans proline' 0 C--N 1.356 0.973 0 CA-C-N 123.529 2.296 . . . . 64.409999999999997 111.226 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.5 39.37 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.906 0 N-CA-C 108.479 -0.934 . . . . 72.230000000000004 108.479 179.053 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.462 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.5 p 174.96 157.13 0.16 Allowed 'General case' 0 C--N 1.354 0.766 0 CA-C-O 117.714 -1.136 . . . . 72.129999999999995 111.01 -177.043 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.462 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.1 m-85 -144.53 176.7 9.2 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-O 118.248 -0.882 . . . . 73.400000000000006 110.285 -179.722 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.414 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.17 169.63 1.08 Allowed 'General case' 0 C--N 1.355 0.812 0 CA-C-N 119.652 1.115 . . . . 63.43 111.534 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.513 0 C-N-CA 119.303 -1.427 . . . . 62.409999999999997 111.491 176.457 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.65 0 CA-C-O 117.919 -1.49 . . . . 72.150000000000006 113.325 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.76 -141.77 3.23 Favored Glycine 0 C--N 1.354 1.577 0 CA-C-N 120.159 1.98 . . . . 63.310000000000002 111.527 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.62 46.01 1.11 Allowed 'General case' 0 C--N 1.358 0.935 0 CA-C-N 119.898 1.849 . . . . 72.430000000000007 111.018 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.66 -137.95 7.81 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 117.788 -1.562 . . . . 24.350000000000001 110.844 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -100.76 -24.7 14.34 Favored 'General case' 0 C--N 1.359 0.99 0 CA-C-O 116.653 -1.641 . . . . 75.430000000000007 114.039 -172.54 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.3 t -114.21 135.25 22.15 Favored Pre-proline 0 C--N 1.356 0.891 0 CA-C-O 115.384 -2.246 . . . . 75.25 108.685 -171.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -65.96 144.27 75.83 Favored 'Trans proline' 0 C--N 1.361 1.21 0 CA-C-N 123.884 2.423 . . . . 72.540000000000006 111.788 -176.673 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -81.37 -50.67 9.2 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.255 -1.017 . . . . 75.329999999999998 108.255 178.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -149.22 172.2 15.24 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.472 -0.775 . . . . 62.119999999999997 109.863 -177.686 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -127.13 168.59 14.44 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.466 -0.778 . . . . 72.129999999999995 109.506 -177.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.411 ' O ' ' N ' ' A' ' 13' ' ' GLY . 3.1 m -94.65 -176.99 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.805 0 N-CA-C 107.334 -1.358 . . . . 75.310000000000002 107.334 176.181 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -55.2 76.47 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 CA-C-N 118.309 0.504 . . . . 74.310000000000002 111.895 170.44 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' VAL . . . 57.49 78.44 0.13 Allowed Glycine 0 C--N 1.354 1.576 0 CA-C-O 118.056 -1.414 . . . . 64.420000000000002 114.097 172.521 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -161.26 -61.86 0.05 Allowed 'General case' 0 C--N 1.356 0.88 0 CA-C-N 119.414 1.607 . . . . 52.140000000000001 111.805 173.084 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -174.52 145.51 0.99 Allowed Pre-proline 0 C--N 1.355 0.833 0 CA-C-O 115.777 -2.059 . . . . 75.019999999999996 108.448 -178.605 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.56 168.52 24.26 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.677 2.349 . . . . 74.219999999999999 111.205 -178.511 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.7 mt -137.45 44.3 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 107.751 -1.203 . . . . 63.340000000000003 107.751 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.45 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.0 p 170.03 155.6 0.05 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.878 -1.058 . . . . 63.329999999999998 110.496 -179.548 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.45 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.9 m-85 -141.88 175.82 9.42 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.291 -0.862 . . . . 53.119999999999997 109.984 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.437 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -57.98 172.13 0.45 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.497 1.044 . . . . 71.230000000000004 111.484 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 1.641 0 N-CA-C 108.308 -1.917 . . . . 75.150000000000006 108.308 174.304 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 CA-C-O 118.357 -1.246 . . . . 73.510000000000005 112.267 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.62 -143.19 3.87 Favored Glycine 0 C--N 1.355 1.592 0 CA-C-O 117.135 -1.925 . . . . 65.439999999999998 111.655 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.52 45.79 1.12 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.957 1.878 . . . . 74.200000000000003 111.105 -178.489 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.94 -144.2 14.27 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.169 -1.351 . . . . 33.539999999999999 110.707 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.7 m-70 -88.78 -40.81 12.93 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 118.829 1.314 . . . . 74.540000000000006 113.026 -176.468 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -99.26 135.5 20.73 Favored Pre-proline 0 C--N 1.354 0.775 0 CA-C-O 115.233 -2.318 . . . . 72.109999999999999 109.389 -166.288 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -66.8 144.89 73.05 Favored 'Trans proline' 0 C--N 1.364 1.344 0 CA-C-N 124.001 2.464 . . . . 73.409999999999997 111.879 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -82.64 -51.28 7.89 Favored 'General case' 0 C--N 1.359 0.989 0 N-CA-C 108.392 -0.966 . . . . 72.409999999999997 108.392 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -149.53 172.95 14.16 Favored 'General case' 0 C--N 1.356 0.861 0 CA-C-O 118.155 -0.926 . . . . 72.420000000000002 109.747 -177.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -126.36 168.55 14.01 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 118.551 -0.738 . . . . 74.109999999999999 109.974 -176.916 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -90.09 -169.99 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.881 0 N-CA-C 106.645 -1.613 . . . . 64.239999999999995 106.645 177.516 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -70.73 75.12 0.6 Allowed 'General case' 0 C--N 1.353 0.718 0 CA-C-N 119.479 1.036 . . . . 71.120000000000005 109.153 176.198 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.1 77.45 0.35 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 118.107 -1.385 . . . . 64.209999999999994 113.058 173.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -160.03 -65.12 0.07 Allowed 'General case' 0 C--N 1.357 0.919 0 CA-C-N 119.188 1.494 . . . . 55.100000000000001 111.279 171.45 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.09 154.56 3.41 Favored Pre-proline 0 C--N 1.355 0.814 0 CA-C-O 116.027 -1.94 . . . . 74.310000000000002 107.6 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -80.87 155.99 20.5 Favored 'Trans proline' 0 C--N 1.36 1.174 0 CA-C-N 123.698 2.357 . . . . 64.0 111.257 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.5 mm -118.73 17.75 6.85 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-O 118.284 -0.865 . . . . 73.329999999999998 109.23 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 7.1 m -165.9 158.87 15.29 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 121.102 1.774 . . . . 71.239999999999995 110.558 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -142.8 174.94 10.21 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 119.789 1.177 . . . . 73.109999999999999 110.713 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.432 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.18 174.02 0.43 Allowed 'General case' 0 C--N 1.356 0.855 0 CA-C-N 119.242 0.928 . . . . 73.200000000000003 111.266 -174.162 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.483 0 N-CA-C 109.036 -1.626 . . . . 70.109999999999999 109.036 175.558 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.734 0 CA-C-O 118.463 -1.187 . . . . 75.299999999999997 112.278 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.77 -147.08 6.17 Favored Glycine 0 C--N 1.355 1.597 0 CA-C-O 117.486 -1.73 . . . . 71.319999999999993 111.859 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.2 46.34 1.15 Allowed 'General case' 0 C--N 1.357 0.925 0 CA-C-N 119.78 1.79 . . . . 72.129999999999995 111.357 -178.508 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.18 -144.69 15.42 Favored Glycine 0 C--N 1.354 1.57 0 CA-C-O 117.9 -1.5 . . . . 54.439999999999998 110.249 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -87.76 -43.1 12.13 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-N 119.142 1.471 . . . . 71.319999999999993 112.926 -177.352 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -96.4 134.98 22.74 Favored Pre-proline 0 C--N 1.354 0.764 0 CA-C-O 115.199 -2.334 . . . . 64.200000000000003 109.814 -165.681 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.22 145.05 83.19 Favored 'Trans proline' 0 C--N 1.363 1.323 0 CA-C-N 124.146 2.517 . . . . 72.530000000000001 112.257 -177.432 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 75.9 mt-10 -82.45 -52.14 7.16 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 108.177 -1.045 . . . . 54.43 108.177 178.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -149.32 173.0 13.98 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-O 118.414 -0.803 . . . . 73.010000000000005 109.685 -177.4 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -126.4 169.55 12.85 Favored 'General case' 0 C--N 1.354 0.804 0 CA-C-O 118.505 -0.759 . . . . 71.230000000000004 110.095 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -93.41 -171.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 N-CA-C 106.872 -1.529 . . . . 74.400000000000006 106.872 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.3 mtt-85 -70.38 76.1 0.55 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.826 1.194 . . . . 74.010000000000005 109.879 173.719 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.57 76.97 0.4 Allowed Glycine 0 C--N 1.355 1.613 0 CA-C-O 118.048 -1.418 . . . . 52.140000000000001 113.267 172.176 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -160.59 -67.16 0.07 Allowed 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.203 1.502 . . . . 75.439999999999998 110.934 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.07 153.06 3.04 Favored Pre-proline 0 C--N 1.353 0.753 0 CA-C-O 115.754 -2.07 . . . . 75.209999999999994 107.253 -178.423 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.38 171.51 15.9 Favored 'Trans proline' 0 C--N 1.357 1.022 0 CA-C-N 123.911 2.433 . . . . 40.140000000000001 111.661 -177.218 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.3 mt -135.9 41.37 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.799 -1.186 . . . . 73.239999999999995 107.799 177.072 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.434 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 2.7 p 174.5 156.65 0.15 Allowed 'General case' 0 C--N 1.354 0.774 0 CA-C-O 117.809 -1.091 . . . . 61.020000000000003 110.731 -178.034 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.434 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.7 m-85 -143.76 175.69 9.8 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.133 -0.937 . . . . 75.400000000000006 110.071 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.78 176.15 0.22 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.654 1.115 . . . . 73.239999999999995 111.351 -174.614 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.574 0 CA-C-N 120.227 1.376 . . . . 61.340000000000003 110.641 176.51 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.715 0 CA-C-O 118.521 -1.155 . . . . 73.299999999999997 111.246 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.3 -146.45 5.82 Favored Glycine 0 C--N 1.354 1.58 0 CA-C-O 117.389 -1.784 . . . . 74.450000000000003 111.753 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.96 45.92 1.09 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.718 1.759 . . . . 65.040000000000006 111.318 -178.481 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.7 -139.65 9.72 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.806 -1.552 . . . . 74.519999999999996 110.62 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -93.52 -38.81 11.2 Favored 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.045 1.422 . . . . 63.119999999999997 113.151 -174.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.4 t -101.67 135.17 19.83 Favored Pre-proline 0 C--N 1.354 0.799 0 CA-C-O 115.149 -2.358 . . . . 73.340000000000003 109.495 -167.635 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.94 144.53 76.89 Favored 'Trans proline' 0 C--N 1.362 1.255 0 CA-C-N 124.165 2.523 . . . . 63.020000000000003 112.218 -176.905 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -81.87 -51.77 7.77 Favored 'General case' 0 C--N 1.358 0.94 0 CA-C-N 119.486 1.039 . . . . 70.310000000000002 108.313 178.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -149.19 172.38 14.93 Favored 'General case' 0 C--N 1.353 0.757 0 CA-C-O 118.342 -0.837 . . . . 64.439999999999998 110.116 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -124.77 171.34 10.19 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-O 118.665 -0.683 . . . . 74.450000000000003 110.016 -176.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 m -94.87 -166.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 107.484 -1.302 . . . . 71.540000000000006 107.484 -178.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 tpt180 -71.01 67.22 0.41 Allowed 'General case' 0 C--N 1.355 0.813 0 CA-C-N 119.801 1.182 . . . . 75.319999999999993 109.292 173.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.15 79.39 0.29 Allowed Glycine 0 C--N 1.355 1.604 0 CA-C-O 117.844 -1.531 . . . . 74.010000000000005 113.546 176.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -161.1 -71.81 0.06 Allowed 'General case' 0 C--N 1.358 0.972 0 CA-C-N 119.579 1.689 . . . . 72.319999999999993 110.48 170.044 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -163.17 154.56 14.73 Favored Pre-proline 0 C--N 1.355 0.828 0 CA-C-O 116.058 -1.925 . . . . 73.109999999999999 107.249 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -78.07 169.28 20.65 Favored 'Trans proline' 0 C--N 1.358 1.069 0 CA-C-N 123.577 2.313 . . . . 71.150000000000006 111.238 -177.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -133.37 36.38 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.702 -1.221 . . . . 73.340000000000003 107.702 175.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -173.86 158.73 3.27 Favored 'General case' 0 C--N 1.353 0.742 0 CA-C-O 116.702 -1.618 . . . . 24.43 110.204 -177.122 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.5 m-85 -145.21 173.64 11.77 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-N 119.538 1.063 . . . . 63.119999999999997 110.053 174.382 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.5 171.31 0.85 Allowed 'General case' 0 C--N 1.354 0.793 0 CA-C-N 119.711 1.141 . . . . 74.340000000000003 111.049 -174.267 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.496 0 CA-C-N 120.471 1.487 . . . . 55.409999999999997 111.472 175.135 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 CA-C-O 118.486 -1.174 . . . . 73.150000000000006 112.13 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.15 -144.12 5.18 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.496 -1.724 . . . . 62.350000000000001 112.252 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.94 44.78 1.26 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.526 1.663 . . . . 74.150000000000006 111.042 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.64 -141.69 9.42 Favored Glycine 0 C--N 1.353 1.521 0 CA-C-O 118.076 -1.402 . . . . 72.109999999999999 110.825 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -93.01 -39.24 11.22 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 118.69 1.245 . . . . 71.150000000000006 113.177 -175.404 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.1 t -99.62 135.12 20.67 Favored Pre-proline 0 C--N 1.353 0.743 0 CA-C-O 115.385 -2.245 . . . . 55.399999999999999 109.233 -168.246 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -66.78 144.27 70.7 Favored 'Trans proline' 0 C--N 1.362 1.244 0 CA-C-N 123.907 2.431 . . . . 64.030000000000001 112.22 -177.631 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.9 mt-10 -86.13 -51.53 6.25 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 118.9 0.773 . . . . 32.130000000000003 109.167 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -132.18 174.31 10.34 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 118.91 -0.567 . . . . 71.230000000000004 109.543 -174.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -134.06 171.8 13.72 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.099 -0.704 . . . . 64.319999999999993 109.099 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -104.28 -165.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.775 0 N-CA-C 106.939 -1.504 . . . . 64.209999999999994 106.939 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -74.95 67.22 1.66 Allowed 'General case' 0 C--N 1.352 0.705 0 CA-C-N 119.602 1.092 . . . . 63.149999999999999 108.93 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 66.75 80.63 0.18 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 117.963 -1.465 . . . . 65.549999999999997 113.615 175.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -164.87 -64.03 0.03 OUTLIER 'General case' 0 C--N 1.358 0.941 0 CA-C-N 119.486 1.643 . . . . 70.230000000000004 111.028 172.626 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -169.87 143.28 2.09 Favored Pre-proline 0 C--N 1.354 0.773 0 CA-C-O 115.756 -2.069 . . . . 73.010000000000005 108.364 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -73.74 173.19 14.37 Favored 'Trans proline' 0 C--N 1.359 1.094 0 CA-C-N 123.956 2.449 . . . . 64.519999999999996 111.087 -177.481 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -135.05 38.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 108.631 -0.877 . . . . 63.43 108.631 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.9 p 175.52 156.88 0.2 Allowed 'General case' 0 C--N 1.355 0.835 0 CA-C-O 117.706 -1.14 . . . . 65.409999999999997 110.902 -176.802 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.6 m-85 -144.81 176.38 9.49 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-O 118.291 -0.861 . . . . 74.439999999999998 110.542 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.23 174.4 0.29 Allowed 'General case' 0 C--N 1.355 0.823 0 CA-C-N 119.369 0.986 . . . . 75.430000000000007 112.117 -174.293 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.639 0 N-CA-C 109.34 -1.504 . . . . 64.230000000000004 109.34 176.648 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 CA-C-O 118.529 -1.151 . . . . 65.230000000000004 112.108 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.29 -144.97 5.58 Favored Glycine 0 C--N 1.355 1.617 0 CA-C-O 117.43 -1.761 . . . . 54.340000000000003 111.61 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.34 45.6 1.23 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-N 119.717 1.759 . . . . 41.340000000000003 111.099 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.35 -145.79 17.03 Favored Glycine 0 C--N 1.354 1.53 0 CA-C-O 118.256 -1.302 . . . . 70.209999999999994 110.529 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -85.89 -45.99 11.02 Favored 'General case' 0 C--N 1.357 0.892 0 CA-C-N 118.928 1.364 . . . . 61.25 112.91 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -92.76 134.74 27.16 Favored Pre-proline 0 C--N 1.354 0.795 0 CA-C-O 115.312 -2.28 . . . . 74.329999999999998 109.678 -164.787 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.45 143.8 64.73 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 123.876 2.42 . . . . 62.140000000000001 112.281 -177.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -86.11 -47.44 9.52 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 118.885 0.766 . . . . 72.439999999999998 109.364 177.924 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -135.83 175.76 9.3 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 118.668 -0.682 . . . . 64.299999999999997 109.724 -173.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -136.14 170.41 16.06 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 118.771 -0.633 . . . . 74.019999999999996 109.301 178.263 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.66 -167.53 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.787 0 N-CA-C 106.854 -1.536 . . . . 61.32 106.854 -178.554 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -76.05 65.62 2.11 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-N 120.309 1.413 . . . . 75.239999999999995 109.286 175.357 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 72.85 79.67 0.46 Allowed Glycine 0 C--N 1.356 1.66 0 CA-C-O 117.884 -1.509 . . . . 73.5 113.552 175.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -165.16 -65.81 0.03 OUTLIER 'General case' 0 C--N 1.359 1.019 0 CA-C-N 119.582 1.691 . . . . 75.109999999999999 111.376 171.616 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.4 t -169.49 142.95 2.2 Favored Pre-proline 0 C--N 1.355 0.813 0 CA-C-O 115.644 -2.122 . . . . 64.439999999999998 108.437 179.363 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.51 172.77 15.04 Favored 'Trans proline' 0 C--N 1.359 1.098 0 CA-C-N 124.036 2.477 . . . . 63.020000000000003 111.542 -176.447 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -135.46 40.71 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.927 0 N-CA-C 108.629 -0.878 . . . . 75.420000000000002 108.629 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.457 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.2 p 173.85 156.75 0.13 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-O 117.713 -1.137 . . . . 72.340000000000003 110.617 -178.785 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.457 ' CD1' ' C ' ' A' ' 18' ' ' SER . 33.1 m-85 -144.18 177.37 8.64 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-O 118.324 -0.846 . . . . 75.319999999999993 110.636 -178.765 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.409 ' O ' ' N ' ' A' ' 4' ' ' GLY . 7.9 m-30 -60.03 173.97 0.56 Allowed 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.547 1.067 . . . . 73.010000000000005 111.346 -174.018 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.634 0 N-CA-C 110.375 -1.09 . . . . 75.409999999999997 110.375 176.184 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.687 0 CA-C-O 118.063 -1.41 . . . . 73.310000000000002 112.331 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.46 -140.75 3.81 Favored Glycine 0 C--N 1.354 1.546 0 CA-C-N 120.011 1.906 . . . . 64.109999999999999 112.287 178.971 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.12 44.95 1.25 Allowed 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.799 1.799 . . . . 63.100000000000001 110.947 -178.491 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.07 -141.44 8.85 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.971 -1.46 . . . . 64.120000000000005 110.939 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -94.99 -34.71 12.25 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 117.224 -1.37 . . . . 73.120000000000005 112.927 -173.197 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -105.76 136.16 19.31 Favored Pre-proline 0 C--N 1.355 0.817 0 CA-C-O 115.362 -2.256 . . . . 74.109999999999999 109.159 -169.799 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -66.75 144.57 72.07 Favored 'Trans proline' 0 C--N 1.362 1.267 0 CA-C-N 124.097 2.499 . . . . 71.230000000000004 112.29 -177.346 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -86.77 -51.53 6.04 Favored 'General case' 0 C--N 1.358 0.956 0 CA-C-N 119.155 0.889 . . . . 65.439999999999998 108.896 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -131.41 174.52 9.99 Favored 'General case' 0 C--N 1.355 0.84 0 CA-C-O 118.738 -0.648 . . . . 74.140000000000001 109.314 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -134.35 170.39 15.8 Favored 'General case' 0 C--N 1.354 0.765 0 CA-C-O 118.607 -0.711 . . . . 75.030000000000001 109.187 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.21 -169.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.764 0 N-CA-C 106.728 -1.582 . . . . 65.439999999999998 106.728 -179.154 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 86.8 mtm-85 -77.69 68.58 3.8 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-N 120.061 1.3 . . . . 73.0 109.249 174.687 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 75.03 77.78 0.67 Allowed Glycine 0 C--N 1.358 1.754 0 CA-C-O 117.768 -1.573 . . . . 62.5 113.618 173.056 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -165.63 -65.45 0.03 OUTLIER 'General case' 0 C--N 1.358 0.971 0 CA-C-N 119.517 1.659 . . . . 74.25 111.42 172.225 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -171.0 143.77 1.68 Allowed Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.644 -2.122 . . . . 71.120000000000005 108.327 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -73.15 172.43 15.56 Favored 'Trans proline' 0 C--N 1.359 1.079 0 CA-C-N 123.989 2.46 . . . . 74.219999999999999 111.517 -176.889 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -134.14 38.82 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.939 0 N-CA-C 108.506 -0.924 . . . . 74.129999999999995 108.506 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.469 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 173.93 156.18 0.13 Allowed 'General case' 0 C--N 1.355 0.826 0 CA-C-N 119.735 1.152 . . . . 62.030000000000001 110.79 -176.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.469 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.2 m-85 -144.43 176.74 9.15 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-O 118.288 -0.863 . . . . 72.310000000000002 110.556 -178.337 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.409 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.46 176.39 0.19 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-N 119.2 0.909 . . . . 74.409999999999997 112.144 -174.279 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.632 0 N-CA-C 109.864 -1.295 . . . . 53.049999999999997 109.864 176.758 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.118 -1.379 . . . . 63.100000000000001 112.618 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.46 -141.94 3.6 Favored Glycine 0 C--N 1.355 1.6 0 CA-C-N 120.001 1.9 . . . . 73.140000000000001 111.735 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.93 46.01 1.17 Allowed 'General case' 0 C--N 1.357 0.912 0 CA-C-N 119.965 1.882 . . . . 60.439999999999998 111.169 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.01 -145.0 14.56 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.075 -1.403 . . . . 54.229999999999997 110.415 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 4.0 m80 -87.85 -42.29 12.64 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-N 118.86 1.33 . . . . 75.049999999999997 112.808 -177.103 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.7 t -96.87 134.96 22.37 Favored Pre-proline 0 C--N 1.353 0.734 0 CA-C-O 115.402 -2.237 . . . . 72.0 109.788 -166.157 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.95 143.77 67.59 Favored 'Trans proline' 0 C--N 1.362 1.253 0 CA-C-N 124.028 2.474 . . . . 65.209999999999994 112.158 -177.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 -86.18 -49.5 7.69 Favored 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.238 0.927 . . . . 64.109999999999999 109.111 178.266 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -133.13 175.54 9.29 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.697 -0.668 . . . . 75.25 109.331 -174.093 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -135.87 169.86 16.91 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.15 -0.685 . . . . 71.540000000000006 109.15 177.505 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -101.3 -169.4 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.757 0 N-CA-C 106.502 -1.666 . . . . 74.109999999999999 106.502 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.7 mtm180 -74.4 70.64 1.73 Allowed 'General case' 0 C--N 1.354 0.764 0 CA-C-N 120.038 1.29 . . . . 73.310000000000002 109.725 173.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.05 79.07 0.29 Allowed Glycine 0 C--N 1.355 1.619 0 CA-C-O 118.087 -1.396 . . . . 45.439999999999998 113.373 173.322 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -164.75 -64.7 0.04 OUTLIER 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.249 1.524 . . . . 73.129999999999995 110.903 172.371 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -170.99 143.2 1.6 Allowed Pre-proline 0 C--N 1.355 0.805 0 CA-C-O 115.551 -2.166 . . . . 75.239999999999995 108.416 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.16 172.52 15.38 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 124.023 2.472 . . . . 72.129999999999995 111.544 -176.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.3 mt -134.92 40.81 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.957 0 N-CA-C 108.587 -0.894 . . . . 70.409999999999997 108.587 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.6 p 172.8 156.56 0.1 Allowed 'General case' 0 C--N 1.353 0.754 0 CA-C-O 117.776 -1.107 . . . . 70.420000000000002 110.581 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.8 m-85 -142.99 176.7 8.89 Favored 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.169 -0.92 . . . . 71.349999999999994 110.238 -178.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.423 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.84 173.07 0.46 Allowed 'General case' 0 C--N 1.355 0.807 0 CA-C-N 119.619 1.099 . . . . 75.299999999999997 111.272 -174.031 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.48 0 N-CA-C 108.656 -1.778 . . . . 73.420000000000002 108.656 174.73 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 CA-C-O 118.275 -1.292 . . . . 62.210000000000001 112.026 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.49 -142.66 4.1 Favored Glycine 0 C--N 1.355 1.588 0 CA-C-O 117.224 -1.875 . . . . 74.030000000000001 111.812 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.48 45.71 1.13 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.972 1.886 . . . . 60.049999999999997 111.289 -178.877 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.4 -145.96 17.54 Favored Glycine 0 C--N 1.354 1.549 0 CA-C-O 118.179 -1.345 . . . . 61.119999999999997 110.626 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -85.71 -43.8 13.08 Favored 'General case' 0 C--N 1.357 0.894 0 CA-C-N 118.904 1.352 . . . . 73.239999999999995 112.884 -177.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.0 t -95.06 134.48 24.65 Favored Pre-proline 0 C--N 1.353 0.726 0 CA-C-O 115.257 -2.306 . . . . 74.319999999999993 109.959 -165.394 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -66.63 144.32 71.78 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 124.024 2.473 . . . . 72.439999999999998 112.229 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -86.67 -52.22 5.66 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.322 0.965 . . . . 62.520000000000003 108.755 178.333 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -131.09 174.51 9.95 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 118.713 -0.661 . . . . 73.150000000000006 109.392 -174.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -134.42 170.72 15.32 Favored 'General case' 0 C--N 1.353 0.755 0 N-CA-C 109.038 -0.727 . . . . 73.25 109.038 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -102.38 -169.53 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 N-CA-C 106.933 -1.506 . . . . 65.400000000000006 106.933 -178.863 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.2 ttm180 -70.05 70.71 0.37 Allowed 'General case' 0 C--N 1.352 0.688 0 CA-C-N 119.394 0.997 . . . . 74.420000000000002 109.312 172.281 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.43 81.63 0.1 OUTLIER Glycine 0 C--N 1.355 1.591 0 CA-C-O 117.956 -1.469 . . . . 63.530000000000001 113.918 174.621 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -164.94 -64.41 0.03 OUTLIER 'General case' 0 C--N 1.357 0.911 0 CA-C-N 119.525 1.662 . . . . 72.519999999999996 110.966 171.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -170.37 142.95 1.83 Allowed Pre-proline 0 C--N 1.354 0.783 0 CA-C-O 115.616 -2.135 . . . . 71.129999999999995 108.387 178.804 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.3 172.51 15.46 Favored 'Trans proline' 0 C--N 1.359 1.115 0 CA-C-N 124.016 2.47 . . . . 73.329999999999998 111.237 -177.06 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -134.35 38.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 N-CA-C 108.46 -0.941 . . . . 75.140000000000001 108.46 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.0 p 175.26 157.01 0.18 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.581 -1.199 . . . . 62.420000000000002 110.733 -176.707 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.1 m-85 -144.89 176.26 9.6 Favored 'General case' 0 C--N 1.358 0.97 0 CA-C-O 118.286 -0.864 . . . . 74.109999999999999 110.499 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.417 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.09 171.21 0.56 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-N 119.565 1.075 . . . . 74.510000000000005 111.57 -174.185 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.484 0 C-N-CA 119.503 -1.332 . . . . 63.25 112.417 176.404 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.368 -1.24 . . . . 74.540000000000006 112.596 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.34 -143.97 5.16 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 117.271 -1.85 . . . . 70.0 112.876 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.82 44.54 1.09 Allowed 'General case' 0 C--N 1.358 0.961 0 CA-C-N 119.585 1.693 . . . . 63.43 112.072 -177.494 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.5 -144.74 12.41 Favored Glycine 0 C--N 1.353 1.486 0 CA-C-O 118.144 -1.365 . . . . 63.350000000000001 110.533 178.522 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -89.33 -40.79 12.54 Favored 'General case' 0 C--N 1.358 0.959 0 CA-C-N 118.951 1.376 . . . . 63.5 113.46 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.6 t -95.93 133.6 25.1 Favored Pre-proline 0 C--N 1.354 0.761 0 CA-C-O 115.422 -2.228 . . . . 74.430000000000007 109.526 -166.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -65.45 145.33 82.51 Favored 'Trans proline' 0 C--N 1.362 1.275 0 CA-C-N 123.891 2.425 . . . . 72.420000000000002 112.058 -177.319 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 78.8 mt-10 -81.99 -51.71 7.78 Favored 'General case' 0 C--N 1.359 0.985 0 N-CA-C 108.352 -0.981 . . . . 72.200000000000003 108.352 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.5 p90 -150.04 172.59 15.01 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 118.506 -0.759 . . . . 74.239999999999995 110.279 -177.948 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -125.64 170.95 11.0 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 118.668 -0.682 . . . . 71.409999999999997 109.484 -177.503 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -94.42 -166.9 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.868 0 N-CA-C 107.67 -1.233 . . . . 51.119999999999997 107.67 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.4 tpt85 -68.52 67.75 0.13 Allowed 'General case' 0 C--N 1.354 0.779 0 CA-C-N 119.335 0.971 . . . . 73.329999999999998 109.544 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.58 80.48 0.2 Allowed Glycine 0 C--N 1.356 1.646 0 CA-C-O 117.882 -1.51 . . . . 64.030000000000001 113.591 177.406 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -161.31 -66.19 0.06 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-N 119.495 1.648 . . . . 74.310000000000002 111.314 170.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -171.42 153.59 3.61 Favored Pre-proline 0 C--N 1.356 0.85 0 CA-C-O 115.966 -1.969 . . . . 65.140000000000001 106.763 -177.857 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -79.97 169.47 17.81 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.657 2.342 . . . . 70.209999999999994 111.644 -177.462 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.0 mt -135.71 41.89 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.92 0 N-CA-C 107.591 -1.262 . . . . 62.450000000000003 107.591 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.446 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.3 OUTLIER 175.65 157.33 0.21 Allowed 'General case' 0 C--N 1.352 0.71 0 CA-C-O 117.809 -1.091 . . . . 74.200000000000003 110.753 -178.503 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.446 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.2 m-85 -144.99 174.97 10.57 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-O 118.208 -0.901 . . . . 74.409999999999997 110.113 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.67 175.49 0.25 Allowed 'General case' 0 C--N 1.356 0.87 0 CA-C-N 119.143 0.883 . . . . 70.420000000000002 112.208 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.582 0 N-CA-C 109.746 -1.342 . . . . 74.420000000000002 109.746 176.645 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.635 0 CA-C-O 118.427 -1.207 . . . . 73.209999999999994 112.322 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.85 -141.16 3.36 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.217 -1.88 . . . . 44.130000000000003 111.493 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.49 45.5 1.21 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 119.881 1.84 . . . . 74.040000000000006 111.167 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.15 -145.73 15.36 Favored Glycine 0 C--N 1.353 1.496 0 CA-C-O 118.323 -1.265 . . . . 33.210000000000001 110.705 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -88.31 -40.6 13.47 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-N 118.557 1.179 . . . . 65.209999999999994 113.115 -176.74 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.9 t -98.09 134.89 21.66 Favored Pre-proline 0 C--N 1.353 0.758 0 CA-C-O 115.502 -2.189 . . . . 73.019999999999996 109.498 -166.999 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -67.41 144.52 67.88 Favored 'Trans proline' 0 C--N 1.362 1.288 0 CA-C-N 123.763 2.38 . . . . 72.329999999999998 112.121 -178.094 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -87.15 -49.65 7.15 Favored 'General case' 0 C--N 1.358 0.961 0 CA-C-N 118.869 0.759 . . . . 52.539999999999999 109.301 178.077 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -133.46 175.71 9.18 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.744 -0.646 . . . . 71.540000000000006 109.677 -174.206 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -137.04 166.86 22.69 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.63 -0.7 . . . . 73.400000000000006 109.411 177.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -96.03 -168.03 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.841 0 N-CA-C 106.424 -1.695 . . . . 64.120000000000005 106.424 178.28 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.7 mtp180 -74.85 71.23 1.99 Allowed 'General case' 0 C--N 1.354 0.772 0 CA-C-N 120.3 1.409 . . . . 74.239999999999995 109.329 176.735 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.43 78.23 0.37 Allowed Glycine 0 C--N 1.355 1.624 0 CA-C-O 118.093 -1.393 . . . . 73.209999999999994 112.978 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -163.01 -63.42 0.04 OUTLIER 'General case' 0 C--N 1.357 0.899 0 CA-C-N 119.26 1.53 . . . . 63.119999999999997 111.28 172.819 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -170.12 144.11 2.12 Favored Pre-proline 0 C--N 1.355 0.821 0 CA-C-O 115.91 -1.995 . . . . 24.239999999999998 108.643 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -76.03 158.26 38.19 Favored 'Trans proline' 0 C--N 1.36 1.137 0 CA-C-N 123.585 2.316 . . . . 64.010000000000005 110.93 -178.837 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.405 HG22 ' O ' ' A' ' 17' ' ' ILE . 15.9 mm -119.99 22.59 5.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.916 0 O-C-N 123.916 0.76 . . . . 53.020000000000003 109.764 -176.661 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.443 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 12.1 p -175.19 157.58 2.27 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-N 120.451 1.478 . . . . 74.329999999999998 110.753 -175.672 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.0 m-85 -142.34 177.68 8.1 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.139 -0.934 . . . . 62.520000000000003 110.887 -176.442 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.412 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -58.3 172.77 0.42 Allowed 'General case' 0 C--N 1.355 0.815 0 CA-C-N 119.538 1.063 . . . . 74.230000000000004 111.593 -174.246 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.596 0 N-CA-C 108.817 -1.713 . . . . 64.230000000000004 108.817 175.011 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 CA-C-O 118.379 -1.234 . . . . 71.400000000000006 112.442 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.3 -141.73 3.25 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.221 -1.877 . . . . 71.120000000000005 111.235 179.697 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.51 45.99 1.04 Allowed 'General case' 0 C--N 1.356 0.886 0 CA-C-N 120.05 1.925 . . . . 75.219999999999999 111.52 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.95 -146.53 19.68 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.18 -1.344 . . . . 74.099999999999994 110.371 179.35 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -87.11 -41.01 14.13 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-N 118.931 1.366 . . . . 72.519999999999996 113.19 -178.209 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.45 133.73 25.41 Favored Pre-proline 0 C--N 1.353 0.744 0 CA-C-O 115.43 -2.224 . . . . 65.329999999999998 109.536 -166.2 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.46 144.27 72.69 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.915 2.434 . . . . 73.519999999999996 111.684 -178.077 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -82.24 -50.75 8.63 Favored 'General case' 0 C--N 1.356 0.876 0 N-CA-C 108.411 -0.959 . . . . 71.230000000000004 108.411 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -148.9 172.59 14.44 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 118.368 -0.825 . . . . 73.450000000000003 109.729 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -126.08 168.24 14.26 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.513 -0.756 . . . . 44.25 109.808 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -91.95 -171.07 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.835 0 N-CA-C 105.918 -1.882 . . . . 61.140000000000001 105.918 175.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.8 mtt-85 -71.2 76.81 0.71 Allowed 'General case' 0 C--N 1.353 0.75 0 CA-C-N 120.366 1.439 . . . . 51.520000000000003 110.071 177.029 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.53 75.93 0.44 Allowed Glycine 0 C--N 1.355 1.631 0 CA-C-O 118.104 -1.387 . . . . 54.539999999999999 112.985 172.283 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -161.9 -61.5 0.05 OUTLIER 'General case' 0 C--N 1.356 0.886 0 CA-C-N 119.212 1.506 . . . . 73.349999999999994 111.801 173.491 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -173.87 144.67 1.05 Allowed Pre-proline 0 C--N 1.355 0.832 0 CA-C-O 115.892 -2.004 . . . . 72.129999999999995 109.035 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.6 156.07 31.8 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 123.608 2.324 . . . . 74.340000000000003 110.79 -178.75 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 15.7 mm -118.85 21.42 5.96 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-O 118.625 -0.702 . . . . 73.340000000000003 109.427 -176.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.437 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 13.4 p -174.9 158.62 2.59 Favored 'General case' 0 C--N 1.356 0.868 0 CA-C-N 120.435 1.47 . . . . 64.420000000000002 110.994 -175.047 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.437 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -142.05 176.6 8.82 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.136 -0.935 . . . . 65.340000000000003 111.013 -177.042 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.417 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.2 m-30 -58.72 173.12 0.44 Allowed 'General case' 0 C--N 1.356 0.852 0 CA-C-N 119.609 1.095 . . . . 64.120000000000005 111.372 -174.468 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.587 0 C-N-CA 119.614 -1.279 . . . . 61.0 110.956 177.397 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.648 0 CA-C-O 117.923 -1.487 . . . . 53.329999999999998 113.841 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -164.96 -142.69 3.48 Favored Glycine 0 C--N 1.353 1.502 0 CA-C-N 120.06 1.93 . . . . 72.409999999999997 111.708 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.51 47.66 1.11 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 120.021 1.911 . . . . 75.299999999999997 111.209 -178.978 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.67 -145.71 18.21 Favored Glycine 0 C--N 1.354 1.551 0 CA-C-O 118.007 -1.44 . . . . 73.010000000000005 109.813 179.098 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -88.18 -41.72 12.8 Favored 'General case' 0 C--N 1.356 0.879 0 CA-C-N 119.029 1.415 . . . . 61.219999999999999 113.221 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -94.51 133.67 26.59 Favored Pre-proline 0 C--N 1.354 0.771 0 CA-C-O 115.456 -2.211 . . . . 71.209999999999994 109.712 -165.922 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.0 144.25 75.47 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 123.937 2.442 . . . . 73.540000000000006 111.634 -177.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -82.12 -50.07 9.47 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.473 -0.936 . . . . 71.400000000000006 108.473 178.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -149.92 173.09 14.19 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.398 -0.81 . . . . 73.200000000000003 109.732 -177.316 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -127.95 169.2 14.25 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.509 -0.757 . . . . 72.439999999999998 109.6 -178.217 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -92.49 -170.9 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.852 0 N-CA-C 107.109 -1.441 . . . . 72.120000000000005 107.109 177.345 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -69.86 73.8 0.43 Allowed 'General case' 0 C--N 1.352 0.679 0 CA-C-N 119.203 0.91 . . . . 64.209999999999994 109.441 174.628 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.79 76.8 0.43 Allowed Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.034 -1.426 . . . . 71.209999999999994 113.563 173.567 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -160.67 -66.16 0.06 Allowed 'General case' 0 C--N 1.356 0.853 0 CA-C-N 119.244 1.522 . . . . 43.409999999999997 111.077 170.188 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -170.91 152.15 3.52 Favored Pre-proline 0 C--N 1.357 0.913 0 CA-C-O 116.018 -1.944 . . . . 74.530000000000001 108.36 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -76.32 165.21 29.75 Favored 'Trans proline' 0 C--N 1.356 0.933 0 CA-C-N 123.474 2.277 . . . . 65.540000000000006 111.479 -177.442 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.9 mt -135.81 47.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.886 0 N-CA-C 107.382 -1.34 . . . . 71.439999999999998 107.382 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.435 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.9 p 166.32 156.53 0.03 OUTLIER 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.032 -0.985 . . . . 73.319999999999993 110.175 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' A' ' 18' ' ' SER . 34.3 m-85 -141.79 178.1 7.72 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 117.877 -1.059 . . . . 74.209999999999994 109.828 179.538 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.444 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.86 177.6 0.14 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 119.693 1.133 . . . . 73.099999999999994 110.751 -175.72 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.57 0 CA-C-N 120.615 1.552 . . . . 65.120000000000005 109.915 176.231 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.694 0 CA-C-O 117.858 -1.524 . . . . 74.109999999999999 113.611 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.06 -143.02 3.58 Favored Glycine 0 C--N 1.354 1.583 0 CA-C-N 120.216 2.008 . . . . 72.519999999999996 111.261 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.17 45.23 1.07 Allowed 'General case' 0 C--N 1.357 0.899 0 CA-C-N 120.067 1.934 . . . . 74.25 111.464 -178.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.74 -145.53 16.85 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.166 -1.352 . . . . 45.399999999999999 110.657 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -87.6 -39.99 14.6 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-N 118.778 1.289 . . . . 73.230000000000004 112.911 -176.785 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -98.77 134.54 21.51 Favored Pre-proline 0 C--N 1.354 0.79 0 CA-C-O 115.368 -2.254 . . . . 74.319999999999993 109.743 -166.713 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.99 147.31 84.43 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 124.019 2.471 . . . . 74.540000000000006 112.136 -177.339 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.4 mt-10 -83.93 -50.64 7.85 Favored 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.341 0.973 . . . . 71.140000000000001 108.38 178.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -151.5 174.64 13.16 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.417 -0.801 . . . . 61.119999999999997 110.412 -176.781 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -127.94 178.24 6.31 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.88 -1.057 . . . . 51.420000000000002 109.484 -176.571 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.36 -162.23 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.947 0 N-CA-C 105.265 -2.124 . . . . 55.520000000000003 105.265 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 70.0 mmt-85 -75.99 73.19 2.88 Favored 'General case' 0 C--N 1.355 0.804 0 CA-C-N 121.32 1.873 . . . . 72.239999999999995 108.221 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.05 79.71 0.24 Allowed Glycine 0 C--N 1.354 1.561 0 CA-C-O 118.382 -1.232 . . . . 64.030000000000001 110.858 176.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -156.21 -69.53 0.11 Allowed 'General case' 0 C--N 1.356 0.849 0 CA-C-N 118.846 1.323 . . . . 74.5 111.067 176.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 178.53 150.8 0.44 Allowed Pre-proline 0 C--N 1.353 0.759 0 CA-C-O 116.063 -1.922 . . . . 71.230000000000004 106.836 -177.389 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -75.58 167.21 26.98 Favored 'Trans proline' 0 C--N 1.356 0.968 0 CA-C-N 124.027 2.474 . . . . 63.409999999999997 110.814 -176.14 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mt -134.08 37.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.854 0 N-CA-C 107.908 -1.145 . . . . 65.010000000000005 107.908 178.606 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.43 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.3 p 171.75 155.71 0.08 Allowed 'General case' 0 C--N 1.354 0.801 0 CA-C-O 117.546 -1.216 . . . . 71.510000000000005 110.205 -175.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.43 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -141.34 175.83 9.35 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-O 118.244 -0.884 . . . . 73.329999999999998 110.332 -178.76 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.69 171.89 0.58 Allowed 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.636 1.107 . . . . 60.049999999999997 111.377 -174.274 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.538 0 C-N-CA 119.351 -1.404 . . . . 63.200000000000003 112.024 176.21 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.733 0 CA-C-O 118.102 -1.388 . . . . 42.109999999999999 113.273 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.15 -143.25 3.7 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-O 117.208 -1.885 . . . . 25.510000000000002 111.309 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -149.03 44.99 0.99 Allowed 'General case' 0 C--N 1.357 0.923 0 CA-C-N 120.158 1.979 . . . . 55.229999999999997 111.711 -179.046 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.03 -146.48 18.43 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 118.112 -1.382 . . . . 73.540000000000006 110.534 179.226 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 m170 -87.97 -38.52 15.47 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-N 119.012 1.406 . . . . 73.200000000000003 113.145 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.94 133.2 24.57 Favored Pre-proline 0 C--N 1.353 0.749 0 CA-C-O 115.339 -2.267 . . . . 73.299999999999997 109.688 -167.149 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -66.35 146.45 80.68 Favored 'Trans proline' 0 C--N 1.363 1.321 0 CA-C-N 123.987 2.46 . . . . 43.420000000000002 112.003 -177.063 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 -82.78 -50.58 8.52 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.317 -0.994 . . . . 52.450000000000003 108.317 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -150.69 173.57 14.01 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.544 -0.741 . . . . 71.239999999999995 110.302 -177.37 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.7 176.95 6.85 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 118.042 -0.98 . . . . 74.420000000000002 109.415 -176.197 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.0 -167.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.902 0 N-CA-C 105.068 -2.197 . . . . 72.409999999999997 105.068 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -74.13 75.78 1.77 Allowed 'General case' 0 C--N 1.354 0.767 0 CA-C-N 120.686 1.584 . . . . 74.230000000000004 108.907 178.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.96 76.59 0.33 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.134 -1.37 . . . . 73.329999999999998 111.179 175.309 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -156.83 -69.75 0.1 Allowed 'General case' 0 C--N 1.355 0.838 0 CA-C-N 119.028 1.414 . . . . 71.109999999999999 111.389 178.603 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -178.39 143.68 0.46 Allowed Pre-proline 0 C--N 1.354 0.787 0 CA-C-O 116.011 -1.947 . . . . 75.120000000000005 108.465 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -71.75 165.62 31.97 Favored 'Trans proline' 0 C--N 1.358 1.027 0 CA-C-N 123.791 2.39 . . . . 52.43 110.233 -177.787 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.44 37.72 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.877 0 N-CA-C 107.915 -1.142 . . . . 62.350000000000001 107.915 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.5 p 173.46 154.46 0.1 Allowed 'General case' 0 C--N 1.355 0.833 0 CA-C-O 117.494 -1.241 . . . . 74.340000000000003 110.185 -176.017 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.7 m-85 -141.57 175.63 9.53 Favored 'General case' 0 C--N 1.357 0.925 0 CA-C-O 118.3 -0.857 . . . . 74.409999999999997 110.246 -178.676 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -59.75 169.39 1.4 Allowed 'General case' 0 C--N 1.355 0.82 0 CA-C-N 119.688 1.131 . . . . 73.540000000000006 111.438 -173.201 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.581 0 N-CA-C 109.444 -1.462 . . . . 31.34 109.444 173.683 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.676 0 CA-C-O 118.316 -1.269 . . . . 74.310000000000002 112.64 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.05 -144.66 4.39 Favored Glycine 0 C--N 1.354 1.55 0 CA-C-O 117.351 -1.805 . . . . 72.230000000000004 111.467 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.01 46.26 1.08 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.782 1.791 . . . . 61.399999999999999 111.48 -179.113 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.84 -144.17 14.11 Favored Glycine 0 C--N 1.353 1.508 0 CA-C-O 118.102 -1.388 . . . . 65.230000000000004 110.195 179.151 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -88.95 -42.51 11.76 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.019 1.41 . . . . 74.239999999999995 113.508 -178.213 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.1 t -93.87 133.41 27.8 Favored Pre-proline 0 C--N 1.353 0.755 0 CA-C-O 115.446 -2.216 . . . . 64.150000000000006 109.478 -166.247 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -65.32 144.41 80.35 Favored 'Trans proline' 0 C--N 1.363 1.312 0 CA-C-N 123.943 2.444 . . . . 55.219999999999999 111.866 -177.789 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -81.5 -51.39 8.33 Favored 'General case' 0 C--N 1.358 0.968 0 N-CA-C 108.359 -0.978 . . . . 71.420000000000002 108.359 179.001 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.4 p90 -148.87 172.06 15.29 Favored 'General case' 0 C--N 1.354 0.796 0 CA-C-O 118.535 -0.745 . . . . 74.319999999999993 109.941 -177.846 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -125.01 170.27 11.3 Favored 'General case' 0 C--N 1.355 0.845 0 CA-C-O 118.857 -0.592 . . . . 74.209999999999994 109.614 -177.16 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -94.67 -170.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.808 0 N-CA-C 106.563 -1.643 . . . . 74.409999999999997 106.563 177.409 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.1 mtt180 -70.08 75.32 0.49 Allowed 'General case' 0 C--N 1.354 0.771 0 CA-C-N 119.876 1.216 . . . . 74.150000000000006 109.924 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.72 78.02 0.24 Allowed Glycine 0 C--N 1.355 1.587 0 CA-C-O 118.11 -1.383 . . . . 60.329999999999998 113.579 172.25 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -162.62 -63.31 0.05 OUTLIER 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.204 1.502 . . . . 63.130000000000003 111.296 172.101 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -172.92 143.99 1.17 Allowed Pre-proline 0 C--N 1.356 0.855 0 CA-C-O 115.713 -2.089 . . . . 60.229999999999997 108.281 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.52 170.74 19.61 Favored 'Trans proline' 0 C--N 1.357 0.984 0 CA-C-N 123.835 2.405 . . . . 75.510000000000005 111.17 -177.602 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -135.77 39.94 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.977 0 N-CA-C 108.488 -0.93 . . . . 74.310000000000002 108.488 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.433 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 19.2 p 175.1 155.42 0.15 Allowed 'General case' 0 C--N 1.353 0.747 0 CA-C-O 117.795 -1.097 . . . . 63.520000000000003 110.932 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.6 m-85 -142.59 175.19 9.99 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.049 -0.977 . . . . 72.319999999999993 110.169 -179.756 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.428 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.8 m-30 -58.46 172.43 0.48 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.509 1.05 . . . . 64.239999999999995 111.333 -174.05 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.528 0 N-CA-C 109.18 -1.568 . . . . 74.319999999999993 109.18 174.201 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.681 0 CA-C-O 118.145 -1.364 . . . . 63.0 112.89 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.85 -142.12 3.41 Favored Glycine 0 C--N 1.354 1.552 0 CA-C-O 117.177 -1.902 . . . . 75.109999999999999 112.144 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.8 46.22 1.02 Allowed 'General case' 0 C--N 1.358 0.945 0 CA-C-N 119.887 1.843 . . . . 53.229999999999997 111.697 -178.44 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.62 -144.56 15.59 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.146 -1.363 . . . . 51.43 110.6 179.559 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.2 m80 -87.44 -41.82 13.26 Favored 'General case' 0 C--N 1.356 0.88 0 CA-C-N 118.788 1.294 . . . . 53.43 113.141 -177.016 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -97.45 134.57 22.43 Favored Pre-proline 0 C--N 1.354 0.785 0 CA-C-O 115.397 -2.239 . . . . 61.439999999999998 109.693 -166.186 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -65.74 144.25 77.15 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 123.909 2.432 . . . . 75.099999999999994 111.81 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -81.52 -51.42 8.29 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.48 -0.933 . . . . 71.030000000000001 108.48 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -148.37 172.0 15.11 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-O 118.366 -0.826 . . . . 71.120000000000005 109.553 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -124.34 170.13 11.12 Favored 'General case' 0 C--N 1.355 0.823 0 O-C-N 123.781 0.675 . . . . 74.239999999999995 109.628 -177.084 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 m -92.59 -166.29 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 106.477 -1.675 . . . . 73.409999999999997 106.477 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 42.8 mtp180 -75.52 69.08 2.24 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-N 120.005 1.275 . . . . 74.519999999999996 109.56 175.425 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.29 78.21 0.46 Allowed Glycine 0 C--N 1.356 1.669 0 CA-C-O 118.01 -1.439 . . . . 74.200000000000003 113.208 174.378 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -164.28 -63.45 0.04 OUTLIER 'General case' 0 C--N 1.357 0.916 0 CA-C-N 119.376 1.588 . . . . 64.439999999999998 111.503 172.785 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -171.5 144.52 1.63 Allowed Pre-proline 0 C--N 1.355 0.809 0 CA-C-O 115.511 -2.185 . . . . 63.219999999999999 108.307 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -75.36 171.36 18.41 Favored 'Trans proline' 0 C--N 1.357 1.01 0 CA-C-N 123.95 2.447 . . . . 72.319999999999993 111.361 -177.497 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -136.06 40.33 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 108.413 -0.958 . . . . 74.25 108.413 178.232 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.8 p 174.31 155.93 0.13 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.77 -1.11 . . . . 45.100000000000001 111.08 -177.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.6 m-85 -143.25 175.91 9.53 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-O 118.283 -0.865 . . . . 64.329999999999998 110.559 -179.489 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.0 m-30 -60.13 176.57 0.31 Allowed 'General case' 0 C--N 1.356 0.866 0 CA-C-N 119.354 0.979 . . . . 75.209999999999994 111.775 -174.268 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.594 0 C-N-CA 119.514 -1.327 . . . . 72.420000000000002 109.894 173.474 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.119 -1.378 . . . . 73.209999999999994 112.414 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.84 -142.94 3.99 Favored Glycine 0 C--N 1.354 1.566 0 CA-C-N 119.897 1.848 . . . . 61.520000000000003 111.802 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.53 45.75 1.21 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 119.843 1.822 . . . . 64.319999999999993 111.171 -179.013 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.91 -143.57 12.24 Favored Glycine 0 C--N 1.353 1.516 0 CA-C-O 118.049 -1.417 . . . . 55.340000000000003 110.641 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -89.34 -41.49 12.11 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-N 118.765 1.283 . . . . 73.540000000000006 112.89 -176.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.7 t -98.6 135.29 21.14 Favored Pre-proline 0 C--N 1.353 0.748 0 CA-C-O 115.363 -2.256 . . . . 65.150000000000006 109.661 -166.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -66.66 144.7 73.16 Favored 'Trans proline' 0 C--N 1.362 1.254 0 CA-C-N 124.036 2.477 . . . . 62.109999999999999 112.43 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.78 -52.11 5.7 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.275 0.943 . . . . 72.099999999999994 108.893 178.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -132.18 174.69 9.95 Favored 'General case' 0 C--N 1.354 0.778 0 CA-C-O 118.731 -0.652 . . . . 61.439999999999998 109.449 -174.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -134.76 170.56 15.64 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-O 118.742 -0.647 . . . . 73.209999999999994 109.305 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -100.91 -170.4 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.12 -1.437 . . . . 71.019999999999996 107.12 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 ttp180 -78.68 65.81 4.03 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-N 120.003 1.274 . . . . 72.140000000000001 109.177 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 79.73 77.9 0.91 Allowed Glycine 0 C--N 1.356 1.69 0 CA-C-O 117.986 -1.452 . . . . 60.32 113.438 175.436 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -165.23 -71.96 0.03 OUTLIER 'General case' 0 C--N 1.358 0.952 0 CA-C-N 119.452 1.626 . . . . 72.219999999999999 110.8 170.411 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.98 150.69 6.34 Favored Pre-proline 0 C--N 1.355 0.818 0 CA-C-O 115.777 -2.059 . . . . 62.340000000000003 106.996 -179.024 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.67 173.05 15.16 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.733 2.369 . . . . 65.120000000000005 111.432 -176.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -134.25 38.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 108.419 -0.956 . . . . 72.239999999999995 108.419 178.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.468 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.8 p 175.08 157.36 0.17 Allowed 'General case' 0 C--N 1.354 0.781 0 CA-C-O 117.445 -1.264 . . . . 72.239999999999995 110.798 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.468 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -144.54 176.68 9.22 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 118.267 -0.873 . . . . 65.420000000000002 110.378 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.421 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.17 174.45 0.39 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-N 119.567 1.076 . . . . 74.230000000000004 111.382 -174.378 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.508 0 CA-C-N 120.143 1.338 . . . . 74.540000000000006 111.798 176.85 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.293 -1.282 . . . . 71.519999999999996 112.885 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.61 -144.03 4.29 Favored Glycine 0 C--N 1.354 1.543 0 CA-C-O 117.415 -1.769 . . . . 44.109999999999999 111.614 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.61 46.16 1.29 Allowed 'General case' 0 C--N 1.356 0.887 0 CA-C-N 119.751 1.776 . . . . 54.119999999999997 110.677 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.61 -139.63 9.2 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 118.034 -1.426 . . . . 53.020000000000003 110.798 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -95.31 -35.68 11.69 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 117.482 -1.247 . . . . 52.530000000000001 113.285 -173.102 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -105.52 136.13 19.28 Favored Pre-proline 0 C--N 1.355 0.824 0 CA-C-O 115.414 -2.231 . . . . 65.040000000000006 109.285 -169.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -66.99 143.78 67.36 Favored 'Trans proline' 0 C--N 1.361 1.211 0 CA-C-N 123.894 2.427 . . . . 73.209999999999994 112.289 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.3 mt-10 -85.73 -48.73 8.55 Favored 'General case' 0 C--N 1.358 0.954 0 CA-C-N 118.886 0.766 . . . . 65.200000000000003 109.413 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -134.71 175.02 9.93 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.84 -0.6 . . . . 63.310000000000002 109.548 -173.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -135.44 171.19 14.8 Favored 'General case' 0 C--N 1.353 0.744 0 N-CA-C 109.105 -0.702 . . . . 72.25 109.105 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.5 m -103.31 -170.32 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.746 0 N-CA-C 107.225 -1.398 . . . . 61.420000000000002 107.225 -177.428 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -72.5 71.32 0.94 Allowed 'General case' 0 C--N 1.353 0.735 0 CA-C-N 119.146 0.885 . . . . 71.219999999999999 108.885 172.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.24 80.41 0.2 Allowed Glycine 0 C--N 1.355 1.595 0 CA-C-O 118.19 -1.339 . . . . 73.439999999999998 113.812 173.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -164.25 -70.9 0.04 OUTLIER 'General case' 0 C--N 1.357 0.895 0 CA-C-N 119.241 1.52 . . . . 73.099999999999994 110.37 170.558 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.83 150.27 6.32 Favored Pre-proline 0 C--N 1.355 0.826 0 CA-C-O 115.871 -2.014 . . . . 55.030000000000001 106.839 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -75.42 172.77 15.69 Favored 'Trans proline' 0 C--N 1.356 0.93 0 CA-C-N 123.58 2.314 . . . . 74.450000000000003 111.319 -176.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.1 mt -135.32 41.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.981 0 N-CA-C 108.321 -0.992 . . . . 74.209999999999994 108.321 178.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.449 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 171.99 156.77 0.09 Allowed 'General case' 0 C--N 1.354 0.803 0 CA-C-O 117.889 -1.053 . . . . 71.209999999999994 110.676 -179.266 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.9 m-85 -142.96 177.8 8.11 Favored 'General case' 0 C--N 1.358 0.96 0 CA-C-O 118.106 -0.95 . . . . 62.130000000000003 110.123 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.1 m-30 -59.43 175.73 0.31 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.713 1.142 . . . . 74.409999999999997 111.234 -174.716 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.611 0 N-CA-C 109.932 -1.267 . . . . 70.230000000000004 109.932 176.422 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.66 0 CA-C-O 118.663 -1.076 . . . . 74.310000000000002 111.942 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.98 -144.98 5.52 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.497 -1.724 . . . . 71.430000000000007 111.852 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.99 45.67 1.17 Allowed 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.633 1.716 . . . . 53.539999999999999 111.374 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.25 -142.47 11.79 Favored Glycine 0 C--N 1.354 1.532 0 CA-C-O 118.033 -1.426 . . . . 60.130000000000003 110.494 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.3 m170 -88.57 -45.99 9.44 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 118.983 1.391 . . . . 63.210000000000001 113.144 -177.21 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -93.2 134.39 27.13 Favored Pre-proline 0 C--N 1.353 0.732 0 CA-C-O 115.637 -2.125 . . . . 71.150000000000006 109.44 -165.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -66.64 143.99 70.47 Favored 'Trans proline' 0 C--N 1.363 1.3 0 CA-C-N 123.822 2.401 . . . . 71.140000000000001 112.183 -177.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.4 mt-10 -86.31 -50.82 6.65 Favored 'General case' 0 C--N 1.358 0.935 0 CA-C-N 118.806 0.73 . . . . 63.240000000000002 109.211 178.02 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -133.44 174.0 10.88 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-O 118.853 -0.594 . . . . 71.409999999999997 109.939 -174.343 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -135.07 170.82 15.32 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 118.694 -0.669 . . . . 74.310000000000002 109.256 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -102.63 -169.63 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.737 0 N-CA-C 107.031 -1.47 . . . . 64.549999999999997 107.031 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -73.45 70.98 1.28 Allowed 'General case' 0 C--N 1.353 0.729 0 CA-C-N 119.643 1.11 . . . . 74.019999999999996 108.875 173.027 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.97 80.33 0.22 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.118 -1.379 . . . . 61.219999999999999 113.621 173.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.67 -68.87 0.05 OUTLIER 'General case' 0 C--N 1.356 0.858 0 CA-C-N 119.155 1.477 . . . . 75.019999999999996 109.959 170.066 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -168.56 149.44 4.42 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.964 -1.97 . . . . 72.150000000000006 106.895 178.773 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -75.53 173.42 14.53 Favored 'Trans proline' 0 C--N 1.356 0.973 0 CA-C-N 123.529 2.296 . . . . 64.409999999999997 111.226 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.5 39.37 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.906 0 N-CA-C 108.479 -0.934 . . . . 72.230000000000004 108.479 179.053 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.462 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.5 p 174.96 157.13 0.16 Allowed 'General case' 0 C--N 1.354 0.766 0 CA-C-O 117.714 -1.136 . . . . 72.129999999999995 111.01 -177.043 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.462 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.1 m-85 -144.53 176.7 9.2 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-O 118.248 -0.882 . . . . 73.400000000000006 110.285 -179.722 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.414 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.17 169.63 1.08 Allowed 'General case' 0 C--N 1.355 0.812 0 CA-C-N 119.652 1.115 . . . . 63.43 111.534 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.513 0 C-N-CA 119.303 -1.427 . . . . 62.409999999999997 111.491 176.457 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.65 0 CA-C-O 117.919 -1.49 . . . . 72.150000000000006 113.325 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.76 -141.77 3.23 Favored Glycine 0 C--N 1.354 1.577 0 CA-C-N 120.159 1.98 . . . . 63.310000000000002 111.527 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.62 46.01 1.11 Allowed 'General case' 0 C--N 1.358 0.935 0 CA-C-N 119.898 1.849 . . . . 72.430000000000007 111.018 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.66 -137.95 7.81 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 117.788 -1.562 . . . . 24.350000000000001 110.844 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -100.76 -24.7 14.34 Favored 'General case' 0 C--N 1.359 0.99 0 CA-C-O 116.653 -1.641 . . . . 75.430000000000007 114.039 -172.54 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.3 t -114.21 135.25 22.15 Favored Pre-proline 0 C--N 1.356 0.891 0 CA-C-O 115.384 -2.246 . . . . 75.25 108.685 -171.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -65.96 144.27 75.83 Favored 'Trans proline' 0 C--N 1.361 1.21 0 CA-C-N 123.884 2.423 . . . . 72.540000000000006 111.788 -176.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -81.37 -50.67 9.2 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.255 -1.017 . . . . 75.329999999999998 108.255 178.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -149.22 172.2 15.24 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.472 -0.775 . . . . 62.119999999999997 109.863 -177.686 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -127.13 168.59 14.44 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.466 -0.778 . . . . 72.129999999999995 109.506 -177.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.411 ' O ' ' N ' ' A' ' 13' ' ' GLY . 3.1 m -94.65 -176.99 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.805 0 N-CA-C 107.334 -1.358 . . . . 75.310000000000002 107.334 176.181 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -55.2 76.47 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 CA-C-N 118.309 0.504 . . . . 74.310000000000002 111.895 170.44 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' VAL . . . 57.49 78.44 0.13 Allowed Glycine 0 C--N 1.354 1.576 0 CA-C-O 118.056 -1.414 . . . . 64.420000000000002 114.097 172.521 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -161.26 -61.86 0.05 Allowed 'General case' 0 C--N 1.356 0.88 0 CA-C-N 119.414 1.607 . . . . 52.140000000000001 111.805 173.084 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -174.52 145.51 0.99 Allowed Pre-proline 0 C--N 1.355 0.833 0 CA-C-O 115.777 -2.059 . . . . 75.019999999999996 108.448 -178.605 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.56 168.52 24.26 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.677 2.349 . . . . 74.219999999999999 111.205 -178.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.7 mt -137.45 44.3 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 107.751 -1.203 . . . . 63.340000000000003 107.751 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.45 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.0 p 170.03 155.6 0.05 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.878 -1.058 . . . . 63.329999999999998 110.496 -179.548 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.45 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.9 m-85 -141.88 175.82 9.42 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.291 -0.862 . . . . 53.119999999999997 109.984 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.437 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -57.98 172.13 0.45 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.497 1.044 . . . . 71.230000000000004 111.484 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 1.641 0 N-CA-C 108.308 -1.917 . . . . 75.150000000000006 108.308 174.304 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 CA-C-O 118.357 -1.246 . . . . 73.510000000000005 112.267 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.62 -143.19 3.87 Favored Glycine 0 C--N 1.355 1.592 0 CA-C-O 117.135 -1.925 . . . . 65.439999999999998 111.655 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.52 45.79 1.12 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.957 1.878 . . . . 74.200000000000003 111.105 -178.489 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.94 -144.2 14.27 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.169 -1.351 . . . . 33.539999999999999 110.707 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.7 m-70 -88.78 -40.81 12.93 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 118.829 1.314 . . . . 74.540000000000006 113.026 -176.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -99.26 135.5 20.73 Favored Pre-proline 0 C--N 1.354 0.775 0 CA-C-O 115.233 -2.318 . . . . 72.109999999999999 109.389 -166.288 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -66.8 144.89 73.05 Favored 'Trans proline' 0 C--N 1.364 1.344 0 CA-C-N 124.001 2.464 . . . . 73.409999999999997 111.879 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -82.64 -51.28 7.89 Favored 'General case' 0 C--N 1.359 0.989 0 N-CA-C 108.392 -0.966 . . . . 72.409999999999997 108.392 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -149.53 172.95 14.16 Favored 'General case' 0 C--N 1.356 0.861 0 CA-C-O 118.155 -0.926 . . . . 72.420000000000002 109.747 -177.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -126.36 168.55 14.01 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 118.551 -0.738 . . . . 74.109999999999999 109.974 -176.916 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -90.09 -169.99 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.881 0 N-CA-C 106.645 -1.613 . . . . 64.239999999999995 106.645 177.516 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -70.73 75.12 0.6 Allowed 'General case' 0 C--N 1.353 0.718 0 CA-C-N 119.479 1.036 . . . . 71.120000000000005 109.153 176.198 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.1 77.45 0.35 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 118.107 -1.385 . . . . 64.209999999999994 113.058 173.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -160.03 -65.12 0.07 Allowed 'General case' 0 C--N 1.357 0.919 0 CA-C-N 119.188 1.494 . . . . 55.100000000000001 111.279 171.45 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.09 154.56 3.41 Favored Pre-proline 0 C--N 1.355 0.814 0 CA-C-O 116.027 -1.94 . . . . 74.310000000000002 107.6 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -80.87 155.99 20.5 Favored 'Trans proline' 0 C--N 1.36 1.174 0 CA-C-N 123.698 2.357 . . . . 64.0 111.257 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.5 mm -118.73 17.75 6.85 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-O 118.284 -0.865 . . . . 73.329999999999998 109.23 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 7.1 m -165.9 158.87 15.29 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 121.102 1.774 . . . . 71.239999999999995 110.558 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -142.8 174.94 10.21 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 119.789 1.177 . . . . 73.109999999999999 110.713 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.432 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.18 174.02 0.43 Allowed 'General case' 0 C--N 1.356 0.855 0 CA-C-N 119.242 0.928 . . . . 73.200000000000003 111.266 -174.162 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.483 0 N-CA-C 109.036 -1.626 . . . . 70.109999999999999 109.036 175.558 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.734 0 CA-C-O 118.463 -1.187 . . . . 75.299999999999997 112.278 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.77 -147.08 6.17 Favored Glycine 0 C--N 1.355 1.597 0 CA-C-O 117.486 -1.73 . . . . 71.319999999999993 111.859 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.2 46.34 1.15 Allowed 'General case' 0 C--N 1.357 0.925 0 CA-C-N 119.78 1.79 . . . . 72.129999999999995 111.357 -178.508 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.18 -144.69 15.42 Favored Glycine 0 C--N 1.354 1.57 0 CA-C-O 117.9 -1.5 . . . . 54.439999999999998 110.249 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -87.76 -43.1 12.13 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-N 119.142 1.471 . . . . 71.319999999999993 112.926 -177.352 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -96.4 134.98 22.74 Favored Pre-proline 0 C--N 1.354 0.764 0 CA-C-O 115.199 -2.334 . . . . 64.200000000000003 109.814 -165.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.22 145.05 83.19 Favored 'Trans proline' 0 C--N 1.363 1.323 0 CA-C-N 124.146 2.517 . . . . 72.530000000000001 112.257 -177.432 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 75.9 mt-10 -82.45 -52.14 7.16 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 108.177 -1.045 . . . . 54.43 108.177 178.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -149.32 173.0 13.98 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-O 118.414 -0.803 . . . . 73.010000000000005 109.685 -177.4 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -126.4 169.55 12.85 Favored 'General case' 0 C--N 1.354 0.804 0 CA-C-O 118.505 -0.759 . . . . 71.230000000000004 110.095 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -93.41 -171.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 N-CA-C 106.872 -1.529 . . . . 74.400000000000006 106.872 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.3 mtt-85 -70.38 76.1 0.55 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.826 1.194 . . . . 74.010000000000005 109.879 173.719 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.57 76.97 0.4 Allowed Glycine 0 C--N 1.355 1.613 0 CA-C-O 118.048 -1.418 . . . . 52.140000000000001 113.267 172.176 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -160.59 -67.16 0.07 Allowed 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.203 1.502 . . . . 75.439999999999998 110.934 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.07 153.06 3.04 Favored Pre-proline 0 C--N 1.353 0.753 0 CA-C-O 115.754 -2.07 . . . . 75.209999999999994 107.253 -178.423 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.38 171.51 15.9 Favored 'Trans proline' 0 C--N 1.357 1.022 0 CA-C-N 123.911 2.433 . . . . 40.140000000000001 111.661 -177.218 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.3 mt -135.9 41.37 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.799 -1.186 . . . . 73.239999999999995 107.799 177.072 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.434 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 2.7 p 174.5 156.65 0.15 Allowed 'General case' 0 C--N 1.354 0.774 0 CA-C-O 117.809 -1.091 . . . . 61.020000000000003 110.731 -178.034 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.434 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.7 m-85 -143.76 175.69 9.8 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.133 -0.937 . . . . 75.400000000000006 110.071 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.78 176.15 0.22 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.654 1.115 . . . . 73.239999999999995 111.351 -174.614 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.574 0 CA-C-N 120.227 1.376 . . . . 61.340000000000003 110.641 176.51 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.715 0 CA-C-O 118.521 -1.155 . . . . 73.299999999999997 111.246 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.3 -146.45 5.82 Favored Glycine 0 C--N 1.354 1.58 0 CA-C-O 117.389 -1.784 . . . . 74.450000000000003 111.753 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.96 45.92 1.09 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.718 1.759 . . . . 65.040000000000006 111.318 -178.481 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.7 -139.65 9.72 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.806 -1.552 . . . . 74.519999999999996 110.62 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -93.52 -38.81 11.2 Favored 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.045 1.422 . . . . 63.119999999999997 113.151 -174.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.4 t -101.67 135.17 19.83 Favored Pre-proline 0 C--N 1.354 0.799 0 CA-C-O 115.149 -2.358 . . . . 73.340000000000003 109.495 -167.635 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.94 144.53 76.89 Favored 'Trans proline' 0 C--N 1.362 1.255 0 CA-C-N 124.165 2.523 . . . . 63.020000000000003 112.218 -176.905 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -81.87 -51.77 7.77 Favored 'General case' 0 C--N 1.358 0.94 0 CA-C-N 119.486 1.039 . . . . 70.310000000000002 108.313 178.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -149.19 172.38 14.93 Favored 'General case' 0 C--N 1.353 0.757 0 CA-C-O 118.342 -0.837 . . . . 64.439999999999998 110.116 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -124.77 171.34 10.19 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-O 118.665 -0.683 . . . . 74.450000000000003 110.016 -176.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 m -94.87 -166.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 107.484 -1.302 . . . . 71.540000000000006 107.484 -178.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 tpt180 -71.01 67.22 0.41 Allowed 'General case' 0 C--N 1.355 0.813 0 CA-C-N 119.801 1.182 . . . . 75.319999999999993 109.292 173.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.15 79.39 0.29 Allowed Glycine 0 C--N 1.355 1.604 0 CA-C-O 117.844 -1.531 . . . . 74.010000000000005 113.546 176.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -161.1 -71.81 0.06 Allowed 'General case' 0 C--N 1.358 0.972 0 CA-C-N 119.579 1.689 . . . . 72.319999999999993 110.48 170.044 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -163.17 154.56 14.73 Favored Pre-proline 0 C--N 1.355 0.828 0 CA-C-O 116.058 -1.925 . . . . 73.109999999999999 107.249 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -78.07 169.28 20.65 Favored 'Trans proline' 0 C--N 1.358 1.069 0 CA-C-N 123.577 2.313 . . . . 71.150000000000006 111.238 -177.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -133.37 36.38 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.702 -1.221 . . . . 73.340000000000003 107.702 175.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -173.86 158.73 3.27 Favored 'General case' 0 C--N 1.353 0.742 0 CA-C-O 116.702 -1.618 . . . . 24.43 110.204 -177.122 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.5 m-85 -145.21 173.64 11.77 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-N 119.538 1.063 . . . . 63.119999999999997 110.053 174.382 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.5 171.31 0.85 Allowed 'General case' 0 C--N 1.354 0.793 0 CA-C-N 119.711 1.141 . . . . 74.340000000000003 111.049 -174.267 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.496 0 CA-C-N 120.471 1.487 . . . . 55.409999999999997 111.472 175.135 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 CA-C-O 118.486 -1.174 . . . . 73.150000000000006 112.13 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.15 -144.12 5.18 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.496 -1.724 . . . . 62.350000000000001 112.252 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.94 44.78 1.26 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.526 1.663 . . . . 74.150000000000006 111.042 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.64 -141.69 9.42 Favored Glycine 0 C--N 1.353 1.521 0 CA-C-O 118.076 -1.402 . . . . 72.109999999999999 110.825 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -93.01 -39.24 11.22 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 118.69 1.245 . . . . 71.150000000000006 113.177 -175.404 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.1 t -99.62 135.12 20.67 Favored Pre-proline 0 C--N 1.353 0.743 0 CA-C-O 115.385 -2.245 . . . . 55.399999999999999 109.233 -168.246 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -66.78 144.27 70.7 Favored 'Trans proline' 0 C--N 1.362 1.244 0 CA-C-N 123.907 2.431 . . . . 64.030000000000001 112.22 -177.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.9 mt-10 -86.13 -51.53 6.25 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 118.9 0.773 . . . . 32.130000000000003 109.167 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -132.18 174.31 10.34 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 118.91 -0.567 . . . . 71.230000000000004 109.543 -174.816 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -134.06 171.8 13.72 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.099 -0.704 . . . . 64.319999999999993 109.099 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -104.28 -165.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.775 0 N-CA-C 106.939 -1.504 . . . . 64.209999999999994 106.939 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -74.95 67.22 1.66 Allowed 'General case' 0 C--N 1.352 0.705 0 CA-C-N 119.602 1.092 . . . . 63.149999999999999 108.93 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 66.75 80.63 0.18 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 117.963 -1.465 . . . . 65.549999999999997 113.615 175.119 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -164.87 -64.03 0.03 OUTLIER 'General case' 0 C--N 1.358 0.941 0 CA-C-N 119.486 1.643 . . . . 70.230000000000004 111.028 172.626 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -169.87 143.28 2.09 Favored Pre-proline 0 C--N 1.354 0.773 0 CA-C-O 115.756 -2.069 . . . . 73.010000000000005 108.364 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -73.74 173.19 14.37 Favored 'Trans proline' 0 C--N 1.359 1.094 0 CA-C-N 123.956 2.449 . . . . 64.519999999999996 111.087 -177.481 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -135.05 38.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 108.631 -0.877 . . . . 63.43 108.631 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.9 p 175.52 156.88 0.2 Allowed 'General case' 0 C--N 1.355 0.835 0 CA-C-O 117.706 -1.14 . . . . 65.409999999999997 110.902 -176.802 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.6 m-85 -144.81 176.38 9.49 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-O 118.291 -0.861 . . . . 74.439999999999998 110.542 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.23 174.4 0.29 Allowed 'General case' 0 C--N 1.355 0.823 0 CA-C-N 119.369 0.986 . . . . 75.430000000000007 112.117 -174.293 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.639 0 N-CA-C 109.34 -1.504 . . . . 64.230000000000004 109.34 176.648 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 CA-C-O 118.529 -1.151 . . . . 65.230000000000004 112.108 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.29 -144.97 5.58 Favored Glycine 0 C--N 1.355 1.617 0 CA-C-O 117.43 -1.761 . . . . 54.340000000000003 111.61 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.34 45.6 1.23 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-N 119.717 1.759 . . . . 41.340000000000003 111.099 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.35 -145.79 17.03 Favored Glycine 0 C--N 1.354 1.53 0 CA-C-O 118.256 -1.302 . . . . 70.209999999999994 110.529 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -85.89 -45.99 11.02 Favored 'General case' 0 C--N 1.357 0.892 0 CA-C-N 118.928 1.364 . . . . 61.25 112.91 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -92.76 134.74 27.16 Favored Pre-proline 0 C--N 1.354 0.795 0 CA-C-O 115.312 -2.28 . . . . 74.329999999999998 109.678 -164.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.45 143.8 64.73 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 123.876 2.42 . . . . 62.140000000000001 112.281 -177.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -86.11 -47.44 9.52 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 118.885 0.766 . . . . 72.439999999999998 109.364 177.924 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -135.83 175.76 9.3 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 118.668 -0.682 . . . . 64.299999999999997 109.724 -173.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -136.14 170.41 16.06 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 118.771 -0.633 . . . . 74.019999999999996 109.301 178.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.66 -167.53 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.787 0 N-CA-C 106.854 -1.536 . . . . 61.32 106.854 -178.554 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -76.05 65.62 2.11 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-N 120.309 1.413 . . . . 75.239999999999995 109.286 175.357 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 72.85 79.67 0.46 Allowed Glycine 0 C--N 1.356 1.66 0 CA-C-O 117.884 -1.509 . . . . 73.5 113.552 175.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -165.16 -65.81 0.03 OUTLIER 'General case' 0 C--N 1.359 1.019 0 CA-C-N 119.582 1.691 . . . . 75.109999999999999 111.376 171.616 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.4 t -169.49 142.95 2.2 Favored Pre-proline 0 C--N 1.355 0.813 0 CA-C-O 115.644 -2.122 . . . . 64.439999999999998 108.437 179.363 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.51 172.77 15.04 Favored 'Trans proline' 0 C--N 1.359 1.098 0 CA-C-N 124.036 2.477 . . . . 63.020000000000003 111.542 -176.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -135.46 40.71 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.927 0 N-CA-C 108.629 -0.878 . . . . 75.420000000000002 108.629 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.457 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.2 p 173.85 156.75 0.13 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-O 117.713 -1.137 . . . . 72.340000000000003 110.617 -178.785 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.457 ' CD1' ' C ' ' A' ' 18' ' ' SER . 33.1 m-85 -144.18 177.37 8.64 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-O 118.324 -0.846 . . . . 75.319999999999993 110.636 -178.765 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.409 ' O ' ' N ' ' A' ' 4' ' ' GLY . 7.9 m-30 -60.03 173.97 0.56 Allowed 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.547 1.067 . . . . 73.010000000000005 111.346 -174.018 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.634 0 N-CA-C 110.375 -1.09 . . . . 75.409999999999997 110.375 176.184 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.687 0 CA-C-O 118.063 -1.41 . . . . 73.310000000000002 112.331 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.46 -140.75 3.81 Favored Glycine 0 C--N 1.354 1.546 0 CA-C-N 120.011 1.906 . . . . 64.109999999999999 112.287 178.971 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.12 44.95 1.25 Allowed 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.799 1.799 . . . . 63.100000000000001 110.947 -178.491 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.07 -141.44 8.85 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.971 -1.46 . . . . 64.120000000000005 110.939 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -94.99 -34.71 12.25 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 117.224 -1.37 . . . . 73.120000000000005 112.927 -173.197 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -105.76 136.16 19.31 Favored Pre-proline 0 C--N 1.355 0.817 0 CA-C-O 115.362 -2.256 . . . . 74.109999999999999 109.159 -169.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -66.75 144.57 72.07 Favored 'Trans proline' 0 C--N 1.362 1.267 0 CA-C-N 124.097 2.499 . . . . 71.230000000000004 112.29 -177.346 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -86.77 -51.53 6.04 Favored 'General case' 0 C--N 1.358 0.956 0 CA-C-N 119.155 0.889 . . . . 65.439999999999998 108.896 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -131.41 174.52 9.99 Favored 'General case' 0 C--N 1.355 0.84 0 CA-C-O 118.738 -0.648 . . . . 74.140000000000001 109.314 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -134.35 170.39 15.8 Favored 'General case' 0 C--N 1.354 0.765 0 CA-C-O 118.607 -0.711 . . . . 75.030000000000001 109.187 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.21 -169.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.764 0 N-CA-C 106.728 -1.582 . . . . 65.439999999999998 106.728 -179.154 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 86.8 mtm-85 -77.69 68.58 3.8 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-N 120.061 1.3 . . . . 73.0 109.249 174.687 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 75.03 77.78 0.67 Allowed Glycine 0 C--N 1.358 1.754 0 CA-C-O 117.768 -1.573 . . . . 62.5 113.618 173.056 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -165.63 -65.45 0.03 OUTLIER 'General case' 0 C--N 1.358 0.971 0 CA-C-N 119.517 1.659 . . . . 74.25 111.42 172.225 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -171.0 143.77 1.68 Allowed Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.644 -2.122 . . . . 71.120000000000005 108.327 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -73.15 172.43 15.56 Favored 'Trans proline' 0 C--N 1.359 1.079 0 CA-C-N 123.989 2.46 . . . . 74.219999999999999 111.517 -176.889 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -134.14 38.82 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.939 0 N-CA-C 108.506 -0.924 . . . . 74.129999999999995 108.506 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.469 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 173.93 156.18 0.13 Allowed 'General case' 0 C--N 1.355 0.826 0 CA-C-N 119.735 1.152 . . . . 62.030000000000001 110.79 -176.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.469 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.2 m-85 -144.43 176.74 9.15 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-O 118.288 -0.863 . . . . 72.310000000000002 110.556 -178.337 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.409 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.46 176.39 0.19 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-N 119.2 0.909 . . . . 74.409999999999997 112.144 -174.279 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.632 0 N-CA-C 109.864 -1.295 . . . . 53.049999999999997 109.864 176.758 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.118 -1.379 . . . . 63.100000000000001 112.618 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.46 -141.94 3.6 Favored Glycine 0 C--N 1.355 1.6 0 CA-C-N 120.001 1.9 . . . . 73.140000000000001 111.735 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.93 46.01 1.17 Allowed 'General case' 0 C--N 1.357 0.912 0 CA-C-N 119.965 1.882 . . . . 60.439999999999998 111.169 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.01 -145.0 14.56 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.075 -1.403 . . . . 54.229999999999997 110.415 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 4.0 m80 -87.85 -42.29 12.64 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-N 118.86 1.33 . . . . 75.049999999999997 112.808 -177.103 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.7 t -96.87 134.96 22.37 Favored Pre-proline 0 C--N 1.353 0.734 0 CA-C-O 115.402 -2.237 . . . . 72.0 109.788 -166.157 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.95 143.77 67.59 Favored 'Trans proline' 0 C--N 1.362 1.253 0 CA-C-N 124.028 2.474 . . . . 65.209999999999994 112.158 -177.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 -86.18 -49.5 7.69 Favored 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.238 0.927 . . . . 64.109999999999999 109.111 178.266 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -133.13 175.54 9.29 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.697 -0.668 . . . . 75.25 109.331 -174.093 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -135.87 169.86 16.91 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.15 -0.685 . . . . 71.540000000000006 109.15 177.505 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -101.3 -169.4 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.757 0 N-CA-C 106.502 -1.666 . . . . 74.109999999999999 106.502 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.7 mtm180 -74.4 70.64 1.73 Allowed 'General case' 0 C--N 1.354 0.764 0 CA-C-N 120.038 1.29 . . . . 73.310000000000002 109.725 173.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.05 79.07 0.29 Allowed Glycine 0 C--N 1.355 1.619 0 CA-C-O 118.087 -1.396 . . . . 45.439999999999998 113.373 173.322 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -164.75 -64.7 0.04 OUTLIER 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.249 1.524 . . . . 73.129999999999995 110.903 172.371 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -170.99 143.2 1.6 Allowed Pre-proline 0 C--N 1.355 0.805 0 CA-C-O 115.551 -2.166 . . . . 75.239999999999995 108.416 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.16 172.52 15.38 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 124.023 2.472 . . . . 72.129999999999995 111.544 -176.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.3 mt -134.92 40.81 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.957 0 N-CA-C 108.587 -0.894 . . . . 70.409999999999997 108.587 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.6 p 172.8 156.56 0.1 Allowed 'General case' 0 C--N 1.353 0.754 0 CA-C-O 117.776 -1.107 . . . . 70.420000000000002 110.581 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.8 m-85 -142.99 176.7 8.89 Favored 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.169 -0.92 . . . . 71.349999999999994 110.238 -178.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.423 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.84 173.07 0.46 Allowed 'General case' 0 C--N 1.355 0.807 0 CA-C-N 119.619 1.099 . . . . 75.299999999999997 111.272 -174.031 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.48 0 N-CA-C 108.656 -1.778 . . . . 73.420000000000002 108.656 174.73 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 CA-C-O 118.275 -1.292 . . . . 62.210000000000001 112.026 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.49 -142.66 4.1 Favored Glycine 0 C--N 1.355 1.588 0 CA-C-O 117.224 -1.875 . . . . 74.030000000000001 111.812 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.48 45.71 1.13 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.972 1.886 . . . . 60.049999999999997 111.289 -178.877 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.4 -145.96 17.54 Favored Glycine 0 C--N 1.354 1.549 0 CA-C-O 118.179 -1.345 . . . . 61.119999999999997 110.626 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -85.71 -43.8 13.08 Favored 'General case' 0 C--N 1.357 0.894 0 CA-C-N 118.904 1.352 . . . . 73.239999999999995 112.884 -177.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.0 t -95.06 134.48 24.65 Favored Pre-proline 0 C--N 1.353 0.726 0 CA-C-O 115.257 -2.306 . . . . 74.319999999999993 109.959 -165.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -66.63 144.32 71.78 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 124.024 2.473 . . . . 72.439999999999998 112.229 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -86.67 -52.22 5.66 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.322 0.965 . . . . 62.520000000000003 108.755 178.333 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -131.09 174.51 9.95 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 118.713 -0.661 . . . . 73.150000000000006 109.392 -174.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -134.42 170.72 15.32 Favored 'General case' 0 C--N 1.353 0.755 0 N-CA-C 109.038 -0.727 . . . . 73.25 109.038 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -102.38 -169.53 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 N-CA-C 106.933 -1.506 . . . . 65.400000000000006 106.933 -178.863 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.2 ttm180 -70.05 70.71 0.37 Allowed 'General case' 0 C--N 1.352 0.688 0 CA-C-N 119.394 0.997 . . . . 74.420000000000002 109.312 172.281 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.43 81.63 0.1 OUTLIER Glycine 0 C--N 1.355 1.591 0 CA-C-O 117.956 -1.469 . . . . 63.530000000000001 113.918 174.621 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -164.94 -64.41 0.03 OUTLIER 'General case' 0 C--N 1.357 0.911 0 CA-C-N 119.525 1.662 . . . . 72.519999999999996 110.966 171.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -170.37 142.95 1.83 Allowed Pre-proline 0 C--N 1.354 0.783 0 CA-C-O 115.616 -2.135 . . . . 71.129999999999995 108.387 178.804 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.3 172.51 15.46 Favored 'Trans proline' 0 C--N 1.359 1.115 0 CA-C-N 124.016 2.47 . . . . 73.329999999999998 111.237 -177.06 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -134.35 38.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 N-CA-C 108.46 -0.941 . . . . 75.140000000000001 108.46 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.0 p 175.26 157.01 0.18 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.581 -1.199 . . . . 62.420000000000002 110.733 -176.707 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.1 m-85 -144.89 176.26 9.6 Favored 'General case' 0 C--N 1.358 0.97 0 CA-C-O 118.286 -0.864 . . . . 74.109999999999999 110.499 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.417 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.09 171.21 0.56 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-N 119.565 1.075 . . . . 74.510000000000005 111.57 -174.185 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.484 0 C-N-CA 119.503 -1.332 . . . . 63.25 112.417 176.404 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.368 -1.24 . . . . 74.540000000000006 112.596 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.34 -143.97 5.16 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 117.271 -1.85 . . . . 70.0 112.876 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.82 44.54 1.09 Allowed 'General case' 0 C--N 1.358 0.961 0 CA-C-N 119.585 1.693 . . . . 63.43 112.072 -177.494 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.5 -144.74 12.41 Favored Glycine 0 C--N 1.353 1.486 0 CA-C-O 118.144 -1.365 . . . . 63.350000000000001 110.533 178.522 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -89.33 -40.79 12.54 Favored 'General case' 0 C--N 1.358 0.959 0 CA-C-N 118.951 1.376 . . . . 63.5 113.46 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.6 t -95.93 133.6 25.1 Favored Pre-proline 0 C--N 1.354 0.761 0 CA-C-O 115.422 -2.228 . . . . 74.430000000000007 109.526 -166.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -65.45 145.33 82.51 Favored 'Trans proline' 0 C--N 1.362 1.275 0 CA-C-N 123.891 2.425 . . . . 72.420000000000002 112.058 -177.319 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 78.8 mt-10 -81.99 -51.71 7.78 Favored 'General case' 0 C--N 1.359 0.985 0 N-CA-C 108.352 -0.981 . . . . 72.200000000000003 108.352 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.5 p90 -150.04 172.59 15.01 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 118.506 -0.759 . . . . 74.239999999999995 110.279 -177.948 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -125.64 170.95 11.0 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 118.668 -0.682 . . . . 71.409999999999997 109.484 -177.503 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -94.42 -166.9 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.868 0 N-CA-C 107.67 -1.233 . . . . 51.119999999999997 107.67 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.4 tpt85 -68.52 67.75 0.13 Allowed 'General case' 0 C--N 1.354 0.779 0 CA-C-N 119.335 0.971 . . . . 73.329999999999998 109.544 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.58 80.48 0.2 Allowed Glycine 0 C--N 1.356 1.646 0 CA-C-O 117.882 -1.51 . . . . 64.030000000000001 113.591 177.406 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -161.31 -66.19 0.06 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-N 119.495 1.648 . . . . 74.310000000000002 111.314 170.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -171.42 153.59 3.61 Favored Pre-proline 0 C--N 1.356 0.85 0 CA-C-O 115.966 -1.969 . . . . 65.140000000000001 106.763 -177.857 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -79.97 169.47 17.81 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.657 2.342 . . . . 70.209999999999994 111.644 -177.462 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.0 mt -135.71 41.89 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.92 0 N-CA-C 107.591 -1.262 . . . . 62.450000000000003 107.591 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.446 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.3 OUTLIER 175.65 157.33 0.21 Allowed 'General case' 0 C--N 1.352 0.71 0 CA-C-O 117.809 -1.091 . . . . 74.200000000000003 110.753 -178.503 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.446 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.2 m-85 -144.99 174.97 10.57 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-O 118.208 -0.901 . . . . 74.409999999999997 110.113 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.67 175.49 0.25 Allowed 'General case' 0 C--N 1.356 0.87 0 CA-C-N 119.143 0.883 . . . . 70.420000000000002 112.208 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.582 0 N-CA-C 109.746 -1.342 . . . . 74.420000000000002 109.746 176.645 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.635 0 CA-C-O 118.427 -1.207 . . . . 73.209999999999994 112.322 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.85 -141.16 3.36 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.217 -1.88 . . . . 44.130000000000003 111.493 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.49 45.5 1.21 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 119.881 1.84 . . . . 74.040000000000006 111.167 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.15 -145.73 15.36 Favored Glycine 0 C--N 1.353 1.496 0 CA-C-O 118.323 -1.265 . . . . 33.210000000000001 110.705 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -88.31 -40.6 13.47 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-N 118.557 1.179 . . . . 65.209999999999994 113.115 -176.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.9 t -98.09 134.89 21.66 Favored Pre-proline 0 C--N 1.353 0.758 0 CA-C-O 115.502 -2.189 . . . . 73.019999999999996 109.498 -166.999 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -67.41 144.52 67.88 Favored 'Trans proline' 0 C--N 1.362 1.288 0 CA-C-N 123.763 2.38 . . . . 72.329999999999998 112.121 -178.094 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -87.15 -49.65 7.15 Favored 'General case' 0 C--N 1.358 0.961 0 CA-C-N 118.869 0.759 . . . . 52.539999999999999 109.301 178.077 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -133.46 175.71 9.18 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.744 -0.646 . . . . 71.540000000000006 109.677 -174.206 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -137.04 166.86 22.69 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.63 -0.7 . . . . 73.400000000000006 109.411 177.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -96.03 -168.03 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.841 0 N-CA-C 106.424 -1.695 . . . . 64.120000000000005 106.424 178.28 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.7 mtp180 -74.85 71.23 1.99 Allowed 'General case' 0 C--N 1.354 0.772 0 CA-C-N 120.3 1.409 . . . . 74.239999999999995 109.329 176.735 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.43 78.23 0.37 Allowed Glycine 0 C--N 1.355 1.624 0 CA-C-O 118.093 -1.393 . . . . 73.209999999999994 112.978 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -163.01 -63.42 0.04 OUTLIER 'General case' 0 C--N 1.357 0.899 0 CA-C-N 119.26 1.53 . . . . 63.119999999999997 111.28 172.819 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -170.12 144.11 2.12 Favored Pre-proline 0 C--N 1.355 0.821 0 CA-C-O 115.91 -1.995 . . . . 24.239999999999998 108.643 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -76.03 158.26 38.19 Favored 'Trans proline' 0 C--N 1.36 1.137 0 CA-C-N 123.585 2.316 . . . . 64.010000000000005 110.93 -178.837 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.405 HG22 ' O ' ' A' ' 17' ' ' ILE . 15.9 mm -119.99 22.59 5.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.916 0 O-C-N 123.916 0.76 . . . . 53.020000000000003 109.764 -176.661 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.443 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 12.1 p -175.19 157.58 2.27 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-N 120.451 1.478 . . . . 74.329999999999998 110.753 -175.672 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.0 m-85 -142.34 177.68 8.1 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.139 -0.934 . . . . 62.520000000000003 110.887 -176.442 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.412 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -58.3 172.77 0.42 Allowed 'General case' 0 C--N 1.355 0.815 0 CA-C-N 119.538 1.063 . . . . 74.230000000000004 111.593 -174.246 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.596 0 N-CA-C 108.817 -1.713 . . . . 64.230000000000004 108.817 175.011 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 CA-C-O 118.379 -1.234 . . . . 71.400000000000006 112.442 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.3 -141.73 3.25 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.221 -1.877 . . . . 71.120000000000005 111.235 179.697 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.51 45.99 1.04 Allowed 'General case' 0 C--N 1.356 0.886 0 CA-C-N 120.05 1.925 . . . . 75.219999999999999 111.52 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.95 -146.53 19.68 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.18 -1.344 . . . . 74.099999999999994 110.371 179.35 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -87.11 -41.01 14.13 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-N 118.931 1.366 . . . . 72.519999999999996 113.19 -178.209 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.45 133.73 25.41 Favored Pre-proline 0 C--N 1.353 0.744 0 CA-C-O 115.43 -2.224 . . . . 65.329999999999998 109.536 -166.2 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.46 144.27 72.69 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.915 2.434 . . . . 73.519999999999996 111.684 -178.077 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -82.24 -50.75 8.63 Favored 'General case' 0 C--N 1.356 0.876 0 N-CA-C 108.411 -0.959 . . . . 71.230000000000004 108.411 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -148.9 172.59 14.44 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 118.368 -0.825 . . . . 73.450000000000003 109.729 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -126.08 168.24 14.26 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.513 -0.756 . . . . 44.25 109.808 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -91.95 -171.07 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.835 0 N-CA-C 105.918 -1.882 . . . . 61.140000000000001 105.918 175.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.8 mtt-85 -71.2 76.81 0.71 Allowed 'General case' 0 C--N 1.353 0.75 0 CA-C-N 120.366 1.439 . . . . 51.520000000000003 110.071 177.029 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.53 75.93 0.44 Allowed Glycine 0 C--N 1.355 1.631 0 CA-C-O 118.104 -1.387 . . . . 54.539999999999999 112.985 172.283 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -161.9 -61.5 0.05 OUTLIER 'General case' 0 C--N 1.356 0.886 0 CA-C-N 119.212 1.506 . . . . 73.349999999999994 111.801 173.491 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -173.87 144.67 1.05 Allowed Pre-proline 0 C--N 1.355 0.832 0 CA-C-O 115.892 -2.004 . . . . 72.129999999999995 109.035 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.6 156.07 31.8 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 123.608 2.324 . . . . 74.340000000000003 110.79 -178.75 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 15.7 mm -118.85 21.42 5.96 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-O 118.625 -0.702 . . . . 73.340000000000003 109.427 -176.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.437 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 13.4 p -174.9 158.62 2.59 Favored 'General case' 0 C--N 1.356 0.868 0 CA-C-N 120.435 1.47 . . . . 64.420000000000002 110.994 -175.047 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.437 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -142.05 176.6 8.82 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.136 -0.935 . . . . 65.340000000000003 111.013 -177.042 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.417 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.2 m-30 -58.72 173.12 0.44 Allowed 'General case' 0 C--N 1.356 0.852 0 CA-C-N 119.609 1.095 . . . . 64.120000000000005 111.372 -174.468 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.587 0 C-N-CA 119.614 -1.279 . . . . 61.0 110.956 177.397 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.648 0 CA-C-O 117.923 -1.487 . . . . 53.329999999999998 113.841 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -164.96 -142.69 3.48 Favored Glycine 0 C--N 1.353 1.502 0 CA-C-N 120.06 1.93 . . . . 72.409999999999997 111.708 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.51 47.66 1.11 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 120.021 1.911 . . . . 75.299999999999997 111.209 -178.978 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.67 -145.71 18.21 Favored Glycine 0 C--N 1.354 1.551 0 CA-C-O 118.007 -1.44 . . . . 73.010000000000005 109.813 179.098 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -88.18 -41.72 12.8 Favored 'General case' 0 C--N 1.356 0.879 0 CA-C-N 119.029 1.415 . . . . 61.219999999999999 113.221 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -94.51 133.67 26.59 Favored Pre-proline 0 C--N 1.354 0.771 0 CA-C-O 115.456 -2.211 . . . . 71.209999999999994 109.712 -165.922 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.0 144.25 75.47 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 123.937 2.442 . . . . 73.540000000000006 111.634 -177.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -82.12 -50.07 9.47 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.473 -0.936 . . . . 71.400000000000006 108.473 178.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -149.92 173.09 14.19 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.398 -0.81 . . . . 73.200000000000003 109.732 -177.316 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -127.95 169.2 14.25 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.509 -0.757 . . . . 72.439999999999998 109.6 -178.217 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -92.49 -170.9 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.852 0 N-CA-C 107.109 -1.441 . . . . 72.120000000000005 107.109 177.345 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -69.86 73.8 0.43 Allowed 'General case' 0 C--N 1.352 0.679 0 CA-C-N 119.203 0.91 . . . . 64.209999999999994 109.441 174.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.79 76.8 0.43 Allowed Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.034 -1.426 . . . . 71.209999999999994 113.563 173.567 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -160.67 -66.16 0.06 Allowed 'General case' 0 C--N 1.356 0.853 0 CA-C-N 119.244 1.522 . . . . 43.409999999999997 111.077 170.188 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -170.91 152.15 3.52 Favored Pre-proline 0 C--N 1.357 0.913 0 CA-C-O 116.018 -1.944 . . . . 74.530000000000001 108.36 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -76.32 165.21 29.75 Favored 'Trans proline' 0 C--N 1.356 0.933 0 CA-C-N 123.474 2.277 . . . . 65.540000000000006 111.479 -177.442 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.9 mt -135.81 47.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.886 0 N-CA-C 107.382 -1.34 . . . . 71.439999999999998 107.382 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.435 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.9 p 166.32 156.53 0.03 OUTLIER 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.032 -0.985 . . . . 73.319999999999993 110.175 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' A' ' 18' ' ' SER . 34.3 m-85 -141.79 178.1 7.72 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 117.877 -1.059 . . . . 74.209999999999994 109.828 179.538 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.444 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.86 177.6 0.14 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 119.693 1.133 . . . . 73.099999999999994 110.751 -175.72 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.57 0 CA-C-N 120.615 1.552 . . . . 65.120000000000005 109.915 176.231 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.694 0 CA-C-O 117.858 -1.524 . . . . 74.109999999999999 113.611 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.06 -143.02 3.58 Favored Glycine 0 C--N 1.354 1.583 0 CA-C-N 120.216 2.008 . . . . 72.519999999999996 111.261 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.17 45.23 1.07 Allowed 'General case' 0 C--N 1.357 0.899 0 CA-C-N 120.067 1.934 . . . . 74.25 111.464 -178.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.74 -145.53 16.85 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.166 -1.352 . . . . 45.399999999999999 110.657 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -87.6 -39.99 14.6 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-N 118.778 1.289 . . . . 73.230000000000004 112.911 -176.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -98.77 134.54 21.51 Favored Pre-proline 0 C--N 1.354 0.79 0 CA-C-O 115.368 -2.254 . . . . 74.319999999999993 109.743 -166.713 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.99 147.31 84.43 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 124.019 2.471 . . . . 74.540000000000006 112.136 -177.339 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.4 mt-10 -83.93 -50.64 7.85 Favored 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.341 0.973 . . . . 71.140000000000001 108.38 178.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -151.5 174.64 13.16 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.417 -0.801 . . . . 61.119999999999997 110.412 -176.781 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -127.94 178.24 6.31 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.88 -1.057 . . . . 51.420000000000002 109.484 -176.571 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.36 -162.23 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.947 0 N-CA-C 105.265 -2.124 . . . . 55.520000000000003 105.265 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 70.0 mmt-85 -75.99 73.19 2.88 Favored 'General case' 0 C--N 1.355 0.804 0 CA-C-N 121.32 1.873 . . . . 72.239999999999995 108.221 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.05 79.71 0.24 Allowed Glycine 0 C--N 1.354 1.561 0 CA-C-O 118.382 -1.232 . . . . 64.030000000000001 110.858 176.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -156.21 -69.53 0.11 Allowed 'General case' 0 C--N 1.356 0.849 0 CA-C-N 118.846 1.323 . . . . 74.5 111.067 176.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 178.53 150.8 0.44 Allowed Pre-proline 0 C--N 1.353 0.759 0 CA-C-O 116.063 -1.922 . . . . 71.230000000000004 106.836 -177.389 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -75.58 167.21 26.98 Favored 'Trans proline' 0 C--N 1.356 0.968 0 CA-C-N 124.027 2.474 . . . . 63.409999999999997 110.814 -176.14 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mt -134.08 37.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.854 0 N-CA-C 107.908 -1.145 . . . . 65.010000000000005 107.908 178.606 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.43 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.3 p 171.75 155.71 0.08 Allowed 'General case' 0 C--N 1.354 0.801 0 CA-C-O 117.546 -1.216 . . . . 71.510000000000005 110.205 -175.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.43 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -141.34 175.83 9.35 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-O 118.244 -0.884 . . . . 73.329999999999998 110.332 -178.76 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.69 171.89 0.58 Allowed 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.636 1.107 . . . . 60.049999999999997 111.377 -174.274 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.538 0 C-N-CA 119.351 -1.404 . . . . 63.200000000000003 112.024 176.21 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.733 0 CA-C-O 118.102 -1.388 . . . . 42.109999999999999 113.273 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.15 -143.25 3.7 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-O 117.208 -1.885 . . . . 25.510000000000002 111.309 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -149.03 44.99 0.99 Allowed 'General case' 0 C--N 1.357 0.923 0 CA-C-N 120.158 1.979 . . . . 55.229999999999997 111.711 -179.046 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.03 -146.48 18.43 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 118.112 -1.382 . . . . 73.540000000000006 110.534 179.226 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 m170 -87.97 -38.52 15.47 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-N 119.012 1.406 . . . . 73.200000000000003 113.145 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.94 133.2 24.57 Favored Pre-proline 0 C--N 1.353 0.749 0 CA-C-O 115.339 -2.267 . . . . 73.299999999999997 109.688 -167.149 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -66.35 146.45 80.68 Favored 'Trans proline' 0 C--N 1.363 1.321 0 CA-C-N 123.987 2.46 . . . . 43.420000000000002 112.003 -177.063 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 -82.78 -50.58 8.52 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.317 -0.994 . . . . 52.450000000000003 108.317 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -150.69 173.57 14.01 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.544 -0.741 . . . . 71.239999999999995 110.302 -177.37 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.7 176.95 6.85 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 118.042 -0.98 . . . . 74.420000000000002 109.415 -176.197 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.0 -167.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.902 0 N-CA-C 105.068 -2.197 . . . . 72.409999999999997 105.068 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -74.13 75.78 1.77 Allowed 'General case' 0 C--N 1.354 0.767 0 CA-C-N 120.686 1.584 . . . . 74.230000000000004 108.907 178.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.96 76.59 0.33 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.134 -1.37 . . . . 73.329999999999998 111.179 175.309 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -156.83 -69.75 0.1 Allowed 'General case' 0 C--N 1.355 0.838 0 CA-C-N 119.028 1.414 . . . . 71.109999999999999 111.389 178.603 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -178.39 143.68 0.46 Allowed Pre-proline 0 C--N 1.354 0.787 0 CA-C-O 116.011 -1.947 . . . . 75.120000000000005 108.465 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -71.75 165.62 31.97 Favored 'Trans proline' 0 C--N 1.358 1.027 0 CA-C-N 123.791 2.39 . . . . 52.43 110.233 -177.787 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.44 37.72 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.877 0 N-CA-C 107.915 -1.142 . . . . 62.350000000000001 107.915 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.5 p 173.46 154.46 0.1 Allowed 'General case' 0 C--N 1.355 0.833 0 CA-C-O 117.494 -1.241 . . . . 74.340000000000003 110.185 -176.017 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.7 m-85 -141.57 175.63 9.53 Favored 'General case' 0 C--N 1.357 0.925 0 CA-C-O 118.3 -0.857 . . . . 74.409999999999997 110.246 -178.676 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -59.75 169.39 1.4 Allowed 'General case' 0 C--N 1.355 0.82 0 CA-C-N 119.688 1.131 . . . . 73.540000000000006 111.438 -173.201 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.581 0 N-CA-C 109.444 -1.462 . . . . 31.34 109.444 173.683 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.676 0 CA-C-O 118.316 -1.269 . . . . 74.310000000000002 112.64 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.05 -144.66 4.39 Favored Glycine 0 C--N 1.354 1.55 0 CA-C-O 117.351 -1.805 . . . . 72.230000000000004 111.467 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.01 46.26 1.08 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.782 1.791 . . . . 61.399999999999999 111.48 -179.113 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.84 -144.17 14.11 Favored Glycine 0 C--N 1.353 1.508 0 CA-C-O 118.102 -1.388 . . . . 65.230000000000004 110.195 179.151 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -88.95 -42.51 11.76 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.019 1.41 . . . . 74.239999999999995 113.508 -178.213 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.1 t -93.87 133.41 27.8 Favored Pre-proline 0 C--N 1.353 0.755 0 CA-C-O 115.446 -2.216 . . . . 64.150000000000006 109.478 -166.247 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -65.32 144.41 80.35 Favored 'Trans proline' 0 C--N 1.363 1.312 0 CA-C-N 123.943 2.444 . . . . 55.219999999999999 111.866 -177.789 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -81.5 -51.39 8.33 Favored 'General case' 0 C--N 1.358 0.968 0 N-CA-C 108.359 -0.978 . . . . 71.420000000000002 108.359 179.001 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.4 p90 -148.87 172.06 15.29 Favored 'General case' 0 C--N 1.354 0.796 0 CA-C-O 118.535 -0.745 . . . . 74.319999999999993 109.941 -177.846 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -125.01 170.27 11.3 Favored 'General case' 0 C--N 1.355 0.845 0 CA-C-O 118.857 -0.592 . . . . 74.209999999999994 109.614 -177.16 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -94.67 -170.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.808 0 N-CA-C 106.563 -1.643 . . . . 74.409999999999997 106.563 177.409 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.1 mtt180 -70.08 75.32 0.49 Allowed 'General case' 0 C--N 1.354 0.771 0 CA-C-N 119.876 1.216 . . . . 74.150000000000006 109.924 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.72 78.02 0.24 Allowed Glycine 0 C--N 1.355 1.587 0 CA-C-O 118.11 -1.383 . . . . 60.329999999999998 113.579 172.25 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -162.62 -63.31 0.05 OUTLIER 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.204 1.502 . . . . 63.130000000000003 111.296 172.101 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -172.92 143.99 1.17 Allowed Pre-proline 0 C--N 1.356 0.855 0 CA-C-O 115.713 -2.089 . . . . 60.229999999999997 108.281 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.52 170.74 19.61 Favored 'Trans proline' 0 C--N 1.357 0.984 0 CA-C-N 123.835 2.405 . . . . 75.510000000000005 111.17 -177.602 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -135.77 39.94 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.977 0 N-CA-C 108.488 -0.93 . . . . 74.310000000000002 108.488 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.433 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 19.2 p 175.1 155.42 0.15 Allowed 'General case' 0 C--N 1.353 0.747 0 CA-C-O 117.795 -1.097 . . . . 63.520000000000003 110.932 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.6 m-85 -142.59 175.19 9.99 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.049 -0.977 . . . . 72.319999999999993 110.169 -179.756 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.428 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.8 m-30 -58.46 172.43 0.48 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.509 1.05 . . . . 64.239999999999995 111.333 -174.05 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.528 0 N-CA-C 109.18 -1.568 . . . . 74.319999999999993 109.18 174.201 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.681 0 CA-C-O 118.145 -1.364 . . . . 63.0 112.89 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.85 -142.12 3.41 Favored Glycine 0 C--N 1.354 1.552 0 CA-C-O 117.177 -1.902 . . . . 75.109999999999999 112.144 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.8 46.22 1.02 Allowed 'General case' 0 C--N 1.358 0.945 0 CA-C-N 119.887 1.843 . . . . 53.229999999999997 111.697 -178.44 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.62 -144.56 15.59 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.146 -1.363 . . . . 51.43 110.6 179.559 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.2 m80 -87.44 -41.82 13.26 Favored 'General case' 0 C--N 1.356 0.88 0 CA-C-N 118.788 1.294 . . . . 53.43 113.141 -177.016 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -97.45 134.57 22.43 Favored Pre-proline 0 C--N 1.354 0.785 0 CA-C-O 115.397 -2.239 . . . . 61.439999999999998 109.693 -166.186 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -65.74 144.25 77.15 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 123.909 2.432 . . . . 75.099999999999994 111.81 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -81.52 -51.42 8.29 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.48 -0.933 . . . . 71.030000000000001 108.48 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -148.37 172.0 15.11 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-O 118.366 -0.826 . . . . 71.120000000000005 109.553 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -124.34 170.13 11.12 Favored 'General case' 0 C--N 1.355 0.823 0 O-C-N 123.781 0.675 . . . . 74.239999999999995 109.628 -177.084 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 m -92.59 -166.29 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 106.477 -1.675 . . . . 73.409999999999997 106.477 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 42.8 mtp180 -75.52 69.08 2.24 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-N 120.005 1.275 . . . . 74.519999999999996 109.56 175.425 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.29 78.21 0.46 Allowed Glycine 0 C--N 1.356 1.669 0 CA-C-O 118.01 -1.439 . . . . 74.200000000000003 113.208 174.378 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -164.28 -63.45 0.04 OUTLIER 'General case' 0 C--N 1.357 0.916 0 CA-C-N 119.376 1.588 . . . . 64.439999999999998 111.503 172.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -171.5 144.52 1.63 Allowed Pre-proline 0 C--N 1.355 0.809 0 CA-C-O 115.511 -2.185 . . . . 63.219999999999999 108.307 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -75.36 171.36 18.41 Favored 'Trans proline' 0 C--N 1.357 1.01 0 CA-C-N 123.95 2.447 . . . . 72.319999999999993 111.361 -177.497 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -136.06 40.33 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 108.413 -0.958 . . . . 74.25 108.413 178.232 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.8 p 174.31 155.93 0.13 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.77 -1.11 . . . . 45.100000000000001 111.08 -177.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.6 m-85 -143.25 175.91 9.53 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-O 118.283 -0.865 . . . . 64.329999999999998 110.559 -179.489 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.0 m-30 -60.13 176.57 0.31 Allowed 'General case' 0 C--N 1.356 0.866 0 CA-C-N 119.354 0.979 . . . . 75.209999999999994 111.775 -174.268 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.594 0 C-N-CA 119.514 -1.327 . . . . 72.420000000000002 109.894 173.474 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.119 -1.378 . . . . 73.209999999999994 112.414 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.84 -142.94 3.99 Favored Glycine 0 C--N 1.354 1.566 0 CA-C-N 119.897 1.848 . . . . 61.520000000000003 111.802 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.53 45.75 1.21 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 119.843 1.822 . . . . 64.319999999999993 111.171 -179.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.91 -143.57 12.24 Favored Glycine 0 C--N 1.353 1.516 0 CA-C-O 118.049 -1.417 . . . . 55.340000000000003 110.641 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -89.34 -41.49 12.11 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-N 118.765 1.283 . . . . 73.540000000000006 112.89 -176.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.7 t -98.6 135.29 21.14 Favored Pre-proline 0 C--N 1.353 0.748 0 CA-C-O 115.363 -2.256 . . . . 65.150000000000006 109.661 -166.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -66.66 144.7 73.16 Favored 'Trans proline' 0 C--N 1.362 1.254 0 CA-C-N 124.036 2.477 . . . . 62.109999999999999 112.43 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.78 -52.11 5.7 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.275 0.943 . . . . 72.099999999999994 108.893 178.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -132.18 174.69 9.95 Favored 'General case' 0 C--N 1.354 0.778 0 CA-C-O 118.731 -0.652 . . . . 61.439999999999998 109.449 -174.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -134.76 170.56 15.64 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-O 118.742 -0.647 . . . . 73.209999999999994 109.305 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -100.91 -170.4 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.12 -1.437 . . . . 71.019999999999996 107.12 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 ttp180 -78.68 65.81 4.03 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-N 120.003 1.274 . . . . 72.140000000000001 109.177 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 79.73 77.9 0.91 Allowed Glycine 0 C--N 1.356 1.69 0 CA-C-O 117.986 -1.452 . . . . 60.32 113.438 175.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -165.23 -71.96 0.03 OUTLIER 'General case' 0 C--N 1.358 0.952 0 CA-C-N 119.452 1.626 . . . . 72.219999999999999 110.8 170.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.98 150.69 6.34 Favored Pre-proline 0 C--N 1.355 0.818 0 CA-C-O 115.777 -2.059 . . . . 62.340000000000003 106.996 -179.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.67 173.05 15.16 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.733 2.369 . . . . 65.120000000000005 111.432 -176.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -134.25 38.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 108.419 -0.956 . . . . 72.239999999999995 108.419 178.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.468 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.8 p 175.08 157.36 0.17 Allowed 'General case' 0 C--N 1.354 0.781 0 CA-C-O 117.445 -1.264 . . . . 72.239999999999995 110.798 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.468 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -144.54 176.68 9.22 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 118.267 -0.873 . . . . 65.420000000000002 110.378 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.421 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.17 174.45 0.39 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-N 119.567 1.076 . . . . 74.230000000000004 111.382 -174.378 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.508 0 CA-C-N 120.143 1.338 . . . . 74.540000000000006 111.798 176.85 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.293 -1.282 . . . . 71.519999999999996 112.885 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.61 -144.03 4.29 Favored Glycine 0 C--N 1.354 1.543 0 CA-C-O 117.415 -1.769 . . . . 44.109999999999999 111.614 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.61 46.16 1.29 Allowed 'General case' 0 C--N 1.356 0.887 0 CA-C-N 119.751 1.776 . . . . 54.119999999999997 110.677 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.61 -139.63 9.2 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 118.034 -1.426 . . . . 53.020000000000003 110.798 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -95.31 -35.68 11.69 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 117.482 -1.247 . . . . 52.530000000000001 113.285 -173.102 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -105.52 136.13 19.28 Favored Pre-proline 0 C--N 1.355 0.824 0 CA-C-O 115.414 -2.231 . . . . 65.040000000000006 109.285 -169.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -66.99 143.78 67.36 Favored 'Trans proline' 0 C--N 1.361 1.211 0 CA-C-N 123.894 2.427 . . . . 73.209999999999994 112.289 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.3 mt-10 -85.73 -48.73 8.55 Favored 'General case' 0 C--N 1.358 0.954 0 CA-C-N 118.886 0.766 . . . . 65.200000000000003 109.413 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -134.71 175.02 9.93 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.84 -0.6 . . . . 63.310000000000002 109.548 -173.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -135.44 171.19 14.8 Favored 'General case' 0 C--N 1.353 0.744 0 N-CA-C 109.105 -0.702 . . . . 72.25 109.105 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.5 m -103.31 -170.32 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.746 0 N-CA-C 107.225 -1.398 . . . . 61.420000000000002 107.225 -177.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -72.5 71.32 0.94 Allowed 'General case' 0 C--N 1.353 0.735 0 CA-C-N 119.146 0.885 . . . . 71.219999999999999 108.885 172.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.24 80.41 0.2 Allowed Glycine 0 C--N 1.355 1.595 0 CA-C-O 118.19 -1.339 . . . . 73.439999999999998 113.812 173.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -164.25 -70.9 0.04 OUTLIER 'General case' 0 C--N 1.357 0.895 0 CA-C-N 119.241 1.52 . . . . 73.099999999999994 110.37 170.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.83 150.27 6.32 Favored Pre-proline 0 C--N 1.355 0.826 0 CA-C-O 115.871 -2.014 . . . . 55.030000000000001 106.839 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -75.42 172.77 15.69 Favored 'Trans proline' 0 C--N 1.356 0.93 0 CA-C-N 123.58 2.314 . . . . 74.450000000000003 111.319 -176.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.1 mt -135.32 41.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.981 0 N-CA-C 108.321 -0.992 . . . . 74.209999999999994 108.321 178.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.449 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 171.99 156.77 0.09 Allowed 'General case' 0 C--N 1.354 0.803 0 CA-C-O 117.889 -1.053 . . . . 71.209999999999994 110.676 -179.266 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.9 m-85 -142.96 177.8 8.11 Favored 'General case' 0 C--N 1.358 0.96 0 CA-C-O 118.106 -0.95 . . . . 62.130000000000003 110.123 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.1 m-30 -59.43 175.73 0.31 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.713 1.142 . . . . 74.409999999999997 111.234 -174.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.611 0 N-CA-C 109.932 -1.267 . . . . 70.230000000000004 109.932 176.422 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.66 0 CA-C-O 118.663 -1.076 . . . . 74.310000000000002 111.942 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.98 -144.98 5.52 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.497 -1.724 . . . . 71.430000000000007 111.852 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.99 45.67 1.17 Allowed 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.633 1.716 . . . . 53.539999999999999 111.374 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.25 -142.47 11.79 Favored Glycine 0 C--N 1.354 1.532 0 CA-C-O 118.033 -1.426 . . . . 60.130000000000003 110.494 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.3 m170 -88.57 -45.99 9.44 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 118.983 1.391 . . . . 63.210000000000001 113.144 -177.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -93.2 134.39 27.13 Favored Pre-proline 0 C--N 1.353 0.732 0 CA-C-O 115.637 -2.125 . . . . 71.150000000000006 109.44 -165.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -66.64 143.99 70.47 Favored 'Trans proline' 0 C--N 1.363 1.3 0 CA-C-N 123.822 2.401 . . . . 71.140000000000001 112.183 -177.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.4 mt-10 -86.31 -50.82 6.65 Favored 'General case' 0 C--N 1.358 0.935 0 CA-C-N 118.806 0.73 . . . . 63.240000000000002 109.211 178.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -133.44 174.0 10.88 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-O 118.853 -0.594 . . . . 71.409999999999997 109.939 -174.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -135.07 170.82 15.32 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 118.694 -0.669 . . . . 74.310000000000002 109.256 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -102.63 -169.63 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.737 0 N-CA-C 107.031 -1.47 . . . . 64.549999999999997 107.031 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -73.45 70.98 1.28 Allowed 'General case' 0 C--N 1.353 0.729 0 CA-C-N 119.643 1.11 . . . . 74.019999999999996 108.875 173.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.97 80.33 0.22 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.118 -1.379 . . . . 61.219999999999999 113.621 173.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.67 -68.87 0.05 OUTLIER 'General case' 0 C--N 1.356 0.858 0 CA-C-N 119.155 1.477 . . . . 75.019999999999996 109.959 170.066 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -168.56 149.44 4.42 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.964 -1.97 . . . . 72.150000000000006 106.895 178.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -75.53 173.42 14.53 Favored 'Trans proline' 0 C--N 1.356 0.973 0 CA-C-N 123.529 2.296 . . . . 64.409999999999997 111.226 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.5 39.37 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.906 0 N-CA-C 108.479 -0.934 . . . . 72.230000000000004 108.479 179.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.462 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.5 p 174.96 157.13 0.16 Allowed 'General case' 0 C--N 1.354 0.766 0 CA-C-O 117.714 -1.136 . . . . 72.129999999999995 111.01 -177.043 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.462 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.1 m-85 -144.53 176.7 9.2 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-O 118.248 -0.882 . . . . 73.400000000000006 110.285 -179.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.414 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.17 169.63 1.08 Allowed 'General case' 0 C--N 1.355 0.812 0 CA-C-N 119.652 1.115 . . . . 63.43 111.534 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.513 0 C-N-CA 119.303 -1.427 . . . . 62.409999999999997 111.491 176.457 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.65 0 CA-C-O 117.919 -1.49 . . . . 72.150000000000006 113.325 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.76 -141.77 3.23 Favored Glycine 0 C--N 1.354 1.577 0 CA-C-N 120.159 1.98 . . . . 63.310000000000002 111.527 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.62 46.01 1.11 Allowed 'General case' 0 C--N 1.358 0.935 0 CA-C-N 119.898 1.849 . . . . 72.430000000000007 111.018 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.66 -137.95 7.81 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 117.788 -1.562 . . . . 24.350000000000001 110.844 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -100.76 -24.7 14.34 Favored 'General case' 0 C--N 1.359 0.99 0 CA-C-O 116.653 -1.641 . . . . 75.430000000000007 114.039 -172.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.3 t -114.21 135.25 22.15 Favored Pre-proline 0 C--N 1.356 0.891 0 CA-C-O 115.384 -2.246 . . . . 75.25 108.685 -171.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -65.96 144.27 75.83 Favored 'Trans proline' 0 C--N 1.361 1.21 0 CA-C-N 123.884 2.423 . . . . 72.540000000000006 111.788 -176.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -81.37 -50.67 9.2 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.255 -1.017 . . . . 75.329999999999998 108.255 178.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -149.22 172.2 15.24 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.472 -0.775 . . . . 62.119999999999997 109.863 -177.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -127.13 168.59 14.44 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.466 -0.778 . . . . 72.129999999999995 109.506 -177.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.411 ' O ' ' N ' ' A' ' 13' ' ' GLY . 3.1 m -94.65 -176.99 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.805 0 N-CA-C 107.334 -1.358 . . . . 75.310000000000002 107.334 176.181 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -55.2 76.47 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 CA-C-N 118.309 0.504 . . . . 74.310000000000002 111.895 170.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' VAL . . . 57.49 78.44 0.13 Allowed Glycine 0 C--N 1.354 1.576 0 CA-C-O 118.056 -1.414 . . . . 64.420000000000002 114.097 172.521 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -161.26 -61.86 0.05 Allowed 'General case' 0 C--N 1.356 0.88 0 CA-C-N 119.414 1.607 . . . . 52.140000000000001 111.805 173.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -174.52 145.51 0.99 Allowed Pre-proline 0 C--N 1.355 0.833 0 CA-C-O 115.777 -2.059 . . . . 75.019999999999996 108.448 -178.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.56 168.52 24.26 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.677 2.349 . . . . 74.219999999999999 111.205 -178.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.7 mt -137.45 44.3 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 107.751 -1.203 . . . . 63.340000000000003 107.751 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.45 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.0 p 170.03 155.6 0.05 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.878 -1.058 . . . . 63.329999999999998 110.496 -179.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.45 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.9 m-85 -141.88 175.82 9.42 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.291 -0.862 . . . . 53.119999999999997 109.984 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.437 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -57.98 172.13 0.45 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.497 1.044 . . . . 71.230000000000004 111.484 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 1.641 0 N-CA-C 108.308 -1.917 . . . . 75.150000000000006 108.308 174.304 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 CA-C-O 118.357 -1.246 . . . . 73.510000000000005 112.267 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.62 -143.19 3.87 Favored Glycine 0 C--N 1.355 1.592 0 CA-C-O 117.135 -1.925 . . . . 65.439999999999998 111.655 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.52 45.79 1.12 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.957 1.878 . . . . 74.200000000000003 111.105 -178.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.94 -144.2 14.27 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.169 -1.351 . . . . 33.539999999999999 110.707 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.7 m-70 -88.78 -40.81 12.93 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 118.829 1.314 . . . . 74.540000000000006 113.026 -176.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -99.26 135.5 20.73 Favored Pre-proline 0 C--N 1.354 0.775 0 CA-C-O 115.233 -2.318 . . . . 72.109999999999999 109.389 -166.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -66.8 144.89 73.05 Favored 'Trans proline' 0 C--N 1.364 1.344 0 CA-C-N 124.001 2.464 . . . . 73.409999999999997 111.879 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -82.64 -51.28 7.89 Favored 'General case' 0 C--N 1.359 0.989 0 N-CA-C 108.392 -0.966 . . . . 72.409999999999997 108.392 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -149.53 172.95 14.16 Favored 'General case' 0 C--N 1.356 0.861 0 CA-C-O 118.155 -0.926 . . . . 72.420000000000002 109.747 -177.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -126.36 168.55 14.01 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 118.551 -0.738 . . . . 74.109999999999999 109.974 -176.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -90.09 -169.99 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.881 0 N-CA-C 106.645 -1.613 . . . . 64.239999999999995 106.645 177.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -70.73 75.12 0.6 Allowed 'General case' 0 C--N 1.353 0.718 0 CA-C-N 119.479 1.036 . . . . 71.120000000000005 109.153 176.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.1 77.45 0.35 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 118.107 -1.385 . . . . 64.209999999999994 113.058 173.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -160.03 -65.12 0.07 Allowed 'General case' 0 C--N 1.357 0.919 0 CA-C-N 119.188 1.494 . . . . 55.100000000000001 111.279 171.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.09 154.56 3.41 Favored Pre-proline 0 C--N 1.355 0.814 0 CA-C-O 116.027 -1.94 . . . . 74.310000000000002 107.6 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -80.87 155.99 20.5 Favored 'Trans proline' 0 C--N 1.36 1.174 0 CA-C-N 123.698 2.357 . . . . 64.0 111.257 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.5 mm -118.73 17.75 6.85 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-O 118.284 -0.865 . . . . 73.329999999999998 109.23 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 7.1 m -165.9 158.87 15.29 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 121.102 1.774 . . . . 71.239999999999995 110.558 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -142.8 174.94 10.21 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 119.789 1.177 . . . . 73.109999999999999 110.713 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.432 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.18 174.02 0.43 Allowed 'General case' 0 C--N 1.356 0.855 0 CA-C-N 119.242 0.928 . . . . 73.200000000000003 111.266 -174.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.483 0 N-CA-C 109.036 -1.626 . . . . 70.109999999999999 109.036 175.558 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.734 0 CA-C-O 118.463 -1.187 . . . . 75.299999999999997 112.278 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.77 -147.08 6.17 Favored Glycine 0 C--N 1.355 1.597 0 CA-C-O 117.486 -1.73 . . . . 71.319999999999993 111.859 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.2 46.34 1.15 Allowed 'General case' 0 C--N 1.357 0.925 0 CA-C-N 119.78 1.79 . . . . 72.129999999999995 111.357 -178.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.18 -144.69 15.42 Favored Glycine 0 C--N 1.354 1.57 0 CA-C-O 117.9 -1.5 . . . . 54.439999999999998 110.249 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -87.76 -43.1 12.13 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-N 119.142 1.471 . . . . 71.319999999999993 112.926 -177.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -96.4 134.98 22.74 Favored Pre-proline 0 C--N 1.354 0.764 0 CA-C-O 115.199 -2.334 . . . . 64.200000000000003 109.814 -165.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.22 145.05 83.19 Favored 'Trans proline' 0 C--N 1.363 1.323 0 CA-C-N 124.146 2.517 . . . . 72.530000000000001 112.257 -177.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 75.9 mt-10 -82.45 -52.14 7.16 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 108.177 -1.045 . . . . 54.43 108.177 178.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -149.32 173.0 13.98 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-O 118.414 -0.803 . . . . 73.010000000000005 109.685 -177.4 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -126.4 169.55 12.85 Favored 'General case' 0 C--N 1.354 0.804 0 CA-C-O 118.505 -0.759 . . . . 71.230000000000004 110.095 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -93.41 -171.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 N-CA-C 106.872 -1.529 . . . . 74.400000000000006 106.872 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.3 mtt-85 -70.38 76.1 0.55 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.826 1.194 . . . . 74.010000000000005 109.879 173.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.57 76.97 0.4 Allowed Glycine 0 C--N 1.355 1.613 0 CA-C-O 118.048 -1.418 . . . . 52.140000000000001 113.267 172.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -160.59 -67.16 0.07 Allowed 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.203 1.502 . . . . 75.439999999999998 110.934 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.07 153.06 3.04 Favored Pre-proline 0 C--N 1.353 0.753 0 CA-C-O 115.754 -2.07 . . . . 75.209999999999994 107.253 -178.423 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.38 171.51 15.9 Favored 'Trans proline' 0 C--N 1.357 1.022 0 CA-C-N 123.911 2.433 . . . . 40.140000000000001 111.661 -177.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.3 mt -135.9 41.37 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.799 -1.186 . . . . 73.239999999999995 107.799 177.072 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.434 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 2.7 p 174.5 156.65 0.15 Allowed 'General case' 0 C--N 1.354 0.774 0 CA-C-O 117.809 -1.091 . . . . 61.020000000000003 110.731 -178.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.434 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.7 m-85 -143.76 175.69 9.8 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.133 -0.937 . . . . 75.400000000000006 110.071 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.78 176.15 0.22 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.654 1.115 . . . . 73.239999999999995 111.351 -174.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.574 0 CA-C-N 120.227 1.376 . . . . 61.340000000000003 110.641 176.51 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.715 0 CA-C-O 118.521 -1.155 . . . . 73.299999999999997 111.246 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.3 -146.45 5.82 Favored Glycine 0 C--N 1.354 1.58 0 CA-C-O 117.389 -1.784 . . . . 74.450000000000003 111.753 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.96 45.92 1.09 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.718 1.759 . . . . 65.040000000000006 111.318 -178.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.7 -139.65 9.72 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.806 -1.552 . . . . 74.519999999999996 110.62 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -93.52 -38.81 11.2 Favored 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.045 1.422 . . . . 63.119999999999997 113.151 -174.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.4 t -101.67 135.17 19.83 Favored Pre-proline 0 C--N 1.354 0.799 0 CA-C-O 115.149 -2.358 . . . . 73.340000000000003 109.495 -167.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.94 144.53 76.89 Favored 'Trans proline' 0 C--N 1.362 1.255 0 CA-C-N 124.165 2.523 . . . . 63.020000000000003 112.218 -176.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -81.87 -51.77 7.77 Favored 'General case' 0 C--N 1.358 0.94 0 CA-C-N 119.486 1.039 . . . . 70.310000000000002 108.313 178.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -149.19 172.38 14.93 Favored 'General case' 0 C--N 1.353 0.757 0 CA-C-O 118.342 -0.837 . . . . 64.439999999999998 110.116 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -124.77 171.34 10.19 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-O 118.665 -0.683 . . . . 74.450000000000003 110.016 -176.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 m -94.87 -166.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 107.484 -1.302 . . . . 71.540000000000006 107.484 -178.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 tpt180 -71.01 67.22 0.41 Allowed 'General case' 0 C--N 1.355 0.813 0 CA-C-N 119.801 1.182 . . . . 75.319999999999993 109.292 173.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.15 79.39 0.29 Allowed Glycine 0 C--N 1.355 1.604 0 CA-C-O 117.844 -1.531 . . . . 74.010000000000005 113.546 176.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -161.1 -71.81 0.06 Allowed 'General case' 0 C--N 1.358 0.972 0 CA-C-N 119.579 1.689 . . . . 72.319999999999993 110.48 170.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -163.17 154.56 14.73 Favored Pre-proline 0 C--N 1.355 0.828 0 CA-C-O 116.058 -1.925 . . . . 73.109999999999999 107.249 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -78.07 169.28 20.65 Favored 'Trans proline' 0 C--N 1.358 1.069 0 CA-C-N 123.577 2.313 . . . . 71.150000000000006 111.238 -177.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -133.37 36.38 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.702 -1.221 . . . . 73.340000000000003 107.702 175.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -173.86 158.73 3.27 Favored 'General case' 0 C--N 1.353 0.742 0 CA-C-O 116.702 -1.618 . . . . 24.43 110.204 -177.122 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.5 m-85 -145.21 173.64 11.77 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-N 119.538 1.063 . . . . 63.119999999999997 110.053 174.382 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.5 171.31 0.85 Allowed 'General case' 0 C--N 1.354 0.793 0 CA-C-N 119.711 1.141 . . . . 74.340000000000003 111.049 -174.267 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.496 0 CA-C-N 120.471 1.487 . . . . 55.409999999999997 111.472 175.135 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 CA-C-O 118.486 -1.174 . . . . 73.150000000000006 112.13 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.15 -144.12 5.18 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.496 -1.724 . . . . 62.350000000000001 112.252 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.94 44.78 1.26 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.526 1.663 . . . . 74.150000000000006 111.042 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.64 -141.69 9.42 Favored Glycine 0 C--N 1.353 1.521 0 CA-C-O 118.076 -1.402 . . . . 72.109999999999999 110.825 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -93.01 -39.24 11.22 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 118.69 1.245 . . . . 71.150000000000006 113.177 -175.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.1 t -99.62 135.12 20.67 Favored Pre-proline 0 C--N 1.353 0.743 0 CA-C-O 115.385 -2.245 . . . . 55.399999999999999 109.233 -168.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -66.78 144.27 70.7 Favored 'Trans proline' 0 C--N 1.362 1.244 0 CA-C-N 123.907 2.431 . . . . 64.030000000000001 112.22 -177.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.9 mt-10 -86.13 -51.53 6.25 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 118.9 0.773 . . . . 32.130000000000003 109.167 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -132.18 174.31 10.34 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 118.91 -0.567 . . . . 71.230000000000004 109.543 -174.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -134.06 171.8 13.72 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.099 -0.704 . . . . 64.319999999999993 109.099 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -104.28 -165.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.775 0 N-CA-C 106.939 -1.504 . . . . 64.209999999999994 106.939 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -74.95 67.22 1.66 Allowed 'General case' 0 C--N 1.352 0.705 0 CA-C-N 119.602 1.092 . . . . 63.149999999999999 108.93 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 66.75 80.63 0.18 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 117.963 -1.465 . . . . 65.549999999999997 113.615 175.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -164.87 -64.03 0.03 OUTLIER 'General case' 0 C--N 1.358 0.941 0 CA-C-N 119.486 1.643 . . . . 70.230000000000004 111.028 172.626 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -169.87 143.28 2.09 Favored Pre-proline 0 C--N 1.354 0.773 0 CA-C-O 115.756 -2.069 . . . . 73.010000000000005 108.364 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -73.74 173.19 14.37 Favored 'Trans proline' 0 C--N 1.359 1.094 0 CA-C-N 123.956 2.449 . . . . 64.519999999999996 111.087 -177.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -135.05 38.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 108.631 -0.877 . . . . 63.43 108.631 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.9 p 175.52 156.88 0.2 Allowed 'General case' 0 C--N 1.355 0.835 0 CA-C-O 117.706 -1.14 . . . . 65.409999999999997 110.902 -176.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.6 m-85 -144.81 176.38 9.49 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-O 118.291 -0.861 . . . . 74.439999999999998 110.542 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.23 174.4 0.29 Allowed 'General case' 0 C--N 1.355 0.823 0 CA-C-N 119.369 0.986 . . . . 75.430000000000007 112.117 -174.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.639 0 N-CA-C 109.34 -1.504 . . . . 64.230000000000004 109.34 176.648 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 CA-C-O 118.529 -1.151 . . . . 65.230000000000004 112.108 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.29 -144.97 5.58 Favored Glycine 0 C--N 1.355 1.617 0 CA-C-O 117.43 -1.761 . . . . 54.340000000000003 111.61 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.34 45.6 1.23 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-N 119.717 1.759 . . . . 41.340000000000003 111.099 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.35 -145.79 17.03 Favored Glycine 0 C--N 1.354 1.53 0 CA-C-O 118.256 -1.302 . . . . 70.209999999999994 110.529 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -85.89 -45.99 11.02 Favored 'General case' 0 C--N 1.357 0.892 0 CA-C-N 118.928 1.364 . . . . 61.25 112.91 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -92.76 134.74 27.16 Favored Pre-proline 0 C--N 1.354 0.795 0 CA-C-O 115.312 -2.28 . . . . 74.329999999999998 109.678 -164.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.45 143.8 64.73 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 123.876 2.42 . . . . 62.140000000000001 112.281 -177.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -86.11 -47.44 9.52 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 118.885 0.766 . . . . 72.439999999999998 109.364 177.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -135.83 175.76 9.3 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 118.668 -0.682 . . . . 64.299999999999997 109.724 -173.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -136.14 170.41 16.06 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 118.771 -0.633 . . . . 74.019999999999996 109.301 178.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.66 -167.53 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.787 0 N-CA-C 106.854 -1.536 . . . . 61.32 106.854 -178.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -76.05 65.62 2.11 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-N 120.309 1.413 . . . . 75.239999999999995 109.286 175.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 72.85 79.67 0.46 Allowed Glycine 0 C--N 1.356 1.66 0 CA-C-O 117.884 -1.509 . . . . 73.5 113.552 175.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -165.16 -65.81 0.03 OUTLIER 'General case' 0 C--N 1.359 1.019 0 CA-C-N 119.582 1.691 . . . . 75.109999999999999 111.376 171.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.4 t -169.49 142.95 2.2 Favored Pre-proline 0 C--N 1.355 0.813 0 CA-C-O 115.644 -2.122 . . . . 64.439999999999998 108.437 179.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.51 172.77 15.04 Favored 'Trans proline' 0 C--N 1.359 1.098 0 CA-C-N 124.036 2.477 . . . . 63.020000000000003 111.542 -176.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -135.46 40.71 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.927 0 N-CA-C 108.629 -0.878 . . . . 75.420000000000002 108.629 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.457 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.2 p 173.85 156.75 0.13 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-O 117.713 -1.137 . . . . 72.340000000000003 110.617 -178.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.457 ' CD1' ' C ' ' A' ' 18' ' ' SER . 33.1 m-85 -144.18 177.37 8.64 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-O 118.324 -0.846 . . . . 75.319999999999993 110.636 -178.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.409 ' O ' ' N ' ' A' ' 4' ' ' GLY . 7.9 m-30 -60.03 173.97 0.56 Allowed 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.547 1.067 . . . . 73.010000000000005 111.346 -174.018 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.634 0 N-CA-C 110.375 -1.09 . . . . 75.409999999999997 110.375 176.184 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.687 0 CA-C-O 118.063 -1.41 . . . . 73.310000000000002 112.331 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.46 -140.75 3.81 Favored Glycine 0 C--N 1.354 1.546 0 CA-C-N 120.011 1.906 . . . . 64.109999999999999 112.287 178.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.12 44.95 1.25 Allowed 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.799 1.799 . . . . 63.100000000000001 110.947 -178.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.07 -141.44 8.85 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.971 -1.46 . . . . 64.120000000000005 110.939 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -94.99 -34.71 12.25 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 117.224 -1.37 . . . . 73.120000000000005 112.927 -173.197 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -105.76 136.16 19.31 Favored Pre-proline 0 C--N 1.355 0.817 0 CA-C-O 115.362 -2.256 . . . . 74.109999999999999 109.159 -169.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -66.75 144.57 72.07 Favored 'Trans proline' 0 C--N 1.362 1.267 0 CA-C-N 124.097 2.499 . . . . 71.230000000000004 112.29 -177.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -86.77 -51.53 6.04 Favored 'General case' 0 C--N 1.358 0.956 0 CA-C-N 119.155 0.889 . . . . 65.439999999999998 108.896 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -131.41 174.52 9.99 Favored 'General case' 0 C--N 1.355 0.84 0 CA-C-O 118.738 -0.648 . . . . 74.140000000000001 109.314 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -134.35 170.39 15.8 Favored 'General case' 0 C--N 1.354 0.765 0 CA-C-O 118.607 -0.711 . . . . 75.030000000000001 109.187 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.21 -169.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.764 0 N-CA-C 106.728 -1.582 . . . . 65.439999999999998 106.728 -179.154 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 86.8 mtm-85 -77.69 68.58 3.8 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-N 120.061 1.3 . . . . 73.0 109.249 174.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 75.03 77.78 0.67 Allowed Glycine 0 C--N 1.358 1.754 0 CA-C-O 117.768 -1.573 . . . . 62.5 113.618 173.056 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -165.63 -65.45 0.03 OUTLIER 'General case' 0 C--N 1.358 0.971 0 CA-C-N 119.517 1.659 . . . . 74.25 111.42 172.225 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -171.0 143.77 1.68 Allowed Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.644 -2.122 . . . . 71.120000000000005 108.327 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -73.15 172.43 15.56 Favored 'Trans proline' 0 C--N 1.359 1.079 0 CA-C-N 123.989 2.46 . . . . 74.219999999999999 111.517 -176.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -134.14 38.82 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.939 0 N-CA-C 108.506 -0.924 . . . . 74.129999999999995 108.506 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.469 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 173.93 156.18 0.13 Allowed 'General case' 0 C--N 1.355 0.826 0 CA-C-N 119.735 1.152 . . . . 62.030000000000001 110.79 -176.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.469 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.2 m-85 -144.43 176.74 9.15 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-O 118.288 -0.863 . . . . 72.310000000000002 110.556 -178.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.409 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.46 176.39 0.19 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-N 119.2 0.909 . . . . 74.409999999999997 112.144 -174.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.632 0 N-CA-C 109.864 -1.295 . . . . 53.049999999999997 109.864 176.758 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.118 -1.379 . . . . 63.100000000000001 112.618 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.46 -141.94 3.6 Favored Glycine 0 C--N 1.355 1.6 0 CA-C-N 120.001 1.9 . . . . 73.140000000000001 111.735 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.93 46.01 1.17 Allowed 'General case' 0 C--N 1.357 0.912 0 CA-C-N 119.965 1.882 . . . . 60.439999999999998 111.169 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.01 -145.0 14.56 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.075 -1.403 . . . . 54.229999999999997 110.415 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 4.0 m80 -87.85 -42.29 12.64 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-N 118.86 1.33 . . . . 75.049999999999997 112.808 -177.103 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.7 t -96.87 134.96 22.37 Favored Pre-proline 0 C--N 1.353 0.734 0 CA-C-O 115.402 -2.237 . . . . 72.0 109.788 -166.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.95 143.77 67.59 Favored 'Trans proline' 0 C--N 1.362 1.253 0 CA-C-N 124.028 2.474 . . . . 65.209999999999994 112.158 -177.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 -86.18 -49.5 7.69 Favored 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.238 0.927 . . . . 64.109999999999999 109.111 178.266 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -133.13 175.54 9.29 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.697 -0.668 . . . . 75.25 109.331 -174.093 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -135.87 169.86 16.91 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.15 -0.685 . . . . 71.540000000000006 109.15 177.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -101.3 -169.4 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.757 0 N-CA-C 106.502 -1.666 . . . . 74.109999999999999 106.502 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.7 mtm180 -74.4 70.64 1.73 Allowed 'General case' 0 C--N 1.354 0.764 0 CA-C-N 120.038 1.29 . . . . 73.310000000000002 109.725 173.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.05 79.07 0.29 Allowed Glycine 0 C--N 1.355 1.619 0 CA-C-O 118.087 -1.396 . . . . 45.439999999999998 113.373 173.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -164.75 -64.7 0.04 OUTLIER 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.249 1.524 . . . . 73.129999999999995 110.903 172.371 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -170.99 143.2 1.6 Allowed Pre-proline 0 C--N 1.355 0.805 0 CA-C-O 115.551 -2.166 . . . . 75.239999999999995 108.416 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.16 172.52 15.38 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 124.023 2.472 . . . . 72.129999999999995 111.544 -176.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.3 mt -134.92 40.81 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.957 0 N-CA-C 108.587 -0.894 . . . . 70.409999999999997 108.587 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.6 p 172.8 156.56 0.1 Allowed 'General case' 0 C--N 1.353 0.754 0 CA-C-O 117.776 -1.107 . . . . 70.420000000000002 110.581 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.8 m-85 -142.99 176.7 8.89 Favored 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.169 -0.92 . . . . 71.349999999999994 110.238 -178.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.423 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.84 173.07 0.46 Allowed 'General case' 0 C--N 1.355 0.807 0 CA-C-N 119.619 1.099 . . . . 75.299999999999997 111.272 -174.031 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.48 0 N-CA-C 108.656 -1.778 . . . . 73.420000000000002 108.656 174.73 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 CA-C-O 118.275 -1.292 . . . . 62.210000000000001 112.026 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.49 -142.66 4.1 Favored Glycine 0 C--N 1.355 1.588 0 CA-C-O 117.224 -1.875 . . . . 74.030000000000001 111.812 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.48 45.71 1.13 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.972 1.886 . . . . 60.049999999999997 111.289 -178.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.4 -145.96 17.54 Favored Glycine 0 C--N 1.354 1.549 0 CA-C-O 118.179 -1.345 . . . . 61.119999999999997 110.626 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -85.71 -43.8 13.08 Favored 'General case' 0 C--N 1.357 0.894 0 CA-C-N 118.904 1.352 . . . . 73.239999999999995 112.884 -177.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.0 t -95.06 134.48 24.65 Favored Pre-proline 0 C--N 1.353 0.726 0 CA-C-O 115.257 -2.306 . . . . 74.319999999999993 109.959 -165.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -66.63 144.32 71.78 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 124.024 2.473 . . . . 72.439999999999998 112.229 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -86.67 -52.22 5.66 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.322 0.965 . . . . 62.520000000000003 108.755 178.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -131.09 174.51 9.95 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 118.713 -0.661 . . . . 73.150000000000006 109.392 -174.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -134.42 170.72 15.32 Favored 'General case' 0 C--N 1.353 0.755 0 N-CA-C 109.038 -0.727 . . . . 73.25 109.038 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -102.38 -169.53 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 N-CA-C 106.933 -1.506 . . . . 65.400000000000006 106.933 -178.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.2 ttm180 -70.05 70.71 0.37 Allowed 'General case' 0 C--N 1.352 0.688 0 CA-C-N 119.394 0.997 . . . . 74.420000000000002 109.312 172.281 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.43 81.63 0.1 OUTLIER Glycine 0 C--N 1.355 1.591 0 CA-C-O 117.956 -1.469 . . . . 63.530000000000001 113.918 174.621 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -164.94 -64.41 0.03 OUTLIER 'General case' 0 C--N 1.357 0.911 0 CA-C-N 119.525 1.662 . . . . 72.519999999999996 110.966 171.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -170.37 142.95 1.83 Allowed Pre-proline 0 C--N 1.354 0.783 0 CA-C-O 115.616 -2.135 . . . . 71.129999999999995 108.387 178.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.3 172.51 15.46 Favored 'Trans proline' 0 C--N 1.359 1.115 0 CA-C-N 124.016 2.47 . . . . 73.329999999999998 111.237 -177.06 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -134.35 38.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 N-CA-C 108.46 -0.941 . . . . 75.140000000000001 108.46 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.0 p 175.26 157.01 0.18 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.581 -1.199 . . . . 62.420000000000002 110.733 -176.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.1 m-85 -144.89 176.26 9.6 Favored 'General case' 0 C--N 1.358 0.97 0 CA-C-O 118.286 -0.864 . . . . 74.109999999999999 110.499 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.417 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.09 171.21 0.56 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-N 119.565 1.075 . . . . 74.510000000000005 111.57 -174.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.484 0 C-N-CA 119.503 -1.332 . . . . 63.25 112.417 176.404 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.368 -1.24 . . . . 74.540000000000006 112.596 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.34 -143.97 5.16 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 117.271 -1.85 . . . . 70.0 112.876 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.82 44.54 1.09 Allowed 'General case' 0 C--N 1.358 0.961 0 CA-C-N 119.585 1.693 . . . . 63.43 112.072 -177.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.5 -144.74 12.41 Favored Glycine 0 C--N 1.353 1.486 0 CA-C-O 118.144 -1.365 . . . . 63.350000000000001 110.533 178.522 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -89.33 -40.79 12.54 Favored 'General case' 0 C--N 1.358 0.959 0 CA-C-N 118.951 1.376 . . . . 63.5 113.46 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.6 t -95.93 133.6 25.1 Favored Pre-proline 0 C--N 1.354 0.761 0 CA-C-O 115.422 -2.228 . . . . 74.430000000000007 109.526 -166.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -65.45 145.33 82.51 Favored 'Trans proline' 0 C--N 1.362 1.275 0 CA-C-N 123.891 2.425 . . . . 72.420000000000002 112.058 -177.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 78.8 mt-10 -81.99 -51.71 7.78 Favored 'General case' 0 C--N 1.359 0.985 0 N-CA-C 108.352 -0.981 . . . . 72.200000000000003 108.352 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.5 p90 -150.04 172.59 15.01 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 118.506 -0.759 . . . . 74.239999999999995 110.279 -177.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -125.64 170.95 11.0 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 118.668 -0.682 . . . . 71.409999999999997 109.484 -177.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -94.42 -166.9 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.868 0 N-CA-C 107.67 -1.233 . . . . 51.119999999999997 107.67 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.4 tpt85 -68.52 67.75 0.13 Allowed 'General case' 0 C--N 1.354 0.779 0 CA-C-N 119.335 0.971 . . . . 73.329999999999998 109.544 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.58 80.48 0.2 Allowed Glycine 0 C--N 1.356 1.646 0 CA-C-O 117.882 -1.51 . . . . 64.030000000000001 113.591 177.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -161.31 -66.19 0.06 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-N 119.495 1.648 . . . . 74.310000000000002 111.314 170.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -171.42 153.59 3.61 Favored Pre-proline 0 C--N 1.356 0.85 0 CA-C-O 115.966 -1.969 . . . . 65.140000000000001 106.763 -177.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -79.97 169.47 17.81 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.657 2.342 . . . . 70.209999999999994 111.644 -177.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.0 mt -135.71 41.89 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.92 0 N-CA-C 107.591 -1.262 . . . . 62.450000000000003 107.591 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.446 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.3 OUTLIER 175.65 157.33 0.21 Allowed 'General case' 0 C--N 1.352 0.71 0 CA-C-O 117.809 -1.091 . . . . 74.200000000000003 110.753 -178.503 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.446 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.2 m-85 -144.99 174.97 10.57 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-O 118.208 -0.901 . . . . 74.409999999999997 110.113 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.67 175.49 0.25 Allowed 'General case' 0 C--N 1.356 0.87 0 CA-C-N 119.143 0.883 . . . . 70.420000000000002 112.208 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.582 0 N-CA-C 109.746 -1.342 . . . . 74.420000000000002 109.746 176.645 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.635 0 CA-C-O 118.427 -1.207 . . . . 73.209999999999994 112.322 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.85 -141.16 3.36 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.217 -1.88 . . . . 44.130000000000003 111.493 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.49 45.5 1.21 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 119.881 1.84 . . . . 74.040000000000006 111.167 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.15 -145.73 15.36 Favored Glycine 0 C--N 1.353 1.496 0 CA-C-O 118.323 -1.265 . . . . 33.210000000000001 110.705 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -88.31 -40.6 13.47 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-N 118.557 1.179 . . . . 65.209999999999994 113.115 -176.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.9 t -98.09 134.89 21.66 Favored Pre-proline 0 C--N 1.353 0.758 0 CA-C-O 115.502 -2.189 . . . . 73.019999999999996 109.498 -166.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -67.41 144.52 67.88 Favored 'Trans proline' 0 C--N 1.362 1.288 0 CA-C-N 123.763 2.38 . . . . 72.329999999999998 112.121 -178.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -87.15 -49.65 7.15 Favored 'General case' 0 C--N 1.358 0.961 0 CA-C-N 118.869 0.759 . . . . 52.539999999999999 109.301 178.077 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -133.46 175.71 9.18 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.744 -0.646 . . . . 71.540000000000006 109.677 -174.206 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -137.04 166.86 22.69 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.63 -0.7 . . . . 73.400000000000006 109.411 177.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -96.03 -168.03 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.841 0 N-CA-C 106.424 -1.695 . . . . 64.120000000000005 106.424 178.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.7 mtp180 -74.85 71.23 1.99 Allowed 'General case' 0 C--N 1.354 0.772 0 CA-C-N 120.3 1.409 . . . . 74.239999999999995 109.329 176.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.43 78.23 0.37 Allowed Glycine 0 C--N 1.355 1.624 0 CA-C-O 118.093 -1.393 . . . . 73.209999999999994 112.978 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -163.01 -63.42 0.04 OUTLIER 'General case' 0 C--N 1.357 0.899 0 CA-C-N 119.26 1.53 . . . . 63.119999999999997 111.28 172.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -170.12 144.11 2.12 Favored Pre-proline 0 C--N 1.355 0.821 0 CA-C-O 115.91 -1.995 . . . . 24.239999999999998 108.643 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -76.03 158.26 38.19 Favored 'Trans proline' 0 C--N 1.36 1.137 0 CA-C-N 123.585 2.316 . . . . 64.010000000000005 110.93 -178.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.405 HG22 ' O ' ' A' ' 17' ' ' ILE . 15.9 mm -119.99 22.59 5.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.916 0 O-C-N 123.916 0.76 . . . . 53.020000000000003 109.764 -176.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.443 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 12.1 p -175.19 157.58 2.27 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-N 120.451 1.478 . . . . 74.329999999999998 110.753 -175.672 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.0 m-85 -142.34 177.68 8.1 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.139 -0.934 . . . . 62.520000000000003 110.887 -176.442 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.412 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -58.3 172.77 0.42 Allowed 'General case' 0 C--N 1.355 0.815 0 CA-C-N 119.538 1.063 . . . . 74.230000000000004 111.593 -174.246 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.596 0 N-CA-C 108.817 -1.713 . . . . 64.230000000000004 108.817 175.011 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 CA-C-O 118.379 -1.234 . . . . 71.400000000000006 112.442 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.3 -141.73 3.25 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.221 -1.877 . . . . 71.120000000000005 111.235 179.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.51 45.99 1.04 Allowed 'General case' 0 C--N 1.356 0.886 0 CA-C-N 120.05 1.925 . . . . 75.219999999999999 111.52 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.95 -146.53 19.68 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.18 -1.344 . . . . 74.099999999999994 110.371 179.35 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -87.11 -41.01 14.13 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-N 118.931 1.366 . . . . 72.519999999999996 113.19 -178.209 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.45 133.73 25.41 Favored Pre-proline 0 C--N 1.353 0.744 0 CA-C-O 115.43 -2.224 . . . . 65.329999999999998 109.536 -166.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.46 144.27 72.69 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.915 2.434 . . . . 73.519999999999996 111.684 -178.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -82.24 -50.75 8.63 Favored 'General case' 0 C--N 1.356 0.876 0 N-CA-C 108.411 -0.959 . . . . 71.230000000000004 108.411 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -148.9 172.59 14.44 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 118.368 -0.825 . . . . 73.450000000000003 109.729 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -126.08 168.24 14.26 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.513 -0.756 . . . . 44.25 109.808 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -91.95 -171.07 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.835 0 N-CA-C 105.918 -1.882 . . . . 61.140000000000001 105.918 175.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.8 mtt-85 -71.2 76.81 0.71 Allowed 'General case' 0 C--N 1.353 0.75 0 CA-C-N 120.366 1.439 . . . . 51.520000000000003 110.071 177.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.53 75.93 0.44 Allowed Glycine 0 C--N 1.355 1.631 0 CA-C-O 118.104 -1.387 . . . . 54.539999999999999 112.985 172.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -161.9 -61.5 0.05 OUTLIER 'General case' 0 C--N 1.356 0.886 0 CA-C-N 119.212 1.506 . . . . 73.349999999999994 111.801 173.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -173.87 144.67 1.05 Allowed Pre-proline 0 C--N 1.355 0.832 0 CA-C-O 115.892 -2.004 . . . . 72.129999999999995 109.035 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.6 156.07 31.8 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 123.608 2.324 . . . . 74.340000000000003 110.79 -178.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 15.7 mm -118.85 21.42 5.96 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-O 118.625 -0.702 . . . . 73.340000000000003 109.427 -176.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.437 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 13.4 p -174.9 158.62 2.59 Favored 'General case' 0 C--N 1.356 0.868 0 CA-C-N 120.435 1.47 . . . . 64.420000000000002 110.994 -175.047 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.437 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -142.05 176.6 8.82 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.136 -0.935 . . . . 65.340000000000003 111.013 -177.042 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.417 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.2 m-30 -58.72 173.12 0.44 Allowed 'General case' 0 C--N 1.356 0.852 0 CA-C-N 119.609 1.095 . . . . 64.120000000000005 111.372 -174.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.587 0 C-N-CA 119.614 -1.279 . . . . 61.0 110.956 177.397 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.648 0 CA-C-O 117.923 -1.487 . . . . 53.329999999999998 113.841 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -164.96 -142.69 3.48 Favored Glycine 0 C--N 1.353 1.502 0 CA-C-N 120.06 1.93 . . . . 72.409999999999997 111.708 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.51 47.66 1.11 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 120.021 1.911 . . . . 75.299999999999997 111.209 -178.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.67 -145.71 18.21 Favored Glycine 0 C--N 1.354 1.551 0 CA-C-O 118.007 -1.44 . . . . 73.010000000000005 109.813 179.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -88.18 -41.72 12.8 Favored 'General case' 0 C--N 1.356 0.879 0 CA-C-N 119.029 1.415 . . . . 61.219999999999999 113.221 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -94.51 133.67 26.59 Favored Pre-proline 0 C--N 1.354 0.771 0 CA-C-O 115.456 -2.211 . . . . 71.209999999999994 109.712 -165.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.0 144.25 75.47 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 123.937 2.442 . . . . 73.540000000000006 111.634 -177.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -82.12 -50.07 9.47 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.473 -0.936 . . . . 71.400000000000006 108.473 178.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -149.92 173.09 14.19 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.398 -0.81 . . . . 73.200000000000003 109.732 -177.316 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -127.95 169.2 14.25 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.509 -0.757 . . . . 72.439999999999998 109.6 -178.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -92.49 -170.9 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.852 0 N-CA-C 107.109 -1.441 . . . . 72.120000000000005 107.109 177.345 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -69.86 73.8 0.43 Allowed 'General case' 0 C--N 1.352 0.679 0 CA-C-N 119.203 0.91 . . . . 64.209999999999994 109.441 174.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.79 76.8 0.43 Allowed Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.034 -1.426 . . . . 71.209999999999994 113.563 173.567 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -160.67 -66.16 0.06 Allowed 'General case' 0 C--N 1.356 0.853 0 CA-C-N 119.244 1.522 . . . . 43.409999999999997 111.077 170.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -170.91 152.15 3.52 Favored Pre-proline 0 C--N 1.357 0.913 0 CA-C-O 116.018 -1.944 . . . . 74.530000000000001 108.36 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -76.32 165.21 29.75 Favored 'Trans proline' 0 C--N 1.356 0.933 0 CA-C-N 123.474 2.277 . . . . 65.540000000000006 111.479 -177.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.9 mt -135.81 47.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.886 0 N-CA-C 107.382 -1.34 . . . . 71.439999999999998 107.382 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.435 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.9 p 166.32 156.53 0.03 OUTLIER 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.032 -0.985 . . . . 73.319999999999993 110.175 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' A' ' 18' ' ' SER . 34.3 m-85 -141.79 178.1 7.72 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 117.877 -1.059 . . . . 74.209999999999994 109.828 179.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.444 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.86 177.6 0.14 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 119.693 1.133 . . . . 73.099999999999994 110.751 -175.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.57 0 CA-C-N 120.615 1.552 . . . . 65.120000000000005 109.915 176.231 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.694 0 CA-C-O 117.858 -1.524 . . . . 74.109999999999999 113.611 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.06 -143.02 3.58 Favored Glycine 0 C--N 1.354 1.583 0 CA-C-N 120.216 2.008 . . . . 72.519999999999996 111.261 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.17 45.23 1.07 Allowed 'General case' 0 C--N 1.357 0.899 0 CA-C-N 120.067 1.934 . . . . 74.25 111.464 -178.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.74 -145.53 16.85 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.166 -1.352 . . . . 45.399999999999999 110.657 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -87.6 -39.99 14.6 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-N 118.778 1.289 . . . . 73.230000000000004 112.911 -176.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -98.77 134.54 21.51 Favored Pre-proline 0 C--N 1.354 0.79 0 CA-C-O 115.368 -2.254 . . . . 74.319999999999993 109.743 -166.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.99 147.31 84.43 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 124.019 2.471 . . . . 74.540000000000006 112.136 -177.339 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.4 mt-10 -83.93 -50.64 7.85 Favored 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.341 0.973 . . . . 71.140000000000001 108.38 178.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -151.5 174.64 13.16 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.417 -0.801 . . . . 61.119999999999997 110.412 -176.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -127.94 178.24 6.31 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.88 -1.057 . . . . 51.420000000000002 109.484 -176.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.36 -162.23 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.947 0 N-CA-C 105.265 -2.124 . . . . 55.520000000000003 105.265 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 70.0 mmt-85 -75.99 73.19 2.88 Favored 'General case' 0 C--N 1.355 0.804 0 CA-C-N 121.32 1.873 . . . . 72.239999999999995 108.221 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.05 79.71 0.24 Allowed Glycine 0 C--N 1.354 1.561 0 CA-C-O 118.382 -1.232 . . . . 64.030000000000001 110.858 176.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -156.21 -69.53 0.11 Allowed 'General case' 0 C--N 1.356 0.849 0 CA-C-N 118.846 1.323 . . . . 74.5 111.067 176.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 178.53 150.8 0.44 Allowed Pre-proline 0 C--N 1.353 0.759 0 CA-C-O 116.063 -1.922 . . . . 71.230000000000004 106.836 -177.389 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -75.58 167.21 26.98 Favored 'Trans proline' 0 C--N 1.356 0.968 0 CA-C-N 124.027 2.474 . . . . 63.409999999999997 110.814 -176.14 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mt -134.08 37.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.854 0 N-CA-C 107.908 -1.145 . . . . 65.010000000000005 107.908 178.606 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.43 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.3 p 171.75 155.71 0.08 Allowed 'General case' 0 C--N 1.354 0.801 0 CA-C-O 117.546 -1.216 . . . . 71.510000000000005 110.205 -175.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.43 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -141.34 175.83 9.35 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-O 118.244 -0.884 . . . . 73.329999999999998 110.332 -178.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.69 171.89 0.58 Allowed 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.636 1.107 . . . . 60.049999999999997 111.377 -174.274 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.538 0 C-N-CA 119.351 -1.404 . . . . 63.200000000000003 112.024 176.21 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.733 0 CA-C-O 118.102 -1.388 . . . . 42.109999999999999 113.273 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.15 -143.25 3.7 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-O 117.208 -1.885 . . . . 25.510000000000002 111.309 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -149.03 44.99 0.99 Allowed 'General case' 0 C--N 1.357 0.923 0 CA-C-N 120.158 1.979 . . . . 55.229999999999997 111.711 -179.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.03 -146.48 18.43 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 118.112 -1.382 . . . . 73.540000000000006 110.534 179.226 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 m170 -87.97 -38.52 15.47 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-N 119.012 1.406 . . . . 73.200000000000003 113.145 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.94 133.2 24.57 Favored Pre-proline 0 C--N 1.353 0.749 0 CA-C-O 115.339 -2.267 . . . . 73.299999999999997 109.688 -167.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -66.35 146.45 80.68 Favored 'Trans proline' 0 C--N 1.363 1.321 0 CA-C-N 123.987 2.46 . . . . 43.420000000000002 112.003 -177.063 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 -82.78 -50.58 8.52 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.317 -0.994 . . . . 52.450000000000003 108.317 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -150.69 173.57 14.01 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.544 -0.741 . . . . 71.239999999999995 110.302 -177.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.7 176.95 6.85 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 118.042 -0.98 . . . . 74.420000000000002 109.415 -176.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.0 -167.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.902 0 N-CA-C 105.068 -2.197 . . . . 72.409999999999997 105.068 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -74.13 75.78 1.77 Allowed 'General case' 0 C--N 1.354 0.767 0 CA-C-N 120.686 1.584 . . . . 74.230000000000004 108.907 178.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.96 76.59 0.33 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.134 -1.37 . . . . 73.329999999999998 111.179 175.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -156.83 -69.75 0.1 Allowed 'General case' 0 C--N 1.355 0.838 0 CA-C-N 119.028 1.414 . . . . 71.109999999999999 111.389 178.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -178.39 143.68 0.46 Allowed Pre-proline 0 C--N 1.354 0.787 0 CA-C-O 116.011 -1.947 . . . . 75.120000000000005 108.465 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -71.75 165.62 31.97 Favored 'Trans proline' 0 C--N 1.358 1.027 0 CA-C-N 123.791 2.39 . . . . 52.43 110.233 -177.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.44 37.72 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.877 0 N-CA-C 107.915 -1.142 . . . . 62.350000000000001 107.915 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.5 p 173.46 154.46 0.1 Allowed 'General case' 0 C--N 1.355 0.833 0 CA-C-O 117.494 -1.241 . . . . 74.340000000000003 110.185 -176.017 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.7 m-85 -141.57 175.63 9.53 Favored 'General case' 0 C--N 1.357 0.925 0 CA-C-O 118.3 -0.857 . . . . 74.409999999999997 110.246 -178.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -59.75 169.39 1.4 Allowed 'General case' 0 C--N 1.355 0.82 0 CA-C-N 119.688 1.131 . . . . 73.540000000000006 111.438 -173.201 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.581 0 N-CA-C 109.444 -1.462 . . . . 31.34 109.444 173.683 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.676 0 CA-C-O 118.316 -1.269 . . . . 74.310000000000002 112.64 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.05 -144.66 4.39 Favored Glycine 0 C--N 1.354 1.55 0 CA-C-O 117.351 -1.805 . . . . 72.230000000000004 111.467 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.01 46.26 1.08 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.782 1.791 . . . . 61.399999999999999 111.48 -179.113 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.84 -144.17 14.11 Favored Glycine 0 C--N 1.353 1.508 0 CA-C-O 118.102 -1.388 . . . . 65.230000000000004 110.195 179.151 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -88.95 -42.51 11.76 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.019 1.41 . . . . 74.239999999999995 113.508 -178.213 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.1 t -93.87 133.41 27.8 Favored Pre-proline 0 C--N 1.353 0.755 0 CA-C-O 115.446 -2.216 . . . . 64.150000000000006 109.478 -166.247 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -65.32 144.41 80.35 Favored 'Trans proline' 0 C--N 1.363 1.312 0 CA-C-N 123.943 2.444 . . . . 55.219999999999999 111.866 -177.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -81.5 -51.39 8.33 Favored 'General case' 0 C--N 1.358 0.968 0 N-CA-C 108.359 -0.978 . . . . 71.420000000000002 108.359 179.001 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.4 p90 -148.87 172.06 15.29 Favored 'General case' 0 C--N 1.354 0.796 0 CA-C-O 118.535 -0.745 . . . . 74.319999999999993 109.941 -177.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -125.01 170.27 11.3 Favored 'General case' 0 C--N 1.355 0.845 0 CA-C-O 118.857 -0.592 . . . . 74.209999999999994 109.614 -177.16 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -94.67 -170.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.808 0 N-CA-C 106.563 -1.643 . . . . 74.409999999999997 106.563 177.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.1 mtt180 -70.08 75.32 0.49 Allowed 'General case' 0 C--N 1.354 0.771 0 CA-C-N 119.876 1.216 . . . . 74.150000000000006 109.924 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.72 78.02 0.24 Allowed Glycine 0 C--N 1.355 1.587 0 CA-C-O 118.11 -1.383 . . . . 60.329999999999998 113.579 172.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -162.62 -63.31 0.05 OUTLIER 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.204 1.502 . . . . 63.130000000000003 111.296 172.101 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -172.92 143.99 1.17 Allowed Pre-proline 0 C--N 1.356 0.855 0 CA-C-O 115.713 -2.089 . . . . 60.229999999999997 108.281 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.52 170.74 19.61 Favored 'Trans proline' 0 C--N 1.357 0.984 0 CA-C-N 123.835 2.405 . . . . 75.510000000000005 111.17 -177.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -135.77 39.94 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.977 0 N-CA-C 108.488 -0.93 . . . . 74.310000000000002 108.488 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.433 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 19.2 p 175.1 155.42 0.15 Allowed 'General case' 0 C--N 1.353 0.747 0 CA-C-O 117.795 -1.097 . . . . 63.520000000000003 110.932 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.6 m-85 -142.59 175.19 9.99 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.049 -0.977 . . . . 72.319999999999993 110.169 -179.756 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.428 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.8 m-30 -58.46 172.43 0.48 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.509 1.05 . . . . 64.239999999999995 111.333 -174.05 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.528 0 N-CA-C 109.18 -1.568 . . . . 74.319999999999993 109.18 174.201 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.681 0 CA-C-O 118.145 -1.364 . . . . 63.0 112.89 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.85 -142.12 3.41 Favored Glycine 0 C--N 1.354 1.552 0 CA-C-O 117.177 -1.902 . . . . 75.109999999999999 112.144 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.8 46.22 1.02 Allowed 'General case' 0 C--N 1.358 0.945 0 CA-C-N 119.887 1.843 . . . . 53.229999999999997 111.697 -178.44 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.62 -144.56 15.59 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.146 -1.363 . . . . 51.43 110.6 179.559 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.2 m80 -87.44 -41.82 13.26 Favored 'General case' 0 C--N 1.356 0.88 0 CA-C-N 118.788 1.294 . . . . 53.43 113.141 -177.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -97.45 134.57 22.43 Favored Pre-proline 0 C--N 1.354 0.785 0 CA-C-O 115.397 -2.239 . . . . 61.439999999999998 109.693 -166.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -65.74 144.25 77.15 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 123.909 2.432 . . . . 75.099999999999994 111.81 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -81.52 -51.42 8.29 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.48 -0.933 . . . . 71.030000000000001 108.48 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -148.37 172.0 15.11 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-O 118.366 -0.826 . . . . 71.120000000000005 109.553 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -124.34 170.13 11.12 Favored 'General case' 0 C--N 1.355 0.823 0 O-C-N 123.781 0.675 . . . . 74.239999999999995 109.628 -177.084 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 m -92.59 -166.29 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 106.477 -1.675 . . . . 73.409999999999997 106.477 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 42.8 mtp180 -75.52 69.08 2.24 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-N 120.005 1.275 . . . . 74.519999999999996 109.56 175.425 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.29 78.21 0.46 Allowed Glycine 0 C--N 1.356 1.669 0 CA-C-O 118.01 -1.439 . . . . 74.200000000000003 113.208 174.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -164.28 -63.45 0.04 OUTLIER 'General case' 0 C--N 1.357 0.916 0 CA-C-N 119.376 1.588 . . . . 64.439999999999998 111.503 172.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -171.5 144.52 1.63 Allowed Pre-proline 0 C--N 1.355 0.809 0 CA-C-O 115.511 -2.185 . . . . 63.219999999999999 108.307 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -75.36 171.36 18.41 Favored 'Trans proline' 0 C--N 1.357 1.01 0 CA-C-N 123.95 2.447 . . . . 72.319999999999993 111.361 -177.497 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -136.06 40.33 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 108.413 -0.958 . . . . 74.25 108.413 178.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.8 p 174.31 155.93 0.13 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.77 -1.11 . . . . 45.100000000000001 111.08 -177.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.6 m-85 -143.25 175.91 9.53 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-O 118.283 -0.865 . . . . 64.329999999999998 110.559 -179.489 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.0 m-30 -60.13 176.57 0.31 Allowed 'General case' 0 C--N 1.356 0.866 0 CA-C-N 119.354 0.979 . . . . 75.209999999999994 111.775 -174.268 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.594 0 C-N-CA 119.514 -1.327 . . . . 72.420000000000002 109.894 173.474 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.737 0 CA-C-O 118.119 -1.378 . . . . 73.209999999999994 112.414 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.84 -142.94 3.99 Favored Glycine 0 C--N 1.354 1.566 0 CA-C-N 119.897 1.848 . . . . 61.520000000000003 111.802 179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.53 45.75 1.21 Allowed 'General case' 0 C--N 1.357 0.893 0 CA-C-N 119.843 1.822 . . . . 64.319999999999993 111.171 -179.013 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.421 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.91 -143.57 12.24 Favored Glycine 0 C--N 1.353 1.516 0 CA-C-O 118.049 -1.417 . . . . 55.340000000000003 110.641 -179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 2.3 m80 -89.34 -41.49 12.11 Favored 'General case' 0 C--N 1.356 0.873 0 CA-C-N 118.765 1.283 . . . . 73.540000000000006 112.89 -176.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.7 t -98.6 135.29 21.14 Favored Pre-proline 0 C--N 1.353 0.748 0 CA-C-O 115.363 -2.256 . . . . 65.150000000000006 109.661 -166.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -66.66 144.7 73.16 Favored 'Trans proline' 0 C--N 1.362 1.254 0 CA-C-N 124.036 2.477 . . . . 62.109999999999999 112.43 -177.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.1 mt-10 -86.78 -52.11 5.7 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-N 119.275 0.943 . . . . 72.099999999999994 108.893 178.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 67.0 m-85 -132.18 174.69 9.95 Favored 'General case' 0 C--N 1.354 0.778 0 CA-C-O 118.731 -0.652 . . . . 61.439999999999998 109.449 -174.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.8 m-85 -134.76 170.56 15.64 Favored 'General case' 0 C--N 1.354 0.781 0 CA-C-O 118.742 -0.647 . . . . 73.209999999999994 109.305 178.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -100.91 -170.4 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.793 0 N-CA-C 107.12 -1.437 . . . . 71.019999999999996 107.12 -178.31 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 39.3 ttp180 -78.68 65.81 4.03 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-N 120.003 1.274 . . . . 72.140000000000001 109.177 176.446 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 79.73 77.9 0.91 Allowed Glycine 0 C--N 1.356 1.69 0 CA-C-O 117.986 -1.452 . . . . 60.32 113.438 175.436 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -165.23 -71.96 0.03 OUTLIER 'General case' 0 C--N 1.358 0.952 0 CA-C-N 119.452 1.626 . . . . 72.219999999999999 110.8 170.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.98 150.69 6.34 Favored Pre-proline 0 C--N 1.355 0.818 0 CA-C-O 115.777 -2.059 . . . . 62.340000000000003 106.996 -179.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.9 Cg_endo -75.67 173.05 15.16 Favored 'Trans proline' 0 C--N 1.358 1.046 0 CA-C-N 123.733 2.369 . . . . 65.120000000000005 111.432 -176.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -134.25 38.63 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.918 0 N-CA-C 108.419 -0.956 . . . . 72.239999999999995 108.419 178.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.468 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.8 p 175.08 157.36 0.17 Allowed 'General case' 0 C--N 1.354 0.781 0 CA-C-O 117.445 -1.264 . . . . 72.239999999999995 110.798 -176.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.468 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -144.54 176.68 9.22 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-O 118.267 -0.873 . . . . 65.420000000000002 110.378 -179.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.421 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.17 174.45 0.39 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-N 119.567 1.076 . . . . 74.230000000000004 111.382 -174.378 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.508 0 CA-C-N 120.143 1.338 . . . . 74.540000000000006 111.798 176.85 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.702 0 CA-C-O 118.293 -1.282 . . . . 71.519999999999996 112.885 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -171.61 -144.03 4.29 Favored Glycine 0 C--N 1.354 1.543 0 CA-C-O 117.415 -1.769 . . . . 44.109999999999999 111.614 179.401 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.61 46.16 1.29 Allowed 'General case' 0 C--N 1.356 0.887 0 CA-C-N 119.751 1.776 . . . . 54.119999999999997 110.677 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.61 -139.63 9.2 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 118.034 -1.426 . . . . 53.020000000000003 110.798 -178.545 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -95.31 -35.68 11.69 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 117.482 -1.247 . . . . 52.530000000000001 113.285 -173.102 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -105.52 136.13 19.28 Favored Pre-proline 0 C--N 1.355 0.824 0 CA-C-O 115.414 -2.231 . . . . 65.040000000000006 109.285 -169.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -66.99 143.78 67.36 Favored 'Trans proline' 0 C--N 1.361 1.211 0 CA-C-N 123.894 2.427 . . . . 73.209999999999994 112.289 -177.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.3 mt-10 -85.73 -48.73 8.55 Favored 'General case' 0 C--N 1.358 0.954 0 CA-C-N 118.886 0.766 . . . . 65.200000000000003 109.413 178.052 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 64.9 m-85 -134.71 175.02 9.93 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.84 -0.6 . . . . 63.310000000000002 109.548 -173.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.3 m-85 -135.44 171.19 14.8 Favored 'General case' 0 C--N 1.353 0.744 0 N-CA-C 109.105 -0.702 . . . . 72.25 109.105 177.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.5 m -103.31 -170.32 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.746 0 N-CA-C 107.225 -1.398 . . . . 61.420000000000002 107.225 -177.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 88.1 mtm180 -72.5 71.32 0.94 Allowed 'General case' 0 C--N 1.353 0.735 0 CA-C-N 119.146 0.885 . . . . 71.219999999999999 108.885 172.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.24 80.41 0.2 Allowed Glycine 0 C--N 1.355 1.595 0 CA-C-O 118.19 -1.339 . . . . 73.439999999999998 113.812 173.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -164.25 -70.9 0.04 OUTLIER 'General case' 0 C--N 1.357 0.895 0 CA-C-N 119.241 1.52 . . . . 73.099999999999994 110.37 170.558 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -166.83 150.27 6.32 Favored Pre-proline 0 C--N 1.355 0.826 0 CA-C-O 115.871 -2.014 . . . . 55.030000000000001 106.839 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -75.42 172.77 15.69 Favored 'Trans proline' 0 C--N 1.356 0.93 0 CA-C-N 123.58 2.314 . . . . 74.450000000000003 111.319 -176.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.1 mt -135.32 41.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.981 0 N-CA-C 108.321 -0.992 . . . . 74.209999999999994 108.321 178.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.449 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 171.99 156.77 0.09 Allowed 'General case' 0 C--N 1.354 0.803 0 CA-C-O 117.889 -1.053 . . . . 71.209999999999994 110.676 -179.266 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.449 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.9 m-85 -142.96 177.8 8.11 Favored 'General case' 0 C--N 1.358 0.96 0 CA-C-O 118.106 -0.95 . . . . 62.130000000000003 110.123 -179.296 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.1 m-30 -59.43 175.73 0.31 Allowed 'General case' 0 C--N 1.355 0.81 0 CA-C-N 119.713 1.142 . . . . 74.409999999999997 111.234 -174.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.611 0 N-CA-C 109.932 -1.267 . . . . 70.230000000000004 109.932 176.422 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.66 0 CA-C-O 118.663 -1.076 . . . . 74.310000000000002 111.942 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -176.98 -144.98 5.52 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.497 -1.724 . . . . 71.430000000000007 111.852 179.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.99 45.67 1.17 Allowed 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.633 1.716 . . . . 53.539999999999999 111.374 -179.336 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.414 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.25 -142.47 11.79 Favored Glycine 0 C--N 1.354 1.532 0 CA-C-O 118.033 -1.426 . . . . 60.130000000000003 110.494 179.865 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 3.3 m170 -88.57 -45.99 9.44 Favored 'General case' 0 C--N 1.357 0.897 0 CA-C-N 118.983 1.391 . . . . 63.210000000000001 113.144 -177.21 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.8 t -93.2 134.39 27.13 Favored Pre-proline 0 C--N 1.353 0.732 0 CA-C-O 115.637 -2.125 . . . . 71.150000000000006 109.44 -165.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.6 Cg_endo -66.64 143.99 70.47 Favored 'Trans proline' 0 C--N 1.363 1.3 0 CA-C-N 123.822 2.401 . . . . 71.140000000000001 112.183 -177.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.4 mt-10 -86.31 -50.82 6.65 Favored 'General case' 0 C--N 1.358 0.935 0 CA-C-N 118.806 0.73 . . . . 63.240000000000002 109.211 178.02 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 66.9 m-85 -133.44 174.0 10.88 Favored 'General case' 0 C--N 1.355 0.813 0 CA-C-O 118.853 -0.594 . . . . 71.409999999999997 109.939 -174.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 80.1 m-85 -135.07 170.82 15.32 Favored 'General case' 0 C--N 1.354 0.779 0 CA-C-O 118.694 -0.669 . . . . 74.310000000000002 109.256 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -102.63 -169.63 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.737 0 N-CA-C 107.031 -1.47 . . . . 64.549999999999997 107.031 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 90.0 mtm180 -73.45 70.98 1.28 Allowed 'General case' 0 C--N 1.353 0.729 0 CA-C-N 119.643 1.11 . . . . 74.019999999999996 108.875 173.027 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.97 80.33 0.22 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.118 -1.379 . . . . 61.219999999999999 113.621 173.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -162.67 -68.87 0.05 OUTLIER 'General case' 0 C--N 1.356 0.858 0 CA-C-N 119.155 1.477 . . . . 75.019999999999996 109.959 170.066 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -168.56 149.44 4.42 Favored Pre-proline 0 C--N 1.355 0.843 0 CA-C-O 115.964 -1.97 . . . . 72.150000000000006 106.895 178.773 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -75.53 173.42 14.53 Favored 'Trans proline' 0 C--N 1.356 0.973 0 CA-C-N 123.529 2.296 . . . . 64.409999999999997 111.226 -177.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.2 mt -134.5 39.37 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.906 0 N-CA-C 108.479 -0.934 . . . . 72.230000000000004 108.479 179.053 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.462 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.5 p 174.96 157.13 0.16 Allowed 'General case' 0 C--N 1.354 0.766 0 CA-C-O 117.714 -1.136 . . . . 72.129999999999995 111.01 -177.043 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.462 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.1 m-85 -144.53 176.7 9.2 Favored 'General case' 0 C--N 1.358 0.936 0 CA-C-O 118.248 -0.882 . . . . 73.400000000000006 110.285 -179.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.414 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.17 169.63 1.08 Allowed 'General case' 0 C--N 1.355 0.812 0 CA-C-N 119.652 1.115 . . . . 63.43 111.534 -173.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.513 0 C-N-CA 119.303 -1.427 . . . . 62.409999999999997 111.491 176.457 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.65 0 CA-C-O 117.919 -1.49 . . . . 72.150000000000006 113.325 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.76 -141.77 3.23 Favored Glycine 0 C--N 1.354 1.577 0 CA-C-N 120.159 1.98 . . . . 63.310000000000002 111.527 179.547 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.62 46.01 1.11 Allowed 'General case' 0 C--N 1.358 0.935 0 CA-C-N 119.898 1.849 . . . . 72.430000000000007 111.018 -179.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.66 -137.95 7.81 Favored Glycine 0 C--N 1.353 1.51 0 CA-C-O 117.788 -1.562 . . . . 24.350000000000001 110.844 -179.114 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -100.76 -24.7 14.34 Favored 'General case' 0 C--N 1.359 0.99 0 CA-C-O 116.653 -1.641 . . . . 75.430000000000007 114.039 -172.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.3 t -114.21 135.25 22.15 Favored Pre-proline 0 C--N 1.356 0.891 0 CA-C-O 115.384 -2.246 . . . . 75.25 108.685 -171.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -65.96 144.27 75.83 Favored 'Trans proline' 0 C--N 1.361 1.21 0 CA-C-N 123.884 2.423 . . . . 72.540000000000006 111.788 -176.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.0 mt-10 -81.37 -50.67 9.2 Favored 'General case' 0 C--N 1.357 0.933 0 N-CA-C 108.255 -1.017 . . . . 75.329999999999998 108.255 178.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -149.22 172.2 15.24 Favored 'General case' 0 C--N 1.355 0.819 0 CA-C-O 118.472 -0.775 . . . . 62.119999999999997 109.863 -177.686 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -127.13 168.59 14.44 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.466 -0.778 . . . . 72.129999999999995 109.506 -177.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.411 ' O ' ' N ' ' A' ' 13' ' ' GLY . 3.1 m -94.65 -176.99 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.805 0 N-CA-C 107.334 -1.358 . . . . 75.310000000000002 107.334 176.181 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 8.2 ptm180 -55.2 76.47 0.0 OUTLIER 'General case' 0 C--N 1.352 0.702 0 CA-C-N 118.309 0.504 . . . . 74.310000000000002 111.895 170.44 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . 0.411 ' N ' ' O ' ' A' ' 11' ' ' VAL . . . 57.49 78.44 0.13 Allowed Glycine 0 C--N 1.354 1.576 0 CA-C-O 118.056 -1.414 . . . . 64.420000000000002 114.097 172.521 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -161.26 -61.86 0.05 Allowed 'General case' 0 C--N 1.356 0.88 0 CA-C-N 119.414 1.607 . . . . 52.140000000000001 111.805 173.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -174.52 145.51 0.99 Allowed Pre-proline 0 C--N 1.355 0.833 0 CA-C-O 115.777 -2.059 . . . . 75.019999999999996 108.448 -178.605 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -75.56 168.52 24.26 Favored 'Trans proline' 0 C--N 1.357 0.994 0 CA-C-N 123.677 2.349 . . . . 74.219999999999999 111.205 -178.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 9.7 mt -137.45 44.3 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.9 0 N-CA-C 107.751 -1.203 . . . . 63.340000000000003 107.751 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.45 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.0 p 170.03 155.6 0.05 Allowed 'General case' 0 C--N 1.354 0.797 0 CA-C-O 117.878 -1.058 . . . . 63.329999999999998 110.496 -179.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.45 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.9 m-85 -141.88 175.82 9.42 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.291 -0.862 . . . . 53.119999999999997 109.984 -179.943 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.437 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -57.98 172.13 0.45 Allowed 'General case' 0 C--N 1.354 0.777 0 CA-C-N 119.497 1.044 . . . . 71.230000000000004 111.484 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.356 1.641 0 N-CA-C 108.308 -1.917 . . . . 75.150000000000006 108.308 174.304 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.695 0 CA-C-O 118.357 -1.246 . . . . 73.510000000000005 112.267 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.62 -143.19 3.87 Favored Glycine 0 C--N 1.355 1.592 0 CA-C-O 117.135 -1.925 . . . . 65.439999999999998 111.655 -179.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.52 45.79 1.12 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.957 1.878 . . . . 74.200000000000003 111.105 -178.489 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.94 -144.2 14.27 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 118.169 -1.351 . . . . 33.539999999999999 110.707 -179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.7 m-70 -88.78 -40.81 12.93 Favored 'General case' 0 C--N 1.357 0.93 0 CA-C-N 118.829 1.314 . . . . 74.540000000000006 113.026 -176.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -99.26 135.5 20.73 Favored Pre-proline 0 C--N 1.354 0.775 0 CA-C-O 115.233 -2.318 . . . . 72.109999999999999 109.389 -166.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -66.8 144.89 73.05 Favored 'Trans proline' 0 C--N 1.364 1.344 0 CA-C-N 124.001 2.464 . . . . 73.409999999999997 111.879 -177.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.5 mt-10 -82.64 -51.28 7.89 Favored 'General case' 0 C--N 1.359 0.989 0 N-CA-C 108.392 -0.966 . . . . 72.409999999999997 108.392 178.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -149.53 172.95 14.16 Favored 'General case' 0 C--N 1.356 0.861 0 CA-C-O 118.155 -0.926 . . . . 72.420000000000002 109.747 -177.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 63.1 m-85 -126.36 168.55 14.01 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-O 118.551 -0.738 . . . . 74.109999999999999 109.974 -176.916 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -90.09 -169.99 0.15 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.881 0 N-CA-C 106.645 -1.613 . . . . 64.239999999999995 106.645 177.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -70.73 75.12 0.6 Allowed 'General case' 0 C--N 1.353 0.718 0 CA-C-N 119.479 1.036 . . . . 71.120000000000005 109.153 176.198 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.1 77.45 0.35 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 118.107 -1.385 . . . . 64.209999999999994 113.058 173.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.0 t70 -160.03 -65.12 0.07 Allowed 'General case' 0 C--N 1.357 0.919 0 CA-C-N 119.188 1.494 . . . . 55.100000000000001 111.279 171.45 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.09 154.56 3.41 Favored Pre-proline 0 C--N 1.355 0.814 0 CA-C-O 116.027 -1.94 . . . . 74.310000000000002 107.6 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 81.6 Cg_endo -80.87 155.99 20.5 Favored 'Trans proline' 0 C--N 1.36 1.174 0 CA-C-N 123.698 2.357 . . . . 64.0 111.257 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.5 mm -118.73 17.75 6.85 Favored 'Isoleucine or valine' 0 C--N 1.356 0.89 0 CA-C-O 118.284 -0.865 . . . . 73.329999999999998 109.23 -179.836 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 7.1 m -165.9 158.87 15.29 Favored 'General case' 0 C--N 1.358 0.943 0 CA-C-N 121.102 1.774 . . . . 71.239999999999995 110.558 -174.262 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.5 m-85 -142.8 174.94 10.21 Favored 'General case' 0 C--N 1.358 0.947 0 CA-C-N 119.789 1.177 . . . . 73.109999999999999 110.713 178.904 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.432 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.3 m-30 -59.18 174.02 0.43 Allowed 'General case' 0 C--N 1.356 0.855 0 CA-C-N 119.242 0.928 . . . . 73.200000000000003 111.266 -174.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.483 0 N-CA-C 109.036 -1.626 . . . . 70.109999999999999 109.036 175.558 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.734 0 CA-C-O 118.463 -1.187 . . . . 75.299999999999997 112.278 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.77 -147.08 6.17 Favored Glycine 0 C--N 1.355 1.597 0 CA-C-O 117.486 -1.73 . . . . 71.319999999999993 111.859 -179.539 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.2 46.34 1.15 Allowed 'General case' 0 C--N 1.357 0.925 0 CA-C-N 119.78 1.79 . . . . 72.129999999999995 111.357 -178.508 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.433 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.18 -144.69 15.42 Favored Glycine 0 C--N 1.354 1.57 0 CA-C-O 117.9 -1.5 . . . . 54.439999999999998 110.249 179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.9 m80 -87.76 -43.1 12.13 Favored 'General case' 0 C--N 1.357 0.9 0 CA-C-N 119.142 1.471 . . . . 71.319999999999993 112.926 -177.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.5 t -96.4 134.98 22.74 Favored Pre-proline 0 C--N 1.354 0.764 0 CA-C-O 115.199 -2.334 . . . . 64.200000000000003 109.814 -165.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 41.9 Cg_endo -65.22 145.05 83.19 Favored 'Trans proline' 0 C--N 1.363 1.323 0 CA-C-N 124.146 2.517 . . . . 72.530000000000001 112.257 -177.432 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 75.9 mt-10 -82.45 -52.14 7.16 Favored 'General case' 0 C--N 1.357 0.908 0 N-CA-C 108.177 -1.045 . . . . 54.43 108.177 178.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.7 p90 -149.32 173.0 13.98 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-O 118.414 -0.803 . . . . 73.010000000000005 109.685 -177.4 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 76.7 m-85 -126.4 169.55 12.85 Favored 'General case' 0 C--N 1.354 0.804 0 CA-C-O 118.505 -0.759 . . . . 71.230000000000004 110.095 -176.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -93.41 -171.6 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.878 0 N-CA-C 106.872 -1.529 . . . . 74.400000000000006 106.872 177.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.3 mtt-85 -70.38 76.1 0.55 Allowed 'General case' 0 C--N 1.355 0.806 0 CA-C-N 119.826 1.194 . . . . 74.010000000000005 109.879 173.719 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.57 76.97 0.4 Allowed Glycine 0 C--N 1.355 1.613 0 CA-C-O 118.048 -1.418 . . . . 52.140000000000001 113.267 172.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.6 t70 -160.59 -67.16 0.07 Allowed 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.203 1.502 . . . . 75.439999999999998 110.934 170.41 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -172.07 153.06 3.04 Favored Pre-proline 0 C--N 1.353 0.753 0 CA-C-O 115.754 -2.07 . . . . 75.209999999999994 107.253 -178.423 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -79.38 171.51 15.9 Favored 'Trans proline' 0 C--N 1.357 1.022 0 CA-C-N 123.911 2.433 . . . . 40.140000000000001 111.661 -177.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 7.3 mt -135.9 41.37 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.799 -1.186 . . . . 73.239999999999995 107.799 177.072 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.434 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 2.7 p 174.5 156.65 0.15 Allowed 'General case' 0 C--N 1.354 0.774 0 CA-C-O 117.809 -1.091 . . . . 61.020000000000003 110.731 -178.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.434 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.7 m-85 -143.76 175.69 9.8 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.133 -0.937 . . . . 75.400000000000006 110.071 179.417 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.433 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.78 176.15 0.22 Allowed 'General case' 0 C--N 1.354 0.783 0 CA-C-N 119.654 1.115 . . . . 73.239999999999995 111.351 -174.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.574 0 CA-C-N 120.227 1.376 . . . . 61.340000000000003 110.641 176.51 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.715 0 CA-C-O 118.521 -1.155 . . . . 73.299999999999997 111.246 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -175.3 -146.45 5.82 Favored Glycine 0 C--N 1.354 1.58 0 CA-C-O 117.389 -1.784 . . . . 74.450000000000003 111.753 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.96 45.92 1.09 Allowed 'General case' 0 C--N 1.357 0.901 0 CA-C-N 119.718 1.759 . . . . 65.040000000000006 111.318 -178.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.441 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.7 -139.65 9.72 Favored Glycine 0 C--N 1.354 1.548 0 CA-C-O 117.806 -1.552 . . . . 74.519999999999996 110.62 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 1.3 m80 -93.52 -38.81 11.2 Favored 'General case' 0 C--N 1.357 0.903 0 CA-C-N 119.045 1.422 . . . . 63.119999999999997 113.151 -174.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.4 t -101.67 135.17 19.83 Favored Pre-proline 0 C--N 1.354 0.799 0 CA-C-O 115.149 -2.358 . . . . 73.340000000000003 109.495 -167.635 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -65.94 144.53 76.89 Favored 'Trans proline' 0 C--N 1.362 1.255 0 CA-C-N 124.165 2.523 . . . . 63.020000000000003 112.218 -176.905 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 65.3 mt-10 -81.87 -51.77 7.77 Favored 'General case' 0 C--N 1.358 0.94 0 CA-C-N 119.486 1.039 . . . . 70.310000000000002 108.313 178.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.9 p90 -149.19 172.38 14.93 Favored 'General case' 0 C--N 1.353 0.757 0 CA-C-O 118.342 -0.837 . . . . 64.439999999999998 110.116 -177.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.5 m-85 -124.77 171.34 10.19 Favored 'General case' 0 C--N 1.356 0.848 0 CA-C-O 118.665 -0.683 . . . . 74.450000000000003 110.016 -176.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.2 m -94.87 -166.39 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.833 0 N-CA-C 107.484 -1.302 . . . . 71.540000000000006 107.484 -178.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 12.2 tpt180 -71.01 67.22 0.41 Allowed 'General case' 0 C--N 1.355 0.813 0 CA-C-N 119.801 1.182 . . . . 75.319999999999993 109.292 173.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.15 79.39 0.29 Allowed Glycine 0 C--N 1.355 1.604 0 CA-C-O 117.844 -1.531 . . . . 74.010000000000005 113.546 176.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -161.1 -71.81 0.06 Allowed 'General case' 0 C--N 1.358 0.972 0 CA-C-N 119.579 1.689 . . . . 72.319999999999993 110.48 170.044 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -163.17 154.56 14.73 Favored Pre-proline 0 C--N 1.355 0.828 0 CA-C-O 116.058 -1.925 . . . . 73.109999999999999 107.249 179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -78.07 169.28 20.65 Favored 'Trans proline' 0 C--N 1.358 1.069 0 CA-C-N 123.577 2.313 . . . . 71.150000000000006 111.238 -177.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.8 mt -133.37 36.38 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.892 0 N-CA-C 107.702 -1.221 . . . . 73.340000000000003 107.702 175.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -173.86 158.73 3.27 Favored 'General case' 0 C--N 1.353 0.742 0 CA-C-O 116.702 -1.618 . . . . 24.43 110.204 -177.122 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.5 m-85 -145.21 173.64 11.77 Favored 'General case' 0 C--N 1.355 0.834 0 CA-C-N 119.538 1.063 . . . . 63.119999999999997 110.053 174.382 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -59.5 171.31 0.85 Allowed 'General case' 0 C--N 1.354 0.793 0 CA-C-N 119.711 1.141 . . . . 74.340000000000003 111.049 -174.267 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.496 0 CA-C-N 120.471 1.487 . . . . 55.409999999999997 111.472 175.135 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.651 0 CA-C-O 118.486 -1.174 . . . . 73.150000000000006 112.13 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.15 -144.12 5.18 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.496 -1.724 . . . . 62.350000000000001 112.252 179.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -145.94 44.78 1.26 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.526 1.663 . . . . 74.150000000000006 111.042 -179.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.404 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.64 -141.69 9.42 Favored Glycine 0 C--N 1.353 1.521 0 CA-C-O 118.076 -1.402 . . . . 72.109999999999999 110.825 -179.894 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -93.01 -39.24 11.22 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 118.69 1.245 . . . . 71.150000000000006 113.177 -175.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.1 t -99.62 135.12 20.67 Favored Pre-proline 0 C--N 1.353 0.743 0 CA-C-O 115.385 -2.245 . . . . 55.399999999999999 109.233 -168.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_endo -66.78 144.27 70.7 Favored 'Trans proline' 0 C--N 1.362 1.244 0 CA-C-N 123.907 2.431 . . . . 64.030000000000001 112.22 -177.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.9 mt-10 -86.13 -51.53 6.25 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 118.9 0.773 . . . . 32.130000000000003 109.167 178.184 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 69.9 m-85 -132.18 174.31 10.34 Favored 'General case' 0 C--N 1.355 0.837 0 CA-C-O 118.91 -0.567 . . . . 71.230000000000004 109.543 -174.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.6 m-85 -134.06 171.8 13.72 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.099 -0.704 . . . . 64.319999999999993 109.099 178.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -104.28 -165.7 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.775 0 N-CA-C 106.939 -1.504 . . . . 64.209999999999994 106.939 -177.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 87.3 mtm180 -74.95 67.22 1.66 Allowed 'General case' 0 C--N 1.352 0.705 0 CA-C-N 119.602 1.092 . . . . 63.149999999999999 108.93 173.965 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 66.75 80.63 0.18 Allowed Glycine 0 C--N 1.355 1.612 0 CA-C-O 117.963 -1.465 . . . . 65.549999999999997 113.615 175.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -164.87 -64.03 0.03 OUTLIER 'General case' 0 C--N 1.358 0.941 0 CA-C-N 119.486 1.643 . . . . 70.230000000000004 111.028 172.626 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -169.87 143.28 2.09 Favored Pre-proline 0 C--N 1.354 0.773 0 CA-C-O 115.756 -2.069 . . . . 73.010000000000005 108.364 179.11 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -73.74 173.19 14.37 Favored 'Trans proline' 0 C--N 1.359 1.094 0 CA-C-N 123.956 2.449 . . . . 64.519999999999996 111.087 -177.481 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -135.05 38.68 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.889 0 N-CA-C 108.631 -0.877 . . . . 63.43 108.631 179.623 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 10.9 p 175.52 156.88 0.2 Allowed 'General case' 0 C--N 1.355 0.835 0 CA-C-O 117.706 -1.14 . . . . 65.409999999999997 110.902 -176.802 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 29.6 m-85 -144.81 176.38 9.49 Favored 'General case' 0 C--N 1.358 0.949 0 CA-C-O 118.291 -0.861 . . . . 74.439999999999998 110.542 -179.416 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.404 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.23 174.4 0.29 Allowed 'General case' 0 C--N 1.355 0.823 0 CA-C-N 119.369 0.986 . . . . 75.430000000000007 112.117 -174.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.639 0 N-CA-C 109.34 -1.504 . . . . 64.230000000000004 109.34 176.648 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.637 0 CA-C-O 118.529 -1.151 . . . . 65.230000000000004 112.108 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.29 -144.97 5.58 Favored Glycine 0 C--N 1.355 1.617 0 CA-C-O 117.43 -1.761 . . . . 54.340000000000003 111.61 179.19 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.34 45.6 1.23 Allowed 'General case' 0 C--N 1.358 0.951 0 CA-C-N 119.717 1.759 . . . . 41.340000000000003 111.099 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.35 -145.79 17.03 Favored Glycine 0 C--N 1.354 1.53 0 CA-C-O 118.256 -1.302 . . . . 70.209999999999994 110.529 179.529 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 19.3 m80 -85.89 -45.99 11.02 Favored 'General case' 0 C--N 1.357 0.892 0 CA-C-N 118.928 1.364 . . . . 61.25 112.91 -178.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -92.76 134.74 27.16 Favored Pre-proline 0 C--N 1.354 0.795 0 CA-C-O 115.312 -2.28 . . . . 74.329999999999998 109.678 -164.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 54.8 Cg_endo -67.45 143.8 64.73 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 123.876 2.42 . . . . 62.140000000000001 112.281 -177.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 68.6 mt-10 -86.11 -47.44 9.52 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 118.885 0.766 . . . . 72.439999999999998 109.364 177.924 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 56.6 m-85 -135.83 175.76 9.3 Favored 'General case' 0 C--N 1.355 0.817 0 CA-C-O 118.668 -0.682 . . . . 64.299999999999997 109.724 -173.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 79.0 m-85 -136.14 170.41 16.06 Favored 'General case' 0 C--N 1.354 0.797 0 CA-C-O 118.771 -0.633 . . . . 74.019999999999996 109.301 178.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.66 -167.53 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.787 0 N-CA-C 106.854 -1.536 . . . . 61.32 106.854 -178.554 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 26.3 ttp180 -76.05 65.62 2.11 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-N 120.309 1.413 . . . . 75.239999999999995 109.286 175.357 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 72.85 79.67 0.46 Allowed Glycine 0 C--N 1.356 1.66 0 CA-C-O 117.884 -1.509 . . . . 73.5 113.552 175.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -165.16 -65.81 0.03 OUTLIER 'General case' 0 C--N 1.359 1.019 0 CA-C-N 119.582 1.691 . . . . 75.109999999999999 111.376 171.616 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.4 t -169.49 142.95 2.2 Favored Pre-proline 0 C--N 1.355 0.813 0 CA-C-O 115.644 -2.122 . . . . 64.439999999999998 108.437 179.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.2 Cg_endo -73.51 172.77 15.04 Favored 'Trans proline' 0 C--N 1.359 1.098 0 CA-C-N 124.036 2.477 . . . . 63.020000000000003 111.542 -176.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -135.46 40.71 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.927 0 N-CA-C 108.629 -0.878 . . . . 75.420000000000002 108.629 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.457 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 4.2 p 173.85 156.75 0.13 Allowed 'General case' 0 C--N 1.355 0.825 0 CA-C-O 117.713 -1.137 . . . . 72.340000000000003 110.617 -178.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.457 ' CD1' ' C ' ' A' ' 18' ' ' SER . 33.1 m-85 -144.18 177.37 8.64 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-O 118.324 -0.846 . . . . 75.319999999999993 110.636 -178.765 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.409 ' O ' ' N ' ' A' ' 4' ' ' GLY . 7.9 m-30 -60.03 173.97 0.56 Allowed 'General case' 0 C--N 1.355 0.818 0 CA-C-N 119.547 1.067 . . . . 73.010000000000005 111.346 -174.018 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.634 0 N-CA-C 110.375 -1.09 . . . . 75.409999999999997 110.375 176.184 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.687 0 CA-C-O 118.063 -1.41 . . . . 73.310000000000002 112.331 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.46 -140.75 3.81 Favored Glycine 0 C--N 1.354 1.546 0 CA-C-N 120.011 1.906 . . . . 64.109999999999999 112.287 178.971 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.12 44.95 1.25 Allowed 'General case' 0 C--N 1.358 0.943 0 CA-C-N 119.799 1.799 . . . . 63.100000000000001 110.947 -178.491 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.409 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.07 -141.44 8.85 Favored Glycine 0 C--N 1.354 1.541 0 CA-C-O 117.971 -1.46 . . . . 64.120000000000005 110.939 -179.391 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -94.99 -34.71 12.25 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 117.224 -1.37 . . . . 73.120000000000005 112.927 -173.197 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 66.4 t -105.76 136.16 19.31 Favored Pre-proline 0 C--N 1.355 0.817 0 CA-C-O 115.362 -2.256 . . . . 74.109999999999999 109.159 -169.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_endo -66.75 144.57 72.07 Favored 'Trans proline' 0 C--N 1.362 1.267 0 CA-C-N 124.097 2.499 . . . . 71.230000000000004 112.29 -177.346 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.7 mt-10 -86.77 -51.53 6.04 Favored 'General case' 0 C--N 1.358 0.956 0 CA-C-N 119.155 0.889 . . . . 65.439999999999998 108.896 178.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 68.3 m-85 -131.41 174.52 9.99 Favored 'General case' 0 C--N 1.355 0.84 0 CA-C-O 118.738 -0.648 . . . . 74.140000000000001 109.314 -174.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.3 m-85 -134.35 170.39 15.8 Favored 'General case' 0 C--N 1.354 0.765 0 CA-C-O 118.607 -0.711 . . . . 75.030000000000001 109.187 178.039 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -101.21 -169.13 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.354 0.764 0 N-CA-C 106.728 -1.582 . . . . 65.439999999999998 106.728 -179.154 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 86.8 mtm-85 -77.69 68.58 3.8 Favored 'General case' 0 C--N 1.354 0.763 0 CA-C-N 120.061 1.3 . . . . 73.0 109.249 174.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 75.03 77.78 0.67 Allowed Glycine 0 C--N 1.358 1.754 0 CA-C-O 117.768 -1.573 . . . . 62.5 113.618 173.056 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -165.63 -65.45 0.03 OUTLIER 'General case' 0 C--N 1.358 0.971 0 CA-C-N 119.517 1.659 . . . . 74.25 111.42 172.225 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -171.0 143.77 1.68 Allowed Pre-proline 0 C--N 1.355 0.816 0 CA-C-O 115.644 -2.122 . . . . 71.120000000000005 108.327 -179.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 94.0 Cg_endo -73.15 172.43 15.56 Favored 'Trans proline' 0 C--N 1.359 1.079 0 CA-C-N 123.989 2.46 . . . . 74.219999999999999 111.517 -176.889 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.8 mt -134.14 38.82 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.939 0 N-CA-C 108.506 -0.924 . . . . 74.129999999999995 108.506 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.469 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.7 p 173.93 156.18 0.13 Allowed 'General case' 0 C--N 1.355 0.826 0 CA-C-N 119.735 1.152 . . . . 62.030000000000001 110.79 -176.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.469 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.2 m-85 -144.43 176.74 9.15 Favored 'General case' 0 C--N 1.358 0.974 0 CA-C-O 118.288 -0.863 . . . . 72.310000000000002 110.556 -178.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.409 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.46 176.39 0.19 Allowed 'General case' 0 C--N 1.354 0.791 0 CA-C-N 119.2 0.909 . . . . 74.409999999999997 112.144 -174.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.632 0 N-CA-C 109.864 -1.295 . . . . 53.049999999999997 109.864 176.758 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.118 -1.379 . . . . 63.100000000000001 112.618 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.46 -141.94 3.6 Favored Glycine 0 C--N 1.355 1.6 0 CA-C-N 120.001 1.9 . . . . 73.140000000000001 111.735 179.599 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.93 46.01 1.17 Allowed 'General case' 0 C--N 1.357 0.912 0 CA-C-N 119.965 1.882 . . . . 60.439999999999998 111.169 -178.987 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.01 -145.0 14.56 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.075 -1.403 . . . . 54.229999999999997 110.415 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 4.0 m80 -87.85 -42.29 12.64 Favored 'General case' 0 C--N 1.356 0.886 0 CA-C-N 118.86 1.33 . . . . 75.049999999999997 112.808 -177.103 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.7 t -96.87 134.96 22.37 Favored Pre-proline 0 C--N 1.353 0.734 0 CA-C-O 115.402 -2.237 . . . . 72.0 109.788 -166.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.95 143.77 67.59 Favored 'Trans proline' 0 C--N 1.362 1.253 0 CA-C-N 124.028 2.474 . . . . 65.209999999999994 112.158 -177.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 -86.18 -49.5 7.69 Favored 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.238 0.927 . . . . 64.109999999999999 109.111 178.266 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -133.13 175.54 9.29 Favored 'General case' 0 C--N 1.355 0.809 0 CA-C-O 118.697 -0.668 . . . . 75.25 109.331 -174.093 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.9 m-85 -135.87 169.86 16.91 Favored 'General case' 0 C--N 1.353 0.75 0 N-CA-C 109.15 -0.685 . . . . 71.540000000000006 109.15 177.505 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -101.3 -169.4 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.757 0 N-CA-C 106.502 -1.666 . . . . 74.109999999999999 106.502 -179.732 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 19.7 mtm180 -74.4 70.64 1.73 Allowed 'General case' 0 C--N 1.354 0.764 0 CA-C-N 120.038 1.29 . . . . 73.310000000000002 109.725 173.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.05 79.07 0.29 Allowed Glycine 0 C--N 1.355 1.619 0 CA-C-O 118.087 -1.396 . . . . 45.439999999999998 113.373 173.322 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -164.75 -64.7 0.04 OUTLIER 'General case' 0 C--N 1.357 0.928 0 CA-C-N 119.249 1.524 . . . . 73.129999999999995 110.903 172.371 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -170.99 143.2 1.6 Allowed Pre-proline 0 C--N 1.355 0.805 0 CA-C-O 115.551 -2.166 . . . . 75.239999999999995 108.416 179.209 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -73.16 172.52 15.38 Favored 'Trans proline' 0 C--N 1.358 1.067 0 CA-C-N 124.023 2.472 . . . . 72.129999999999995 111.544 -176.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.3 mt -134.92 40.81 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.957 0 N-CA-C 108.587 -0.894 . . . . 70.409999999999997 108.587 179.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.6 p 172.8 156.56 0.1 Allowed 'General case' 0 C--N 1.353 0.754 0 CA-C-O 117.776 -1.107 . . . . 70.420000000000002 110.581 -179.156 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.8 m-85 -142.99 176.7 8.89 Favored 'General case' 0 C--N 1.358 0.952 0 CA-C-O 118.169 -0.92 . . . . 71.349999999999994 110.238 -178.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.423 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.84 173.07 0.46 Allowed 'General case' 0 C--N 1.355 0.807 0 CA-C-N 119.619 1.099 . . . . 75.299999999999997 111.272 -174.031 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.48 0 N-CA-C 108.656 -1.778 . . . . 73.420000000000002 108.656 174.73 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.693 0 CA-C-O 118.275 -1.292 . . . . 62.210000000000001 112.026 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -174.49 -142.66 4.1 Favored Glycine 0 C--N 1.355 1.588 0 CA-C-O 117.224 -1.875 . . . . 74.030000000000001 111.812 179.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.48 45.71 1.13 Allowed 'General case' 0 C--N 1.357 0.926 0 CA-C-N 119.972 1.886 . . . . 60.049999999999997 111.289 -178.877 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.4 -145.96 17.54 Favored Glycine 0 C--N 1.354 1.549 0 CA-C-O 118.179 -1.345 . . . . 61.119999999999997 110.626 179.715 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.1 m80 -85.71 -43.8 13.08 Favored 'General case' 0 C--N 1.357 0.894 0 CA-C-N 118.904 1.352 . . . . 73.239999999999995 112.884 -177.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.0 t -95.06 134.48 24.65 Favored Pre-proline 0 C--N 1.353 0.726 0 CA-C-O 115.257 -2.306 . . . . 74.319999999999993 109.959 -165.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -66.63 144.32 71.78 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 124.024 2.473 . . . . 72.439999999999998 112.229 -177.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.8 mt-10 -86.67 -52.22 5.66 Favored 'General case' 0 C--N 1.357 0.914 0 CA-C-N 119.322 0.965 . . . . 62.520000000000003 108.755 178.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 71.3 m-85 -131.09 174.51 9.95 Favored 'General case' 0 C--N 1.356 0.851 0 CA-C-O 118.713 -0.661 . . . . 73.150000000000006 109.392 -174.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -134.42 170.72 15.32 Favored 'General case' 0 C--N 1.353 0.755 0 N-CA-C 109.038 -0.727 . . . . 73.25 109.038 178.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -102.38 -169.53 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 N-CA-C 106.933 -1.506 . . . . 65.400000000000006 106.933 -178.863 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 9.2 ttm180 -70.05 70.71 0.37 Allowed 'General case' 0 C--N 1.352 0.688 0 CA-C-N 119.394 0.997 . . . . 74.420000000000002 109.312 172.281 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 63.43 81.63 0.1 OUTLIER Glycine 0 C--N 1.355 1.591 0 CA-C-O 117.956 -1.469 . . . . 63.530000000000001 113.918 174.621 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.4 t70 -164.94 -64.41 0.03 OUTLIER 'General case' 0 C--N 1.357 0.911 0 CA-C-N 119.525 1.662 . . . . 72.519999999999996 110.966 171.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.2 t -170.37 142.95 1.83 Allowed Pre-proline 0 C--N 1.354 0.783 0 CA-C-O 115.616 -2.135 . . . . 71.129999999999995 108.387 178.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -73.3 172.51 15.46 Favored 'Trans proline' 0 C--N 1.359 1.115 0 CA-C-N 124.016 2.47 . . . . 73.329999999999998 111.237 -177.06 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.0 mt -134.35 38.32 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.89 0 N-CA-C 108.46 -0.941 . . . . 75.140000000000001 108.46 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.473 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 11.0 p 175.26 157.01 0.18 Allowed 'General case' 0 C--N 1.354 0.802 0 CA-C-O 117.581 -1.199 . . . . 62.420000000000002 110.733 -176.707 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.473 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.1 m-85 -144.89 176.26 9.6 Favored 'General case' 0 C--N 1.358 0.97 0 CA-C-O 118.286 -0.864 . . . . 74.109999999999999 110.499 -179.368 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.417 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.09 171.21 0.56 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-N 119.565 1.075 . . . . 74.510000000000005 111.57 -174.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.353 1.484 0 C-N-CA 119.503 -1.332 . . . . 63.25 112.417 176.404 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.63 0 CA-C-O 118.368 -1.24 . . . . 74.540000000000006 112.596 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -177.34 -143.97 5.16 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 117.271 -1.85 . . . . 70.0 112.876 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.82 44.54 1.09 Allowed 'General case' 0 C--N 1.358 0.961 0 CA-C-N 119.585 1.693 . . . . 63.43 112.072 -177.494 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -90.5 -144.74 12.41 Favored Glycine 0 C--N 1.353 1.486 0 CA-C-O 118.144 -1.365 . . . . 63.350000000000001 110.533 178.522 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 13.1 m170 -89.33 -40.79 12.54 Favored 'General case' 0 C--N 1.358 0.959 0 CA-C-N 118.951 1.376 . . . . 63.5 113.46 -178.277 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.6 t -95.93 133.6 25.1 Favored Pre-proline 0 C--N 1.354 0.761 0 CA-C-O 115.422 -2.228 . . . . 74.430000000000007 109.526 -166.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.3 Cg_endo -65.45 145.33 82.51 Favored 'Trans proline' 0 C--N 1.362 1.275 0 CA-C-N 123.891 2.425 . . . . 72.420000000000002 112.058 -177.319 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 78.8 mt-10 -81.99 -51.71 7.78 Favored 'General case' 0 C--N 1.359 0.985 0 N-CA-C 108.352 -0.981 . . . . 72.200000000000003 108.352 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.5 p90 -150.04 172.59 15.01 Favored 'General case' 0 C--N 1.353 0.75 0 CA-C-O 118.506 -0.759 . . . . 74.239999999999995 110.279 -177.948 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 74.6 m-85 -125.64 170.95 11.0 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-O 118.668 -0.682 . . . . 71.409999999999997 109.484 -177.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.6 m -94.42 -166.9 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.868 0 N-CA-C 107.67 -1.233 . . . . 51.119999999999997 107.67 -179.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 17.4 tpt85 -68.52 67.75 0.13 Allowed 'General case' 0 C--N 1.354 0.779 0 CA-C-N 119.335 0.971 . . . . 73.329999999999998 109.544 174.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.58 80.48 0.2 Allowed Glycine 0 C--N 1.356 1.646 0 CA-C-O 117.882 -1.51 . . . . 64.030000000000001 113.591 177.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.1 t70 -161.31 -66.19 0.06 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-N 119.495 1.648 . . . . 74.310000000000002 111.314 170.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -171.42 153.59 3.61 Favored Pre-proline 0 C--N 1.356 0.85 0 CA-C-O 115.966 -1.969 . . . . 65.140000000000001 106.763 -177.857 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 66.2 Cg_endo -79.97 169.47 17.81 Favored 'Trans proline' 0 C--N 1.357 1.013 0 CA-C-N 123.657 2.342 . . . . 70.209999999999994 111.644 -177.462 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 10.0 mt -135.71 41.89 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.92 0 N-CA-C 107.591 -1.262 . . . . 62.450000000000003 107.591 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.446 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 0.3 OUTLIER 175.65 157.33 0.21 Allowed 'General case' 0 C--N 1.352 0.71 0 CA-C-O 117.809 -1.091 . . . . 74.200000000000003 110.753 -178.503 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.446 ' CD1' ' C ' ' A' ' 18' ' ' SER . 30.2 m-85 -144.99 174.97 10.57 Favored 'General case' 0 C--N 1.357 0.931 0 CA-C-O 118.208 -0.901 . . . . 74.409999999999997 110.113 178.314 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.9 m-30 -58.67 175.49 0.25 Allowed 'General case' 0 C--N 1.356 0.87 0 CA-C-N 119.143 0.883 . . . . 70.420000000000002 112.208 -174.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.582 0 N-CA-C 109.746 -1.342 . . . . 74.420000000000002 109.746 176.645 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.635 0 CA-C-O 118.427 -1.207 . . . . 73.209999999999994 112.322 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -172.85 -141.16 3.36 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.217 -1.88 . . . . 44.130000000000003 111.493 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -146.49 45.5 1.21 Allowed 'General case' 0 C--N 1.357 0.896 0 CA-C-N 119.881 1.84 . . . . 74.040000000000006 111.167 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -91.15 -145.73 15.36 Favored Glycine 0 C--N 1.353 1.496 0 CA-C-O 118.323 -1.265 . . . . 33.210000000000001 110.705 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 8.1 m-70 -88.31 -40.6 13.47 Favored 'General case' 0 C--N 1.357 0.899 0 CA-C-N 118.557 1.179 . . . . 65.209999999999994 113.115 -176.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.9 t -98.09 134.89 21.66 Favored Pre-proline 0 C--N 1.353 0.758 0 CA-C-O 115.502 -2.189 . . . . 73.019999999999996 109.498 -166.999 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -67.41 144.52 67.88 Favored 'Trans proline' 0 C--N 1.362 1.288 0 CA-C-N 123.763 2.38 . . . . 72.329999999999998 112.121 -178.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -87.15 -49.65 7.15 Favored 'General case' 0 C--N 1.358 0.961 0 CA-C-N 118.869 0.759 . . . . 52.539999999999999 109.301 178.077 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 61.7 m-85 -133.46 175.71 9.18 Favored 'General case' 0 C--N 1.355 0.847 0 CA-C-O 118.744 -0.646 . . . . 71.540000000000006 109.677 -174.206 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 77.5 m-85 -137.04 166.86 22.69 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.63 -0.7 . . . . 73.400000000000006 109.411 177.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.2 m -96.03 -168.03 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.841 0 N-CA-C 106.424 -1.695 . . . . 64.120000000000005 106.424 178.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 53.7 mtp180 -74.85 71.23 1.99 Allowed 'General case' 0 C--N 1.354 0.772 0 CA-C-N 120.3 1.409 . . . . 74.239999999999995 109.329 176.735 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 69.43 78.23 0.37 Allowed Glycine 0 C--N 1.355 1.624 0 CA-C-O 118.093 -1.393 . . . . 73.209999999999994 112.978 174.127 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -163.01 -63.42 0.04 OUTLIER 'General case' 0 C--N 1.357 0.899 0 CA-C-N 119.26 1.53 . . . . 63.119999999999997 111.28 172.819 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -170.12 144.11 2.12 Favored Pre-proline 0 C--N 1.355 0.821 0 CA-C-O 115.91 -1.995 . . . . 24.239999999999998 108.643 179.805 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -76.03 158.26 38.19 Favored 'Trans proline' 0 C--N 1.36 1.137 0 CA-C-N 123.585 2.316 . . . . 64.010000000000005 110.93 -178.837 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.405 HG22 ' O ' ' A' ' 17' ' ' ILE . 15.9 mm -119.99 22.59 5.26 Favored 'Isoleucine or valine' 0 C--N 1.357 0.916 0 O-C-N 123.916 0.76 . . . . 53.020000000000003 109.764 -176.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.443 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 12.1 p -175.19 157.58 2.27 Favored 'General case' 0 C--N 1.356 0.856 0 CA-C-N 120.451 1.478 . . . . 74.329999999999998 110.753 -175.672 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.443 ' CD1' ' C ' ' A' ' 18' ' ' SER . 25.0 m-85 -142.34 177.68 8.1 Favored 'General case' 0 C--N 1.357 0.924 0 CA-C-O 118.139 -0.934 . . . . 62.520000000000003 110.887 -176.442 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.412 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.6 m-30 -58.3 172.77 0.42 Allowed 'General case' 0 C--N 1.355 0.815 0 CA-C-N 119.538 1.063 . . . . 74.230000000000004 111.593 -174.246 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.596 0 N-CA-C 108.817 -1.713 . . . . 64.230000000000004 108.817 175.011 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.642 0 CA-C-O 118.379 -1.234 . . . . 71.400000000000006 112.442 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.3 -141.73 3.25 Favored Glycine 0 C--N 1.353 1.525 0 CA-C-O 117.221 -1.877 . . . . 71.120000000000005 111.235 179.697 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.51 45.99 1.04 Allowed 'General case' 0 C--N 1.356 0.886 0 CA-C-N 120.05 1.925 . . . . 75.219999999999999 111.52 -179.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.95 -146.53 19.68 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.18 -1.344 . . . . 74.099999999999994 110.371 179.35 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -87.11 -41.01 14.13 Favored 'General case' 0 C--N 1.356 0.881 0 CA-C-N 118.931 1.366 . . . . 72.519999999999996 113.19 -178.209 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 61.1 t -95.45 133.73 25.41 Favored Pre-proline 0 C--N 1.353 0.744 0 CA-C-O 115.43 -2.224 . . . . 65.329999999999998 109.536 -166.2 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_endo -66.46 144.27 72.69 Favored 'Trans proline' 0 C--N 1.363 1.315 0 CA-C-N 123.915 2.434 . . . . 73.519999999999996 111.684 -178.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 63.8 mt-10 -82.24 -50.75 8.63 Favored 'General case' 0 C--N 1.356 0.876 0 N-CA-C 108.411 -0.959 . . . . 71.230000000000004 108.411 178.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 34.3 p90 -148.9 172.59 14.44 Favored 'General case' 0 C--N 1.353 0.74 0 CA-C-O 118.368 -0.825 . . . . 73.450000000000003 109.729 -177.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -126.08 168.24 14.26 Favored 'General case' 0 C--N 1.355 0.824 0 CA-C-O 118.513 -0.756 . . . . 44.25 109.808 -177.069 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.0 m -91.95 -171.07 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.835 0 N-CA-C 105.918 -1.882 . . . . 61.140000000000001 105.918 175.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 66.8 mtt-85 -71.2 76.81 0.71 Allowed 'General case' 0 C--N 1.353 0.75 0 CA-C-N 120.366 1.439 . . . . 51.520000000000003 110.071 177.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 67.53 75.93 0.44 Allowed Glycine 0 C--N 1.355 1.631 0 CA-C-O 118.104 -1.387 . . . . 54.539999999999999 112.985 172.283 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.2 t70 -161.9 -61.5 0.05 OUTLIER 'General case' 0 C--N 1.356 0.886 0 CA-C-N 119.212 1.506 . . . . 73.349999999999994 111.801 173.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -173.87 144.67 1.05 Allowed Pre-proline 0 C--N 1.355 0.832 0 CA-C-O 115.892 -2.004 . . . . 72.129999999999995 109.035 -178.621 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_endo -77.6 156.07 31.8 Favored 'Trans proline' 0 C--N 1.36 1.166 0 CA-C-N 123.608 2.324 . . . . 74.340000000000003 110.79 -178.75 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 15.7 mm -118.85 21.42 5.96 Favored 'Isoleucine or valine' 0 C--N 1.357 0.901 0 CA-C-O 118.625 -0.702 . . . . 73.340000000000003 109.427 -176.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.437 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 13.4 p -174.9 158.62 2.59 Favored 'General case' 0 C--N 1.356 0.868 0 CA-C-N 120.435 1.47 . . . . 64.420000000000002 110.994 -175.047 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.437 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -142.05 176.6 8.82 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-O 118.136 -0.935 . . . . 65.340000000000003 111.013 -177.042 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.417 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.2 m-30 -58.72 173.12 0.44 Allowed 'General case' 0 C--N 1.356 0.852 0 CA-C-N 119.609 1.095 . . . . 64.120000000000005 111.372 -174.468 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.587 0 C-N-CA 119.614 -1.279 . . . . 61.0 110.956 177.397 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.222 -0.648 0 CA-C-O 117.923 -1.487 . . . . 53.329999999999998 113.841 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -164.96 -142.69 3.48 Favored Glycine 0 C--N 1.353 1.502 0 CA-C-N 120.06 1.93 . . . . 72.409999999999997 111.708 179.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -147.51 47.66 1.11 Allowed 'General case' 0 C--N 1.357 0.932 0 CA-C-N 120.021 1.911 . . . . 75.299999999999997 111.209 -178.978 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.444 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.67 -145.71 18.21 Favored Glycine 0 C--N 1.354 1.551 0 CA-C-O 118.007 -1.44 . . . . 73.010000000000005 109.813 179.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 10.4 m170 -88.18 -41.72 12.8 Favored 'General case' 0 C--N 1.356 0.879 0 CA-C-N 119.029 1.415 . . . . 61.219999999999999 113.221 -178.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 57.5 t -94.51 133.67 26.59 Favored Pre-proline 0 C--N 1.354 0.771 0 CA-C-O 115.456 -2.211 . . . . 71.209999999999994 109.712 -165.922 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -66.0 144.25 75.47 Favored 'Trans proline' 0 C--N 1.363 1.302 0 CA-C-N 123.937 2.442 . . . . 73.540000000000006 111.634 -177.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 69.5 mt-10 -82.12 -50.07 9.47 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.473 -0.936 . . . . 71.400000000000006 108.473 178.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 29.7 p90 -149.92 173.09 14.19 Favored 'General case' 0 C--N 1.354 0.799 0 CA-C-O 118.398 -0.81 . . . . 73.200000000000003 109.732 -177.316 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.8 m-85 -127.95 169.2 14.25 Favored 'General case' 0 C--N 1.356 0.875 0 CA-C-O 118.509 -0.757 . . . . 72.439999999999998 109.6 -178.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.4 m -92.49 -170.9 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.852 0 N-CA-C 107.109 -1.441 . . . . 72.120000000000005 107.109 177.345 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -69.86 73.8 0.43 Allowed 'General case' 0 C--N 1.352 0.679 0 CA-C-N 119.203 0.91 . . . . 64.209999999999994 109.441 174.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.79 76.8 0.43 Allowed Glycine 0 C--N 1.354 1.575 0 CA-C-O 118.034 -1.426 . . . . 71.209999999999994 113.563 173.567 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 2.3 t70 -160.67 -66.16 0.06 Allowed 'General case' 0 C--N 1.356 0.853 0 CA-C-N 119.244 1.522 . . . . 43.409999999999997 111.077 170.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER -170.91 152.15 3.52 Favored Pre-proline 0 C--N 1.357 0.913 0 CA-C-O 116.018 -1.944 . . . . 74.530000000000001 108.36 -179.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.4 Cg_endo -76.32 165.21 29.75 Favored 'Trans proline' 0 C--N 1.356 0.933 0 CA-C-N 123.474 2.277 . . . . 65.540000000000006 111.479 -177.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.9 mt -135.81 47.68 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.886 0 N-CA-C 107.382 -1.34 . . . . 71.439999999999998 107.382 178.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.435 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.9 p 166.32 156.53 0.03 OUTLIER 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.032 -0.985 . . . . 73.319999999999993 110.175 179.41 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.435 ' CD1' ' C ' ' A' ' 18' ' ' SER . 34.3 m-85 -141.79 178.1 7.72 Favored 'General case' 0 C--N 1.356 0.889 0 CA-C-O 117.877 -1.059 . . . . 74.209999999999994 109.828 179.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.444 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.4 m-30 -58.86 177.6 0.14 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-N 119.693 1.133 . . . . 73.099999999999994 110.751 -175.72 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.57 0 CA-C-N 120.615 1.552 . . . . 65.120000000000005 109.915 176.231 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.694 0 CA-C-O 117.858 -1.524 . . . . 74.109999999999999 113.611 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -165.06 -143.02 3.58 Favored Glycine 0 C--N 1.354 1.583 0 CA-C-N 120.216 2.008 . . . . 72.519999999999996 111.261 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.17 45.23 1.07 Allowed 'General case' 0 C--N 1.357 0.899 0 CA-C-N 120.067 1.934 . . . . 74.25 111.464 -178.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.424 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.74 -145.53 16.85 Favored Glycine 0 C--N 1.354 1.529 0 CA-C-O 118.166 -1.352 . . . . 45.399999999999999 110.657 -179.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 5.1 m80 -87.6 -39.99 14.6 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-N 118.778 1.289 . . . . 73.230000000000004 112.911 -176.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 62.2 t -98.77 134.54 21.51 Favored Pre-proline 0 C--N 1.354 0.79 0 CA-C-O 115.368 -2.254 . . . . 74.319999999999993 109.743 -166.713 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -65.99 147.31 84.43 Favored 'Trans proline' 0 C--N 1.363 1.304 0 CA-C-N 124.019 2.471 . . . . 74.540000000000006 112.136 -177.339 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.4 mt-10 -83.93 -50.64 7.85 Favored 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.341 0.973 . . . . 71.140000000000001 108.38 178.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 33.6 p90 -151.5 174.64 13.16 Favored 'General case' 0 C--N 1.354 0.762 0 CA-C-O 118.417 -0.801 . . . . 61.119999999999997 110.412 -176.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -127.94 178.24 6.31 Favored 'General case' 0 C--N 1.355 0.82 0 CA-C-O 117.88 -1.057 . . . . 51.420000000000002 109.484 -176.571 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -104.36 -162.23 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.947 0 N-CA-C 105.265 -2.124 . . . . 55.520000000000003 105.265 179.575 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 70.0 mmt-85 -75.99 73.19 2.88 Favored 'General case' 0 C--N 1.355 0.804 0 CA-C-N 121.32 1.873 . . . . 72.239999999999995 108.221 176.803 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 68.05 79.71 0.24 Allowed Glycine 0 C--N 1.354 1.561 0 CA-C-O 118.382 -1.232 . . . . 64.030000000000001 110.858 176.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 18.9 t0 -156.21 -69.53 0.11 Allowed 'General case' 0 C--N 1.356 0.849 0 CA-C-N 118.846 1.323 . . . . 74.5 111.067 176.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER 178.53 150.8 0.44 Allowed Pre-proline 0 C--N 1.353 0.759 0 CA-C-O 116.063 -1.922 . . . . 71.230000000000004 106.836 -177.389 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 92.1 Cg_endo -75.58 167.21 26.98 Favored 'Trans proline' 0 C--N 1.356 0.968 0 CA-C-N 124.027 2.474 . . . . 63.409999999999997 110.814 -176.14 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 5.0 mt -134.08 37.41 0.71 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.854 0 N-CA-C 107.908 -1.145 . . . . 65.010000000000005 107.908 178.606 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.43 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.3 p 171.75 155.71 0.08 Allowed 'General case' 0 C--N 1.354 0.801 0 CA-C-O 117.546 -1.216 . . . . 71.510000000000005 110.205 -175.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.43 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.3 m-85 -141.34 175.83 9.35 Favored 'General case' 0 C--N 1.357 0.918 0 CA-C-O 118.244 -0.884 . . . . 73.329999999999998 110.332 -178.76 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.424 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -58.69 171.89 0.58 Allowed 'General case' 0 C--N 1.355 0.821 0 CA-C-N 119.636 1.107 . . . . 60.049999999999997 111.377 -174.274 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.538 0 C-N-CA 119.351 -1.404 . . . . 63.200000000000003 112.024 176.21 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.22 -0.733 0 CA-C-O 118.102 -1.388 . . . . 42.109999999999999 113.273 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.15 -143.25 3.7 Favored Glycine 0 C--N 1.355 1.585 0 CA-C-O 117.208 -1.885 . . . . 25.510000000000002 111.309 179.891 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -149.03 44.99 0.99 Allowed 'General case' 0 C--N 1.357 0.923 0 CA-C-N 120.158 1.979 . . . . 55.229999999999997 111.711 -179.046 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.03 -146.48 18.43 Favored Glycine 0 C--N 1.354 1.568 0 CA-C-O 118.112 -1.382 . . . . 73.540000000000006 110.534 179.226 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 18.0 m170 -87.97 -38.52 15.47 Favored 'General case' 0 C--N 1.356 0.867 0 CA-C-N 119.012 1.406 . . . . 73.200000000000003 113.145 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -96.94 133.2 24.57 Favored Pre-proline 0 C--N 1.353 0.749 0 CA-C-O 115.339 -2.267 . . . . 73.299999999999997 109.688 -167.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -66.35 146.45 80.68 Favored 'Trans proline' 0 C--N 1.363 1.321 0 CA-C-N 123.987 2.46 . . . . 43.420000000000002 112.003 -177.063 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 74.4 mt-10 -82.78 -50.58 8.52 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.317 -0.994 . . . . 52.450000000000003 108.317 179.023 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 37.4 p90 -150.69 173.57 14.01 Favored 'General case' 0 C--N 1.354 0.783 0 CA-C-O 118.544 -0.741 . . . . 71.239999999999995 110.302 -177.37 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -126.7 176.95 6.85 Favored 'General case' 0 C--N 1.354 0.789 0 CA-C-O 118.042 -0.98 . . . . 74.420000000000002 109.415 -176.197 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -107.0 -167.11 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.902 0 N-CA-C 105.068 -2.197 . . . . 72.409999999999997 105.068 177.382 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 15.4 mmt85 -74.13 75.78 1.77 Allowed 'General case' 0 C--N 1.354 0.767 0 CA-C-N 120.686 1.584 . . . . 74.230000000000004 108.907 178.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.96 76.59 0.33 Allowed Glycine 0 C--N 1.355 1.599 0 CA-C-O 118.134 -1.37 . . . . 73.329999999999998 111.179 175.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 21.0 t0 -156.83 -69.75 0.1 Allowed 'General case' 0 C--N 1.355 0.838 0 CA-C-N 119.028 1.414 . . . . 71.109999999999999 111.389 178.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.1 t -178.39 143.68 0.46 Allowed Pre-proline 0 C--N 1.354 0.787 0 CA-C-O 116.011 -1.947 . . . . 75.120000000000005 108.465 -179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo -71.75 165.62 31.97 Favored 'Trans proline' 0 C--N 1.358 1.027 0 CA-C-N 123.791 2.39 . . . . 52.43 110.233 -177.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 4.9 mt -134.44 37.72 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.877 0 N-CA-C 107.915 -1.142 . . . . 62.350000000000001 107.915 -179.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.431 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.5 p 173.46 154.46 0.1 Allowed 'General case' 0 C--N 1.355 0.833 0 CA-C-O 117.494 -1.241 . . . . 74.340000000000003 110.185 -176.017 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.431 ' CD1' ' C ' ' A' ' 18' ' ' SER . 27.7 m-85 -141.57 175.63 9.53 Favored 'General case' 0 C--N 1.357 0.925 0 CA-C-O 118.3 -0.857 . . . . 74.409999999999997 110.246 -178.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.7 m-30 -59.75 169.39 1.4 Allowed 'General case' 0 C--N 1.355 0.82 0 CA-C-N 119.688 1.131 . . . . 73.540000000000006 111.438 -173.201 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.581 0 N-CA-C 109.444 -1.462 . . . . 31.34 109.444 173.683 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.676 0 CA-C-O 118.316 -1.269 . . . . 74.310000000000002 112.64 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -170.05 -144.66 4.39 Favored Glycine 0 C--N 1.354 1.55 0 CA-C-O 117.351 -1.805 . . . . 72.230000000000004 111.467 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.01 46.26 1.08 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.782 1.791 . . . . 61.399999999999999 111.48 -179.113 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.428 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -92.84 -144.17 14.11 Favored Glycine 0 C--N 1.353 1.508 0 CA-C-O 118.102 -1.388 . . . . 65.230000000000004 110.195 179.151 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 12.8 m170 -88.95 -42.51 11.76 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.019 1.41 . . . . 74.239999999999995 113.508 -178.213 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 60.1 t -93.87 133.41 27.8 Favored Pre-proline 0 C--N 1.353 0.755 0 CA-C-O 115.446 -2.216 . . . . 64.150000000000006 109.478 -166.247 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_endo -65.32 144.41 80.35 Favored 'Trans proline' 0 C--N 1.363 1.312 0 CA-C-N 123.943 2.444 . . . . 55.219999999999999 111.866 -177.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 71.5 mt-10 -81.5 -51.39 8.33 Favored 'General case' 0 C--N 1.358 0.968 0 N-CA-C 108.359 -0.978 . . . . 71.420000000000002 108.359 179.001 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 31.4 p90 -148.87 172.06 15.29 Favored 'General case' 0 C--N 1.354 0.796 0 CA-C-O 118.535 -0.745 . . . . 74.319999999999993 109.941 -177.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -125.01 170.27 11.3 Favored 'General case' 0 C--N 1.355 0.845 0 CA-C-O 118.857 -0.592 . . . . 74.209999999999994 109.614 -177.16 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.3 m -94.67 -170.43 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.808 0 N-CA-C 106.563 -1.643 . . . . 74.409999999999997 106.563 177.409 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 23.1 mtt180 -70.08 75.32 0.49 Allowed 'General case' 0 C--N 1.354 0.771 0 CA-C-N 119.876 1.216 . . . . 74.150000000000006 109.924 173.533 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 65.72 78.02 0.24 Allowed Glycine 0 C--N 1.355 1.587 0 CA-C-O 118.11 -1.383 . . . . 60.329999999999998 113.579 172.25 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -162.62 -63.31 0.05 OUTLIER 'General case' 0 C--N 1.357 0.904 0 CA-C-N 119.204 1.502 . . . . 63.130000000000003 111.296 172.101 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 1.3 t -172.92 143.99 1.17 Allowed Pre-proline 0 C--N 1.356 0.855 0 CA-C-O 115.713 -2.089 . . . . 60.229999999999997 108.281 -179.352 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -75.52 170.74 19.61 Favored 'Trans proline' 0 C--N 1.357 0.984 0 CA-C-N 123.835 2.405 . . . . 75.510000000000005 111.17 -177.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -135.77 39.94 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.358 0.977 0 N-CA-C 108.488 -0.93 . . . . 74.310000000000002 108.488 178.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.433 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 19.2 p 175.1 155.42 0.15 Allowed 'General case' 0 C--N 1.353 0.747 0 CA-C-O 117.795 -1.097 . . . . 63.520000000000003 110.932 -177.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.433 ' CD1' ' C ' ' A' ' 18' ' ' SER . 32.6 m-85 -142.59 175.19 9.99 Favored 'General case' 0 C--N 1.358 0.968 0 CA-C-O 118.049 -0.977 . . . . 72.319999999999993 110.169 -179.756 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.428 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.8 m-30 -58.46 172.43 0.48 Allowed 'General case' 0 C--N 1.356 0.876 0 CA-C-N 119.509 1.05 . . . . 64.239999999999995 111.333 -174.05 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.354 1.528 0 N-CA-C 109.18 -1.568 . . . . 74.319999999999993 109.18 174.201 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.681 0 CA-C-O 118.145 -1.364 . . . . 63.0 112.89 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.85 -142.12 3.41 Favored Glycine 0 C--N 1.354 1.552 0 CA-C-O 117.177 -1.902 . . . . 75.109999999999999 112.144 -179.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -148.8 46.22 1.02 Allowed 'General case' 0 C--N 1.358 0.945 0 CA-C-N 119.887 1.843 . . . . 53.229999999999997 111.697 -178.44 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.446 ' N ' ' O ' ' A' ' 20' ' ' TYR . . . -93.62 -144.56 15.59 Favored Glycine 0 C--N 1.354 1.556 0 CA-C-O 118.146 -1.363 . . . . 51.43 110.6 179.559 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' HIS . . . . . . . . . . . . . 6.2 m80 -87.44 -41.82 13.26 Favored 'General case' 0 C--N 1.356 0.88 0 CA-C-N 118.788 1.294 . . . . 53.43 113.141 -177.016 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.3 t -97.45 134.57 22.43 Favored Pre-proline 0 C--N 1.354 0.785 0 CA-C-O 115.397 -2.239 . . . . 61.439999999999998 109.693 -166.186 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -65.74 144.25 77.15 Favored 'Trans proline' 0 C--N 1.362 1.278 0 CA-C-N 123.909 2.432 . . . . 75.099999999999994 111.81 -178.003 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 72.9 mt-10 -81.52 -51.42 8.29 Favored 'General case' 0 C--N 1.358 0.947 0 N-CA-C 108.48 -0.933 . . . . 71.030000000000001 108.48 179.216 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 32.7 p90 -148.37 172.0 15.11 Favored 'General case' 0 C--N 1.355 0.814 0 CA-C-O 118.366 -0.826 . . . . 71.120000000000005 109.553 -177.477 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . . . . . . . . . 71.3 m-85 -124.34 170.13 11.12 Favored 'General case' 0 C--N 1.355 0.823 0 O-C-N 123.781 0.675 . . . . 74.239999999999995 109.628 -177.084 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 3.8 m -92.59 -166.29 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.806 0 N-CA-C 106.477 -1.675 . . . . 73.409999999999997 106.477 178.732 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' ARG . . . . . . . . . . . . . 42.8 mtp180 -75.52 69.08 2.24 Favored 'General case' 0 C--N 1.352 0.708 0 CA-C-N 120.005 1.275 . . . . 74.519999999999996 109.56 175.425 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLY . . . . . . . . . . . . . . . 71.29 78.21 0.46 Allowed Glycine 0 C--N 1.356 1.669 0 CA-C-O 118.01 -1.439 . . . . 74.200000000000003 113.208 174.378 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ASP . . . . . . . . . . . . . 1.3 t70 -164.28 -63.45 0.04 OUTLIER 'General case' 0 C--N 1.357 0.916 0 CA-C-N 119.376 1.588 . . . . 64.439999999999998 111.503 172.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -171.5 144.52 1.63 Allowed Pre-proline 0 C--N 1.355 0.809 0 CA-C-O 115.511 -2.185 . . . . 63.219999999999999 108.307 -179.619 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -75.36 171.36 18.41 Favored 'Trans proline' 0 C--N 1.357 1.01 0 CA-C-N 123.95 2.447 . . . . 72.319999999999993 111.361 -177.497 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 6.5 mt -136.06 40.33 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.357 0.901 0 N-CA-C 108.413 -0.958 . . . . 74.25 108.413 178.232 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' SER . . . . . 0.451 ' C ' ' CD1' ' A' ' 19' ' ' PHE . 3.8 p 174.31 155.93 0.13 Allowed 'General case' 0 C--N 1.354 0.784 0 CA-C-O 117.77 -1.11 . . . . 45.100000000000001 111.08 -177.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.451 ' CD1' ' C ' ' A' ' 18' ' ' SER . 28.6 m-85 -143.25 175.91 9.53 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-O 118.283 -0.865 . . . . 64.329999999999998 110.559 -179.489 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' TYR . . . . . 0.446 ' O ' ' N ' ' A' ' 4' ' ' GLY . 8.0 m-30 -60.13 176.57 0.31 Allowed 'General case' 0 C--N 1.356 0.866 0 CA-C-N 119.354 0.979 . . . . 75.209999999999994 111.775 -174.268 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--N 1.355 1.594 0 C-N-CA 119.514 -1.327 . . . . 72.420000000000002 109.894 173.474 . . . . . . . . 0 0 . 1 stop_ save_